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The emergence of multiple drug resistant (MDR) and extremely drug resistant (XDR) 
strains of Mycobacterium tuberculosis (M.tb) against the known anti-tuberculosis 
drug regimens has prompted the need to search for new anti-tubercular drugs. In this 
study we report the design and synthesis of a series of thiazolidinethione derivatives 
and substrate mimics, aimed at targeting the mycothiol biosynthetic pathway which is 
specific to mycobacteria. The strategy involved design of molecules that are expected 
to compete for the UDP-GlcNAc binding site of the glycosyltransferase (MshA) of 
M.tb. The bioactivity of the designed molecules against M.tb in cell free and whole 
cell assays serves as a basis for further inhibitor optimisation. Amongst the 
thiazolidinethione derivatives screened, compounds (Z)-5-(2,4-dichlorobenzylidene)-
2-thioxothiazolidin-4-one (MJ3A) and 2-((Z)-5-(4-hydroxy-3-methoxybenzylidene)-
4-oxo-2-thioxothiazolidin-3-yl)acetic acid (MJ7B) were found to be the most potent 
compounds with a MIC50 of 10 μg/mL. In addition, substrate mimics were 
synthesized and screened for anti-tuberculosis activity. Substrate mimics displayed 
moderate activity, with exception of substrate mimic (4-34) which displayed the 
highest potency. Tunicamycin which is a known glycosyltransferase inhibitor 
displayed the highest potency against M.tb H37Rv whole cells by inhibiting cell 
growth with a MIC50 of 5 μg/mL. Tunicamycin inhibits the transfer of GlcNAc-1-P 
from UDP-GlcNAc to polyprenyl monophosphates in a variety of organisms 
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CHAPTER 1 
Introduction and Background 
1.1 Tuberculosis 
Tuberculosis (TB) is a bacterial infectious respiratory disease, caused by the bacillus 
Mycobacterium tuberculosis (M.tb) and characterized by the formation of tubercles 
and tissue necrosis as a result of host hypersensitivity and inflammation. TB may be 
caused under rare occasions, by other Mycobacterium species such as M. bovis and M. 
africanum.1 Despite being known for more than a century, to date, TB still remains 
one of the leading and most deadly infectious diseases for humans globally.2,3 
 
Each year, approximately nine million new cases of TB are reported and nearly three 
million of these cases result in death, thus making TB a major public health concern.4 
In 1993, the World Heath Organisation (WHO) declared TB as a global health 
emergency. The synergism between human immunodeficiency virus (HIV) and TB 
further amplifies the rapid spread of TB in developing countries, where fewer 
resources are available to ensure proper treatment and where HIV may be prevalent.5 
These pandemics (TB and HIV) are strongly interlinked and form a lethal 
combination, with each other speeding up the progress of one another. According to 
the WHO, at least one-third of the 33.2 million people living with HIV are co-infected 
with TB and around 80% of these patients live in Sub-Saharan Africa.1  
 
1.1.1 Global distribution of tuberculosis 
According to the 2009 WHO global control report the largest number of new TB 
cases occurred in the South-East Asia followed by the African region.1 On average 
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Asian and African regions account for 55% and 31% of the global TB cases 
respectively and the other three regions account for a small fraction of global cases.1 
The WHO 20116 report, has shown a slight improvement on the African region with a 
drop of 5% from 31% in 2009 to 26% in 2010 whereas the Asian region saw an 
increase of 4% from 55% in 2009 to 59% in 2010.  
 
1.1.2 Tuberculosis incidences in South Africa 
South Africa has been identified as one of the 22 high-TB burden countries (HBC) in 
the world (WHO, 2011)6 and it is ranked number three on the global stage (Fielding et 
al.).7 Due to the high increase in the TB burden, the government adopted a global 
strategy for TB control called directly observed treatment, short course (DOTS) 
programme in 1996. This programme was launched by WHO in 1993 and its success 
rate was estimated to be 67%, which is relatively far lower than the WHO standard 
rate of 85% (Gandhi et al.).8 
 
1.2 Drug resistant tuberculosis 
The emergence of multiple drug resistance (MDR) and extremely drug resistant 
(XDR) forms of M.tb strains that are resistant to the combined action of the first and 
second line TB regiment necessitates the use of a new anti-tuberculosis regiment.9 
The current anti-tuberculosis drugs mainly target the biosynthesis of the cell wall.2 
The mycobacterial envelope distinguishes mycobacteria from other species with the 
aid of a complex, robust cell wall with the ability to withstand the hostile macrophage 
environment.10  
These high rates of recurrence of tuberculosis and the emergence of drug resistant 
M.tb strains have led to increased interest and efforts in seeking a better understanding 
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of the molecular mechanisms of drug resistance and new knowledge which seeks to 
identify potential novel metabolic targets for chemotherapeutic intervention.11  
 
1.3 The current tuberculosis therapy 
The current TB therapy is prolonged and involves the use of the combination of first 
line drugs (rifampicin, isoniazid, pyrazinamide, ethambutol and streptomycin) and 
second line drugs (kanamycin, P-aminosalicyclic acid, ethionamide, cycloserine and 
fluoroquinolones) (Fig. 1-1).12 The prolonged usage of multiple drugs leads to non-
compliance by the patients and this paves the way for the drug resistance. The goals 
of TB therapy are to kill tubercle bacilli rapidly, prevent the emergence of drug 
resistance, eliminate persistent bacilli to prevent relapse, and minimize disease 
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1.4 The current anti-TB drug candidates in the drug discovery 
pipeline 
Steady progress has been made towards the identification of the new drug targets, 
drug candidates, and active compounds and thus far very few promising new drugs 
have been identified (Fig. 1-2).13,14 Moxifloxacin (MOXI) and gatifloxacin (GATI) 
are amongst the most promising active fluoroquinolones against M. tuberculosis and 
these drugs have entered the third phase of clinical trials.15 The study by 
Nuermberger, et al.16 showed that the use of the combination of drugs (MOXI, RIF 
and PZA) in mice shortens the treatment period by up to four months. 































































































































































Figure 1-2: Structures of some TB drugs in the developmental stage. 
 
1.5 Design and development of structure based glycosyltransferase 
inhibitors 
In searching for new TB drugs, it is crucial to develop drugs that are active against 
MDR-TB and shorten the duration of treatment by targeting the recalcitrant and 
dormant bacilli. Needless to point out that it is important to identify new approaches 
to achieve these objectives. Developments of new drugs that inhibit novel targets are 
urgently needed.  
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Given the increasing need for the developments of new classes of anti-tuberculosis 
drugs, targeting the enzymes producing low molecular thiols (LMT) is of high interest 
considering the role the LMT play in the mycobacterial detoxification of xenobiotics. 
The current anti-TB drugs available function by inhibiting the synthesis of the 
bacterial cell wall and protein synthesis. The drug candidates under the development 
also target the inhibition of cell wall as well as DNA synthesis. Currently, there are no 
drug candidates that target the enzymes involved in the redox balance of the bacteria. 
 
1.6 Low molecular thiol producing bacteria 
Under normal circumstances, most bacterial species do not survive inside the 
macrophages of the host cells, due to the nature and abundance of the acidic 
phagocytic vacuoles and hydrolytic enzymes.3 However, organisms have developed 
some mechanisms to defend themselves against these harsh conditions within various 
toxic environments of the activated macrophages by producing LMT to protect 
themselves.4  
 
LMT play an important role in the maintenance of the cellular redox homeostasis, as 
well as for the protection of the cells against alkylating agents (N-ethylmaleimide, 
iodoacetamide) and electrophilic toxins (formaldehyde, methylglyoxal etc).17 The 
LMT provides protection against an array of molecules by forming adducts that can 
be enzymatically converted into less harmful substances.18 In most cells, the tripeptide 
glutathione (GSH) is the major LMT. However, many bacteria lack GSH and instead 
synthesize an alternative LMT such as bacillithiol, mycothiol and ergothioneine (Fig. 
1-3). 
 
In mycobacteria, mycothiol (MSH) is the major LMT19 and studies have demonstrated 
that MSH has functions analogous to those of GSH in Gram-negative bacteria.20,21 
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These functions include the protection of M.tb from toxic oxidants and antibiotics.22 
Most eukaryotes and gram negative bacteria produce GSH as their major thiol instead 
of MSH.23,24 Apart from MSH and GSH, filamentous fungi and some members of 
actinobacteria including mycobacteria produce ergothioneine (ESH) in addition to the 
major thiols (Ta et al.).25 ESH is a naturally occurring amino acid and a 2-mercapto 
derivative of histidine.  
 
However, in some low Guanine and Cytosine (GC) content Gram-positive bacteria, 
coenzyme A (CoA) has proven to be a major thiol. Interestingly, further studies on 
CoA related thiols in Bacillus subtilis and Bacillus anthracis lead to the discovery of a 
novel bacterial thiol, bacillithiol (BSH) as their LMT. Recently this thiol was also 













































Ergothioneine (ESH)  
Figure 1-3: Structures of key low molecular major thiols. 
 
1.7 Role of mycothiol (MSH) in cellular detoxification 
Mycothiol (MSH) serves a key role in the detoxification of the alkylating agents, 
which was identified using the fluorescent alkylating agent monobromobimane 
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(mBBr) that can enter cells and react with LMT. Koledin et al.23 and Newton et al.24 
have proposed a mechanism in which MSH detoxifies the harmful toxins entering 
bacterial cells (Fig. 1-4). According to this mechanism MSH reacts with the mBBr 
upon their entry into the cells to form a bimane-labelled MSH (MSmB) complex 
which is subsequently hydrolyzed by mycothiol-S-conjugate amidase (Mca) to form a 
mercapturic acid (AcCsymB) and GlcN-Ins. The mercapturic acid is excreted from 
the cells whereas GlcN-Ins is retained in the cells for the regeneration of the MSH 





























































Mercapturic acid  
Figure 1-4: The detoxification of harmful thiol reactive agents from the cells. 
 
1.8 The discovery of LMT 
The term mycothiol (MSH), (1-O-[2-[[(2R)-2-(acetylamino)-3-mercapto-1-oxopropyl] 
amino]-2-deoxy-α-D-glucopyranosyl]-D-myo-inositol) was coined for the first time in 
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1994 and its trivial name was proposed by Spies and Steenkamp.26 MSH was first 
isolated from Streptomyces strain AJ9463 as the disulfide (MSSM) by Sakuda et al.27 
and shortly there after it was reported by two independent studies of Newton et al.28 
and Spies et al.26 whereby it was derived from Mycobacterium bovis. Sakuda et al.27 
eventually proposed the absolute structure of MSH based on NMR analysis and acid 
hydrolysis experiments. The structure was found to be comprised of three major 
components of MSH L-cysteine residue with an acetylated amino group and the 
carboxyl group linked via an amide group to D-glucosamine, which in turn forms an 
α-(1-1)-glycosidic bond with D-myo-inositol (Fig. 1-5). From the structure analysis it 
was noted that MSH was in actual fact discovered in the previous year by Newton and 
co-workers, labeled as U17, while working on the Streptomycetes cell extracts devoid 
of GSH.28 Jardine et al.29 first presented a detailed chemo-enzymatic synthesis of 
MSH. MSH and BSH share some structural similarities and this has facilitated the 
identification of the biosynthetic genes for BSH in the model organism B. anthracis. 
 
BSH was first discovered in B. anthracis cell extracts30 and also in B. subtilis as a 
mixed disulphide with OhrR.31 Following its discovery, the structural analysis was 
achieved from the isolated metabolite from D. Radiodurans, indicating a compound 
with L-malate glycosidically linked to glucosamine, which is rare in natural 
products.32 The structure of BSH resembles that of MSH with the difference being 
that the myo-inositol has been replaced by malic acid and the cysteine is not N-
acetylated. The biosynthetic pathway of BSH has been established with the aid of the 
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1.9 BSH biosynthesis 
The partial biosynthetic pathway of BSH have been established33 (Fig. 1-5) and three 
of the biosynthetic enzymes (BshA, BshB, BshC) in the pathway have been 
successfully identified and characterized thus far. The first step in the biosynthetic 
pathway involves the formation of GlcNAc-Mal using L-malate and UDP-N-acetyl 
glucosamine as substrates, catalyzed by BshA.33,34,35 This is followed by the 
hydrolysis of the N-acetyl group from GlcNAc-Mal to generate GlcN-Mal.33,34 The 
final step involves the ligation of cysteine by BshC to generate BSH (Cys-GlcN-Mal). 
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1.10 MSH biosynthesis 
The biosynthetic pathway of MSH have been established36 (Fig. 1-6) and four of the 
five biosynthetic enzymes (MshA, MshB, MshC and MshD) in the pathway have been 
successfully identified and characterized thus far.37 The enzymes involved in MSH 
biosynthesis have been found to be interesting as potential drug targets in the 
treatment of tuberculosis. 
 
Figure 1-6: Biosynthetic pathway of mycothiol. 
 
The first obligate step in the biosynthesis of MSH involves the glycosyltransferase 
(MshA). This enzyme catalyzes the formation of 3-phospho-1-D-myo-inosityl-2-
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UDP-N-acetylglucosamine (UDP-GlcNAc) to 1-L-myo-inositol-1-phosphate (1-L-Ins-
1-P) (Fig. 1-7), which is subsequently dephosphorylated by a yet to be identified 
phosphatase to generate GlcNAc-Ins.38 Following the dephosphorylation of GlcNAc-
Ins-3P, a zinc dependent N-acetyl hydrolase (MshB) catalyzes the hydrolysis of the N-
acetyl group to give the free amino sugar GlcNH2-Ins.37 The resultant GlcNH2-Ins is 
ligated with cysteine in a reaction catalyzed by MshC (ligase).39 The final step in the 
MSH synthesis is carried out by MshD (mycothiol synthase) which transfers an acetyl 
group from acetyl-CoA to 1D-myo-inosityl 2-amido-2-deoxy-α-D-glucopyranoside.23 
 
 
Figure 1-7: Summary of proposed catalytic mechanism for production of GlcNAc-Ins-P by MshA. 
 
1.10.1 Glycosyltransferase (MshA) 
The gene encoding MshA, Rv0486 (mshA) was discovered by Newton et al.40 while 
working on M. smegmatis and demonstrated more than 75% sequence similarity with 
the corresponding gene in M. tb in a 446-residue overlap.40 Based on the amino acid 
sequence homology and three-dimensional structure, MshA was grouped into the 
Carbohydrate-Active Enzyme database (CAZy) family GT-4, all of which have been 
found to be retaining glycosyltransferases and have a GT-B fold.36,41  
 
The GT-4 is the second largest CAZy database family which comprises of 90 distinct 
families, which include several other key enzymes such as sucrose synthase, sucrose 
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enzymes catalyze the transfer of a sugar residue from an activated nucleotide sugar 
donor to a specific acceptor molecule, resulting in the formation of a glycosidic bond. 
The transfer of sugar residue occurs with either retention or inversion of the 
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                            B 
Figure 1-8: Illustration of enzyme mechanism (A: inversion and B: retention) of the anomeric carbon. 
 
1.10.1.1 MshA as drug target  
The mutated strains of M. smegmatis with modifications of genes encoding the MSH 
biosynthetic enzymes (MshA, MshB, MshC and MshD) have been investigated for 
MSH production and drug susceptibility.23,39,40,43 Since most of the genes for 
mycothiol biosynthesis have been identified using the non-pathogenic M. smegmatis, 
similar strategies have been used to generate the corresponding mutants of M.tb. With 
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involved in the biosynthesis of MSH presents potential as specific chemotherapeutic 
targets against actinomycetes including mycobacteria species.40,43  
 
Previous studies by Newton et al. have elucidated that the mshA gene was essential 
for the production of GlcNAc-Ins and therefore synthesis of MSH in M. smegmatis.40 
Further disruptions of the mshA gene in M. tb Erdman have indicated that the gene 
was essential for the growth of this pathogen.44 Gene knockout studies of MshA-D 
and their effects on intracellular MSH levels in various MSH producing bacteria have 
been reported.39,40,43 The most widely studied MshA-D gene knockouts effects have 
been done in M. smegmatis. A comparative analysis of M. smegmatis MshA-D 
mutants to antibiotics, pH, oxidative stress and osmotic stress have showed that 
mutants which are devoid of MSH show a greater increase in sensitivity to 
electrophiles, oxidants and a range of antibiotics. MshA mutants lead to no production 
of MSH and MSH biosynthetic intermidiates as compared to MshB-D mutants, which 
retain reduced levels of MSH and MSH biosynthetic intermidiates.  
 
Two independent studies by Buchmeier et al44 and Rawat et al43 have demonstrated 
that the inactivation of the mshB gene does not completely block the biosynthesis of 
MSH in both the M. smegmatis and M.tb. These observations were attributable to the 
presence of a MshB orthologue, mycothiol amidase (Mca), which act as an alternative 
deacetylase in the absence of MshB, leading to modest production of GlcNAc-Ins in 
both species.39,45  
 
Further studies on MSH by Newton et al. and Buchmeier et al. have respectively 
investigated and demonstrated that inactivation of the mshD gene in M. smegmatis 
and M.tb does not fully block the MSH production. Their findings were therefore 
attributed to the low levels of MSH being produced in both mshD mutants by the 
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chemical transacetylation reaction of acetyl-CoA with Cys-GlcN-Ins that accumulates 
at high levels in both mshD mutants.45,46 Thus far, MshA is a key enzyme in the 
biosynthetic pathway of MSH and it would therefore be very interesting to find what 
are the implications of complete blockade of this enzyme. 
 
1.10.1.2 The crystal structure of MshA 
The crystal structure of MshA (Fig. 1-9) consists of two β/α/β Rossman-fold domains 
connected by a short hinge region.41 According to Vetting et al.36, the N-terminal 
domain consists of an eight-stranded β-sheet (β8, β7, β6, β5, β1, β2, β4, and β3) 
which is bounded by six-α-helices (α1-α5 and α14) whereas the C-terminal domain is 
made up of a six-stranded β-sheet (β11, β10, β9, β12, β13 and β14) which is bound to 
eight α-helices (α6–α13). The study further demonstrated that the active site was 
located between N- and C- terminal domains and it is > 30 Å from the dimer interface 

















Figure 1-9: Shows a ribbon like crystal structure of cgMshA monomer (Helices: blue, strands: orange 
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1.10.2 Deacetylase (MshB) 
MshB is a metal-dependent hydrolase that catalyses the hydrolysis of the N-acetyl 
group to give the free amino sugar GlcNH2-Ins, homologous to the mycothiol 
dependent detoxification enzyme mycothiol S-conjugate amidase (Mca).47 Previous 
structural analysis of MshB has indicated Zn2+ as an active metal coordinator, 
however recent MshB structural analysis by Huang and Hernick48 reported the high 
activity of iron coordinated by two histidine moieties (His13 and His147) and 
aspartame (Asp16) and two water molecules whereby one water molecule is displaced 
during the binding of MshB to the α-GlcN-Ins.  
 
The catalytic mechanism for MshB was proposed by Maynes et al.49 based on the 
crystal structure. According to this mechanism, Asp15 residue serves as a general 
base for the deprotonation of water molecule and the resulting hydroxyl group acts as 
a nucleophile to the amide carbonyl of the acetyl group. The developing negative 
charge on the carbonyl oxygen is stabilized by hydrogen bonding to the protonated 
His144. The last step of the deacetylation is accomplished by the proton transfer to 
the nitrogen of α-GlcN-Ins which is mediated through the acid function of Asp15. The 
mechanism for metal coordination by MshB is depicted in Figure 1-10. 






















































Figure 1-10: Proposed catalytic mechanism for MshB. 
 
1.10.3 The ligase (MshC) 
MshC is encoded for by the gene Rv2130c or mshC and it catalyses the ATP-
dependent conjugation of cysteine with GlcNH2-Ins. The mechanism show that ATP 
binds first followed by the coupling of the cysteine residue to give the Cys-AMP 
complex.50,51 Subsequently, a pyrophosphate molecule is released after GlcN-Ins-
amine complex formation followed by the release of CysGlcN-Ins and AMP (Fig. 1-
11). 


















































































Figure 1-11: Catalytic mechanism for MshC. (a) ATP first binds to MshC followed by cysteine (Cys), 
forming an MshC-ATP-Cys complex. MshC releases a pyrophosphate molecule upon formation of the 
cysteine-adenylate compound which is still bound to the active site. (b) αGlcN-Ins bind to MshC and 
the amide bond between αGlcN-Ins and Cys is formed with the cleavage of the adenylate anhydride, 
resulting in Cys-αGlcN-Ins and AMP. 
 
1.10.4 Mycothiol Synthase (MshD) 
Mycothiol synthase (MshD) is the fifth and final enzyme in the MSH biosynthetic 
pathway. MshD belongs to the GCN5 related family of N-acetyltransferases 
(GNATS), which catalyses the transfer of an activated acetyl group from acetyl-CoA 
to the primary amine.52 The presence of mycothiol synthase activity was first 
demonstrated in M. smegmatis53 and the enzyme was later cloned and expressed in 
Escherichia coli.54a The sequence of MshD was found to be twice the length of the 
typical GNAT protein and also exhibited two distinct regions with homology to 
GNATs suggesting that MshD may be composed of two GNAT domains.52 Blanchard 
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and co-workers reported the crystal structure of MshD derived from M.tb. 
Subsequently the catalytic mechanism of this enzyme (synthase) was proposed based 
on its crystal structure (Fig. 1-12).54b According to this mechanism the highly charged 
amino acid Glu234 acts as a base and therefore polarise a structured water molecule. 
The Leu238 and NH stabilize the negative charge developed during the transition 
state of the acetyl carbonyl residue. The Tyr294 protonates the complex to generate 






















Figure 1-12: Catalytic mechanism for MshD. 
 
1.11 Chemical synthesis of MSH 
Since the discovery of MSH, enormous synthetic efforts were made in pursuit of 
chemically synthesized MSH. Previously the D-myo-inositol portion of the MSH was 
reported with the wrong stereochemical orientation and it was referred as L-myo-
inositol.26,55 The ambiguity surrounding the stereochemistry of the MSH structure was 
resolved by the chemical synthesis of bimane-labelled MSH (MSmB) whose optical 
rotation, circular dichroism and Mca substrate properties were reported to be the same 
as that of the MSmB prepared from the cell extracts.56 
 
Several possible methods for the synthesis of MSH have been reported in the 
literature. The classical methods for the synthesis of MSH start with the ketalization 
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of myo-inositol which is cheap and readily available. Vacca et al.57 reported the 
ketalization of myo-inositol by employing 1-ethoxycyclohexene in the presence of 
catalytic amount of p-toluenesulphonic acid monohydrate to yield biscyclohexylidine 
ketals in quantitative yields (Scheme 1-1). 
 
Selective benzylation of 1,2:4,5-dicyclohexylidene-myo-inositol (1-3) gave the 3-
benzyl-1,2:4,5-dicyclohexylidene-myo-inositol (1-4).29 Subsequently, the 3-benzyl-
1,2:4,5-dicyclohexylidene-myo-inositol (1-4) products were resolved as the 
camphanate esters, using known literature procedures to give (D) and (L), 
respectively (Scheme 1-1).57,58  
 
Basic hydrolysis of the camphanate ester and ketal cleavage of desired D enantiomer 
in acetic acid ensured the monobenzylated myo-inositol which was subsequently 
acetylated to give D-1-O-benzyl-2,3,4,5,6-penta-O-actetyl-myo-inositol (Scheme 1-
1).59 
 

























































































Scheme 1-1: Reaction conditions: (i) 1-ethoxycyclohexane, P-TsOH and DMF; (ii) NaH, BnBr and 
toluene; (iii) camphanic acid chloride; Et3N and DCM; (iv) (a) KOH and ethanol; (b) 80 % acetic acid 
(v/v); (v) acetic anhydride and pyridine; (vi) H2 and Pd/C. 
 
Jardine et al. reported the Koenigs-Knorr mediated coupling of (-)-2,3,4,5,6-penta-O-
actetyl-myo-inositol and 3,4,6-tri-O-accetyl-2-deoxy-2-(2,4-dinitrophenylamino)-α-D-
glucopyranosyl bromide to obtain a (1:1) mixture of α/β pseudo-disaccharide in 60% 
yield (Scheme 1-2). Similar glycosylation studies were reported by Nicholas et al. by 
directly coupling 2,3:4,5 cyclohexylidene with 3,4,6-tri-O-acetyl-2-deoxy-2-azido-2-
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deoxy-α-D-glucopyranosyl chloride prior to deprotection of the sugar moiety in the 
presence of silver triflate (AgOTf) and 2,6-diisopropyl-4-methylpyridine to obtain a 
mixture of anomers α/β in 2:1 ratio in 70% yield. Treatment of the protected pseudo-
disaccharides using an anion exchange resin (IR400-OH) was reported and followed 
by the enzymatic coupling of the cysteine to the pseudo-disaccharide in the final 
synthesis of the mycothiol.  
Scheme 1-2: Reaction conditions: (i) AgOTf, 2,6-tert-dibutylpyridine and DCM; (ii) Amberlite IR400 
(OH). 
 
1.12 Concluding remarks 
The enzymes in the MSH pathway has been identified as a potential drug targets for 
drug discovery considering the role MSH is playing in the detoxification of 
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MSH are essential for the production of MSH and could serve as potential drug 
targets for tuberculosis co-therapy. This is based on the fact that the previous studies 
have demonstrated that inhibition of MSH genes responsible for the production of 
these enzymes has significantly reduced the survival of M.tb and M. smegmatis 
mutants. Moreover, the successful inhibition of MSH biosynthetic enzymes will lead 
to the disruption of the MSH-dependent detoxification pathway at two levels: 
biosynthesis and detoxification. 
 
1.13 Scope and objectives of the study 
(i) The primary objective of this work is to design and synthesize selective inhibitors 
targeting the glycosyltransferase MshA, the first committed step in the biosynthesis of 
MSH. These inhibitors incorporate the UDP and sugar components of the natural 
substrate, while altering the pyrophosphate moiety to abolish turnover or enhance the 
binding. Substitution of the anomeric oxygen in oligosaccharides and other 
glycoconjugates with a sulfur atom will present a very interesting class of compounds 
in the form of thioglycosides.60 Furthermore, the thioglycosylated saccharides resists 
glycosidase mediated degradation, thus making them more favorable targeted 
compounds with greater likelihood of reaching their intended target Xhu et al.61 In 
addition to their wide range of applications the S-glycosidic compounds can also be 
used as glycosyl donors, enzyme inhibitors, enzyme resistant scaffolds and enzyme 
mimetic. 
 
(ii) Perform enzyme assays and screen whole cells in order to assess and evaluate the 
effectiveness of the inhibitors synthesized towards the selectivity of MshA. 
 
(iii) In order to achieve these objectives, 1-L-myo-inositol-1-phosphate (1-L-Ins-1-P) 
had to be synthesized. 1-L-Ins-1-P is an important co-substrate required by MshA and 
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it is currently isolated from the yeast cells. This product is isolated in low yields and it 
is too expensive (400$/mg). It was decided to synthesize this substrate as large 
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CHAPTER 2 
Synthesis of 1L-myo-inositol-1-phosphate 
2.1 Introduction 
The synthesis of myo-inositol phosphate derivatives has received widespread attention 
in recent years due to its crucial roles in biological processes such as cellular signal 
transduction, homeostasis and regulation of many other important cellular processes 
in living organisms.1-4 The potential therapeutic uses of myo-inositol derivatives and 
their use as the precursor for the synthesis of other natural products have also been 
reported.5 myo-Inositol belongs to a large family of naturally occurring compounds 
known as the cyclitols and it is by far the most abundant amongst all possible nine 
inositol stereoisomers.6 
 
The nomenclature of inositols has been a subject of debate for many years. In order to 
clear the ongoing confusion about the numbering of cyclitols and also to ensure that 
the cyclitol ring is numbered consistently on the side containing the axial hydroxyl 
group, Agranoff7a has created a mnemonic in the form of turtle with the head erected 
at C-2 and the tail at C-5 (Fig. 2-1). 












                                        A                                                    B 
 
Figure 2-1: (a). Agranoff’s turtle. (b). myo-Inositol.7b The most stable chair conformation with 1-axial 
and 5-equatorial hydroxyl groups, myo-inositol has been said to resemble a turtle (Agranoff, 1978). The 
axial hydroxyl is represented by the turtle’s head (position 2) and the equatorial hydroxyls by the limbs 
and tail. 
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Loewus and Murthy8 indicated that myo-inositol is a meso compound with a plane of 
symmetry that rotates the structure about C-2 and C-5 at fixed positions (Fig. 2-2). 
Therefore the other four carbon atoms consist of two prochiral pairs, C-1: C-3 and C-
4: C-6. If the carbon ring is numbered clockwise, assignment of a single substituent 
on carbon 1 is 1L (Fig. 2-2). On the other hand, if the carbon ring is numbered anti-
























D-myo-inositol L-myo-inositol  
Figure 2-2: D/L-nomenclature and numbering for myo-inositol. 
 
1-L-myo-Inositol-1P (1-L-Ins-1-P) is a product of 1L-myo-inositol-1-phosphate 
synthase (INO1) and it is synthesized enzymatically from glucose 6-phosphate.9,10 
The Rv0046c gene was first identified in M.tb as ino1 encoding an inositol phosphate 
synthase based on the sequence similarity with yeast INO1. This was later confirmed 
genetically by Bachhawat and Mande by showing that the mycobacterial gene 
complemented a Saccharomyces cerevisiae ino1 mutant.11 In M.tb, inositol is supplied 
in the form of 1-L-Ins-1-P from glucose 6-phosphate by means of 1L-myo-inositol-1-
phosphate synthase. M.tb strains carrying the ino1 gene mutation are inositol 
auxotrophs and lack inositol-1-phosphate synthase activity. Although these mutants 
have normal levels of phosphatidyl-inositol mannosides, lipomannan and 
lipoarabinomannan, the mutants produce low levels of MSH and this could be 
attributed to the presence of myo-inositol kinases which generates 1-L-Ins-1-P which 
is required for the synthesis of MSH. Two independent studies of Loewus et al. and 
Stephens et al. have demonstrated that the inositol kinases activity produce 1-L-Ins-1-
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P in wheat germ and Dictyostelium discoideum respectively.12,13 In yeast 
(Saccharomyces cerevisiae), biosynthesis of 1-L-Ins-1-P is a tightly regulated 
processes.14 
 
The history of myo-inositol-1-phosphate in the literature dates back to 1959.15 Ballou 
and Pizer reported the synthesis of myo-inositol-1-phosphate from the base hydrolysis 
of phosphoinositide isolated from soybean.15 Subsequently absolute configuration and 
the optical rotation between the synthetic and naturally occurring myo-inositol-1-
phosphate was established. Ballou and Pizer synthesized an asymmetric myo-inositol-
1-phosphate using galactinol as a starting material and compared it with the naturally 
occurring soybean myo-inositol-1-phosphate. The synthetic compound was found to 
have assumed the absolute configuration of galactinol whereas the soybean myo-
inositol-1-phosphate was found to be its mirror image (Fig. 2-3).16 Lardy17 proposed 
that the synthetic compound be called D-myo-inositol-1-phosphate whereas the 
soybean isolate would be referred to as L-myo-inositol-1-phosphate (Fig. 2-3). The 
previous study by Sculimbrene et al.18 also reported the synthesis of optically pure 
enantiomers of D-myo-inositol-1-phosphate and D-myo-inositol-3-phosphate by using 
an enantioselective pentapeptide catalyst. The first comprehensive linear synthesis of 
optically pure 1-L-Ins-1-P enantiomer was reported by Billington and co-workers.19 













Synthetic compound Soybean compound  
 
Figure 2-3: Mirror images of myo-inositol phosphate. 
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A key objective in this research effort is to synthesize 1-L-Ins-1-P (Fig 2-4) which is 
the required co-substrate for the enzyme, MshA, in the first step of mycothiol 


































Figure 2-4: The structures of 1-L-Ins-1-P (clockwise) or 1-D-Ins-3-P (anti-clockwise). 
 
2.2 Rationale for synthesizing 1-L-Ins-1-P 
In order to discover inhibitors of glycosyltransferase (MshA) activity, an adequate 
supply of 1-L-Ins-1-P was necessary. Although 1-L-Ins-1-P is commercially available 
in small quantities, it was prudent to synthesize it in our laboratory as large quantities 
were needed to conduct several assay experiments. Also, the commercially available 
substrate is primarily isolated from yeasts cells, it took many months for delivery, is 
costly and unsustainable at 400 $/mg. It is for this reason that considerable effort has 
been devoted towards the synthesis of 1-L-Ins-1-P. To the best of our knowledge 
there is no known report that has presented the full synthetic details of 1-L-Ins-1-P 
other than that of Spiers et al.20a It was for this reason that the synthesis of 1-L-Ins-1-
P was pursued. Furthermore, the synthesis of 1-L-Ins-1-P also produces the inositol 
part required for MSH synthesis. While MSH synthesis was not part of the objectives 
of this project, it was required by another project in our lab. 
 
2.3 Retrosynthetic approach of 1-L-Ins-1-P 
In order to synthesize the target molecule (1-L-Ins-1-P), a selectively protected L-
myo-inositol derivative is required. To resolve this problem, a retrosynthetic approach 
was envisaged as outlined in Fig. 2-5. A selectively protected L-myo-inositol 
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derivative (I) could be obtained indirectly from commercially available myo-inositol. 











































































Figure 2-5: Retrosynthetic analysis of 1-L-Ins-1-P. L-myo-Inositol leads to the synthesis of 1-L-Ins-1-
P whereas D-myo-inositol is crucial for the synthesis of MSH. D-myo-inositol is highlighted in red 
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2.4 Synthetic approach toward the 1-L-Ins-1-P 
2.4.1 Ketal protecting groups of myo-inositol 
The synthesis of our target molecule 1-L-Ins-1-P (Fig. 2-4) started with ketalization of 
myo-inositol, which is a cheap and readily available starting material. The ketalization 
of myo-inositol was carried out using 1-ethoxycyclohexene which was synthesized in 
situ using a mixture of cyclohexanone dimethyl ketal and p-toluenesulphonic acid 
monohydrate following the procedure reported by Vacca et al.21 The reaction resulted 
in the formation of three bis-cyclohexylidene ketals of myo-inositol (2-1), (2-2) and 
(2-3) (Scheme 2-1) in good yield. Partial hydrolysis of the trans-ketal 
diastereoisomers (2-1), (2-2) and (2-3) in the presence of a catalytic amount of p-
toluenesulphonic acid gave mono-ketal, (2-4) as the major product. The product was 
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2.4.2 Synthesis of 3,4,5,6-tetra-O-benzyl-1,2-O-cyclohexylidene-D/L-myo-inositol 
The global benzylation of 1,2-O-cyclohexylidene-myo-inositol (2-4) with excess 
benzyl bromide in the presence of NaH afforded 3,4,5,6-tetra-O-benzyl-1,2-O-
























Scheme 2-2 Reaction conditions: (iii) BnBr, NaH, DMF, 0 C - 80 C; 85% (iv) 80% aq. AcOH; 79%. 
 
The structure of compound (2-5) was confirmed by 1H NMR with the appearance of 
signals resonating at δH 7.45 – 7.17 ppm (m, 20H). Thus, confirming the presence of 
the benzyl aromatic protons. The other diagnostic feature was the presence of signals 
at δ 1.84 – 1.30 ppm (m, 10H), which confirmed the presence of cyclohexyl 
methylene protons. Also evidence of benzylation was the presence of benzyl 
methylene protons integrating for eight protons resonating between δH 4.90 and δH 
4.72 ppm as a multiplet. 13C NMR spectroscopy further confirmed the structure by 
indicating the presence of key benzyl signals resonating at δC 138.71 - 127.45 ppm. 
 
Hydrolysis of 3,4,5,6-tetra-O-benzyl-1,2-O-cyclohexylidene-DL-myo-inositol (2-5) in 
aqueous acetic acid gave a racemic mixture of 3,4,5,6-tetra-O-benzyl-myo-inositol (2-6) 
(Scheme 2-2). The structure of 3,4,5,6-tetra-O-benzyl-myo-inositol (2-6) was confirmed 
by the 1H NMR spectrum and by comparison with a spectrum reported in literature.22 
The key diagnostic being the disappearance of the signals associated with the 
cyclohexylidene protons and the appearance of a broad singlet peak at δH 2.5 ppm 
integrating for two protons corresponded to the two hydroxyl groups of the diol. In 
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addition, the IR spectrum of 3,4,5,6-tetra-O-benzyl-myo-inositol (2-6) showed 
absorption at νmax/cm-1 3400, confirming the presence of a hydroxyl group. 
 
2.4.3 Regioselective allylation of the 1,2-diol (2-7) 
The 3,4,5,6-tetra-O-benzyl-myo-inositol (2-6) derivative of myo-inositol comprises of 
an equatorial hydroxyl group at the C-1 position and the axial hydroxyl group at C-2 
position, thus selection of the desired hydroxyl remains a challenge. However, this 
problem has been overcome by selective temporary allyl protection of the hydroxyl 
group at C-1, followed by the benzyl protection of the remaining hydroxyl groups and 
finally removing the C-1 protecting group using a deallylation procedure. Thus, the 
regioselective allylation23 of 3,4,5,6-tetra-O-benzyl-myo-inositol (2-6) was achieved 
by sequential treatment of 3,4,5,6-tetra-O-benzyl-myo-inositol (2-6) with Bu2SnO 
followed by allyl bromide to give 1-O-allyl-3,4,5,6-tetra-O-benzyl-DL-myo-inositol 
(2-7) in 63% yield (Scheme 2-3).24 
 
The allylation mechanism involves the formation of dibutylstannylidene acetals. Xue 
and Guo25 proposed that the regioselective allylation of the diol occurs as a result of 
steric hindrance at 1-position of the tin complex (Fig. 2-6) which is more sterically 
hindered than the 6-position. It can be suggested that the selective allylation of an 
equatorial hydroxyl group of 3,4,5,6-tetra-O-benzyl-DL-myo-inositol (2-6) is 
favoured because it is less hindered as compared to an axial hydroxyl group because 
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The structure of 1-O-allyl-3,4,5,6-tetra-O-benzyl-DL-myo-inositol (2-7) was 
confirmed by 1H NMR analysis, which indicated the presence of the allyl moiety as 
well as the inositol ring protons, H-1 and H-2 with a small coupling of J = 2.8 Hz and 
larger coupling of J = 9.5 Hz between H-1 and H-6 and thus confirming the axial 
orientation of the H-1 proton. Furthermore, there was a presence of a multiplet around 
δH 5.93 ppm for H-2' and a doublet of doublets which resonated at δH 5.28 and δH 5.18 
ppm for H-3'a and H-3'b, respectively. In addition, there was two upfield signals for 






























Scheme 2-3 Reaction conditions: (v) (a) Bu2SnO, toluene, reflux; (b) allyl bromide, DMF, 80 C, 4hr; 
83% (vi) BnBr, NaH, DMF; 90%. 
 
In addition, the IR spectrum of 1-O-allyl -3,4,5,6-tetra-O-benzyl-DL-myo-inositol (2-
7) showed an absorption νmax/cm-1 3400, confirming the presence of a hydroxyl group. 
The mono-benzylation of an axial hydroxyl group ensured a fully protected 1-O-allyl 
-2,3,4,5,6-penta-O-benzyl-DL-myo-inositol (2-8) in 90% yield (Scheme 2-4). The 
structure was confirmed by its 1H and 13C NMR spectra. 
 
A diagnostic feature was the disappearance of the hydroxyl protons of 1-O-allyl-
3,4,5,6-tetra-O-benzyl-DL-myo-inositol (2-7) and the increase in the ratio of benzylic 
protons of 1-O-allyl-2,3,4,5,6-penta-O-benzyl-DL-myo-inositol (2-8). Allylic and 
myo-inositol ring proton signals remained similar in pattern indicating that no other 
transformation had taken place. 
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Several possible mechanisms for the deallylation of allyl ethers with a palladium 
catalyst exist. Elliott et al.29,30,31 suggested that PdCl2 undergoes an anti-Markovnikov 
methoxy-palladation followed by β-alkoxy cleavage resulting in the formation of the 
desired deprotected hydroxyl group. It was further postulated that the PdCl2 
isomerises the allyl group to the corresponding enol ether and that a low concentration 
of HCl is generated, which catalyses methanolysis of the enol ether.29 
 
Deallylation32 of 1-O-allyl -2,3,4,5,6-penta-O-benzyl-DL-myo-inositol (2-8) (Scheme 
2-4) with PdCl2 in a mixture of methanol/ethanol gave the racemic mixture of 
2,3,4,5,6-penta-O-benzyl-DL-myo-inositol (2-9) in good yield (83%). The 
spectroscopic data indicated the disappearance of signals associated with the allyl 
moiety. In addition, the IR spectra showed the absorption at νmax/cm-1 3450 which 






Scheme 2-4 Reaction conditions: (vii) PdCl2, EtOH-MeOH; 79%. 
 
2.4.4 Resolution of racemic D/L-myo-inositol 
Having successfully synthesized the appropriately protected racemic, 2,3,4,5,6-penta-
O-benzyl-DL-myo-inositol (2-9) with the free hydroxyl group at the C-1 position, the 
next step was to perform a chiral resolution of the racemic 2,3,4,5,6-penta-O-benzyl-
DL-myo-inositol (2-9). The separation was achieved by chiral resolution utilizing the 
camphanate ester of (2-9). Thus, the esterification of the racemic alcohol with (R)(-)-
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chloroform gave a mixture of the diastereoisomeric camphanic esters (2-10) and (2-
11) in quantitative yield (Scheme 2-5).19 
 
The esters were separated by multiple rounds of silica-gel column chromatography to 
effect complete separation in order to obtain diastereoisomerically pure material. 
Furthermore, the correct stereochemistry of the desired stereoisomer 2,3,4,5,6-penta–
O-benzyl-1-O-[(1S-(-)-camphanoyl]-L-myo-inositol (2-10) was confirmed through 
association of its previously reported optical rotation. [[α]20D = -18° (c = 1, CHCl3, for 
D-1-O-[(1S)-(-)-camphanoyl]-2,3,4,5,6-penta-O-benzyl-myo-inositol (2-11) and L-
diastereoisomer, L-1-O-[(1S)-(-)-camphanoyl]-2,3,4,5,6-penta-O-benzyl-myo-inositol 
(2-10), [α]20D = +11.8° (c = 1, CHCl3)].24 The discrepancy in optical rotation could be 
due to the presence of a small amount of the D-diastereoisomer or simply the error in 












































Scheme 2-5 Reaction conditions: (viii) Camphanic acid chloride, Et3N, DMAP, DCM, RT; 48%.  
 
Basic hydrolysis of the desired L-enantiomer (2-10) (Scheme 2-6) with KOH in 
ethanol under gentle reflux gave the desired alcohol (2-12) in low yield (39%) 
following the work-up and column chromatography. The spectroscopic data 
confirmed the disappearance of the protons associated with the camphonate esters. 
 

















Scheme 2-6 Reaction conditions: (ix) KOH, EtOH, reflux, 2hr; 85%. 
 
2.4.5 Attempted phosphorylation of 2,3,4,5,6- pentabenzyl myo-inositol 
The final stage of the synthetic plan (Scheme 2-7) involves phophorylation of penta-
O-benzylated inositol derivative (2-12) followed by deprotection to give the pure 
enantiomer of 1-L-Ins-1-P. The latter strategy worked well for Billington et al.19, who 
reported the synthesis of racemic 1-D/L-myo-inositol-1-P as the crystalline bis-
cyclohexylammonium salt in 95% yield. Although this product was reported without 
spectroscopic data. 
 
Efforts to convert 2,3,4,5,6- pentabenzyl myo-inositol (2-12) to the phosphate ester (2-
13) were attempted, using (PhO)2POCl as phosphorylating agent (Scheme 2-7). Thus, 
(PhO)2POCl in the presence of a catalytic amount of DMAP and Et3N proved to be 
unsuccessful. This is despite varying all reaction parameters as previously reported for 






















Scheme 2-7 Proposed reaction condition: (x) (PhO)2POCl, DCM, Et3N, DMAP, 25 C. 
 
It was reasoned that the phosphorylation of mono-hydroxy pentabenzyl myo-inositol 
(2-12) could not occur due to steric hindrance. This could be attributed to the fact that 
diphenylphosphoryl chloride is a relatively bulky molecule with relatively large 
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vicinal benzyl groups. Figure 2-7 below shows the 3D view of this steric demand of 
this molecule (2-13). 
 




Figure 2-7: 3D possible conformation of (2-13) showing steric demand (Chem3D Ultra, minimized 
energy). 
 
Other phosphorylating agents such as dibenzylphosphoryl chloride have been tried but 
it also did not result in the target phosphate ester. In addition, several attempts were 
made to synthesize small phosphorylating agents in the laboratory with no success. As 
a result we could not proceed with subsequent phosphorylation and deprotection steps 
for the synthesis of 1-L-Ins-1-P using this synthetic approach (Scheme 2-8).  
 





















































Scheme 2-8 Proposed reaction condition: (xi) BnBr, NaH, DMF, (xii) Pd/C, H2, EtOH-H2O. 
 
2.5 Alternative synthetic route to 1-L-Ins-1-P 
Due to the lack of successful synthesis of 1-L-Ins-1-P using the synthetic route 
involving benzyl protection (Section 2.4, scheme 2-7), an alternative route was sought 




















































R= Bn  
Figure 2-8: Retrosynthetic analysis of 1-L-Ins-1-P (Second approach). 
 
As indicated by our retrosynthetic analysis (Fig. 2-8), the total synthesis of 1-L-Ins-1-
P, requires a coupling of the phosphorylating agent to a suitably protected L-myo-
Chapter 2                                                       Synthesis of 1L-myo-inositol-1-phosphate 
50 
inositol enantiomer. The selectively protected enantiomer can be achieved through the 
hydrogenolysis of the benzyl protecting group, followed by the hydrolysis of 
cyclohexylidene and camphor respectively. Finally selectively protected 1L-myo-
inositol can be achieved via the transesterification of the diphenylphosphate groups 
with the dibenzylphosphate group, followed by phosphorylation and chiral resolution 
of the racemic mixture. 
 
Accordingly, the selective protection of myo-inositol using the cyclohexylidene to 
give 2,3:5,6-dicyclohexylidene myo-inositol (2-3), followed by selective mono-
benzylation of myo-inositol at C-1 to give the desired alcohol (2-16) as a racemic 
mixture, which was subsequently separated by chiral resolution of the camphanate 
ester (Scheme 2-9). Hydrogenolysis of the benzyl groups of desired L-enantiomer (2-
17) resulted in the formation of 4-O-camphanoyl-2,3,5,6-di-O-cyclohexylidene-L-
myo-inositol (2-18).  
 
Thus, 4-O-camphanoyl-2,3,5,6-di-O-cyclohexylidene-1-O-benzyl-L-myo-inositol (2-
17) was prepared in two steps from commercially available myo-inositol by the 
method of Billington.19 The benzyl group of (2-17) was removed by hydrogenolysis 
using 10% palladium on carbon in aqueous ethanol to afford 4-O-camphanoyl-
2,3,5,6-di-O-cyclohexylidene-L-myo-inositol (2-18) as a white solid in quantitative 
yield (Scheme 2-9). 

















































Scheme 2-9 Reaction condition: (i) BnBr, NaH, DMF; (ii) Camphanic acid chloride, Et3N, DMAP, 
DCM, RT; (iii) Pd/C, H2, 50 psi, RT; 91%. 
 
4-O-camphanoyl-2,3,5,6-di-O-cyclohexylidene-L-myo-inositol (2-18) was used in the 
subsequent step without any further purification. The 1H NMR spectrum of the crude 
product showed complete disappearance of the benzylic protons. The IR spectrum 
was also used to confirm the presence of the alcohol in 4-O-camphanoyl-2,3,5,6-di-O-
cyclohexylidene-L-myo-inositol (2-18) which indeed confirmed the presence of a 
hydroxyl group with absorption band resonating at νmax/cm-1 3455. 
 
Following the successful synthesis of 4-O-camphanoyl-2,3,5,6-di-O-cyclohexylidene-
L-myo-inositol (2-18), the 4-O-camphanoyl-2,3,5,6-di-O-cyclohexylidene-1-O-
diphenylphosphoryl-L-myo-inositol (2-19) could be synthesised following the 
phosphorylation of (2-18) using the diphenylphosphoryl chloride in the presence of 
catalytic amount of DMAP and Et3N in DCM (Scheme 2-10). Analysis of the 1H 
NMR spectrum revealed the presence of phenyl protons resonating between δH 7.18 
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and 7.23 ppm (m, 10H). The presence of the phosphate group was further confirmed 
by the 31P NMR spectrum, which indicated the presence a strong phosphate resonance 
at -12.45 ppm. This value is consistent with literature value of similar compounds.20a 
 
Transesterification of (2-19) in the presence of benzyl alcohol and strong base (NaH) 
in THF gave 4-O-camphanoyl-2,3,5,6-di-O-cyclohexylidene-1-O-
dibenzylphosphoryl-L-myo-inositol (2-20) (Scheme 2-10). The transesterification of 
the phosphate protecting groups between the phenyl and the benzyl groups deemed 
necessary because benzyl protecting groups are better leaving groups and will 
therefore facilitate the final deprotection of the product in a single step. In addition, 
the transesterification step deemed necessary because it would prevent the possible 
migration of phosphate group from position one to position two of the myo-inositol. 
Analysis of 1H NMR spectroscopic data of 4-O-camphanoyl-2,3,5,6-di-O-
cyclohexylidene-1-O-dibenzylphosphoryl-L-myo-inositol (2-20) indicated the 
presence of methylene protons that resonated between δH 5.12 and 5.25 ppm (m, 4H) 
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Basic hydrolysis of 4-O-camphanoyl-2,3,5,6-di-O-cyclohexylidene-1-O-
dibenzylphosphoryl-L-myo-inositol (2-20) with KOH under the gentle reflux gave the 
2,3,5,6-di-O-cyclohexylidene-1-O-dibenzylphosphoryl-L-myo-inositol (2-21) in low 
yield (Scheme 2-11). The crude 1H NMR spectroscopic data confirmed the presence 
of the benzyl aromatic protons (resonating at δH 7.41 – 7.19 ppm) and benzyl 
methylene protons (resonating at δH 4.89 – 4.70 ppm). The other diagnostic feature 
was the presence of cyclohexylmethylene protons resonating δH 1.80 – 1.28 ppm. 
Most importantly, the crude 1H NMR spectroscopic data confirmed the disappearance 
of the protons associated with the camphonate esters. In addition, crude 31P NMR 
spectroscopic data confirmed the presence of phosphate moiety by showing a strong 
resonance at -13.05 ppm. This product was used in the next step without further 
purification.  
 
Acidic hydrolysis of cyclohexylidene groups of compound (2-21) in aqueous acetic 
acid gave the 1-O-dibenzylphosphoryl-L-myo-inositol (2-22) (Scheme 2-11). The 
structure of (2-22) was confirmed by the analysis of the 1H NMR spectrum and the 
key diagnostic signal was the disappearance of the cyclohexylidene methylene 
protons. The benzylic protons remained intact emphasizing that no transformation had 





































Scheme 2-11 Reaction condition: (vi) KOH, EtOH, reflux, 2 h; 65% (vii) 80% aq. AcOH, reflux, 2 hr; 
42%. 
Chapter 2                                                       Synthesis of 1L-myo-inositol-1-phosphate 
54 
 
Finally, the removal of the remaining two benzyl protecting groups on the phosphate 
moiety via hydrogenation of (2-22) gave 1-L-Ins-1-P (2-15, (Scheme 2-12)) which 
was isolated as a water soluble cream white powder following lyophilization. The 31P, 
13C and 1H NMR spectroscopic data were used to confirm the structure of the target 























Scheme 2-12 Reaction condition: (viii) Pd/C, H2, 50 psi, RT; 71%. 
 
The 1H NMR spectrum data of 1-L-Ins-1-P (2-15) showed the disappearance of key 
signals associated with the benzyl protons which were indicative that the molecule 
was successfully deprotected. Furthermore, the resonance of the H-1 shifted furthest 
downfield to approximately 4.71 ppm and this deshielding could be attributed to the 
phosphorylation on C-1. However, H-1 protons could not be properly integrated in 
this region 4.71 ppm due to the hygroscopic nature of the compound and as such some 
of the signals were suppressed by a huge water peak. The pair of enantiotopic protons 
(H-2 and H-6; H-3 and H-5) resonated at approximately 4.10 and 3.93 ppm 
respectively. This pair of enantiotopic protons was followed by H-4, which resonated 
at 3.81 ppm which was in agreement with that reported in literature.20a,33,34 
 
Furthermore the 13C NMR spectroscopic data corroborated by the 1H NMR spectrum 
showed the appearance of key signals. The 13C NMR gave four resonances of 
different intensities resonating between δC 66.80 and 60.45 ppm and thus confirming 
the symmetry of the molecule (Fig. 2-9).  






























Figure 2-9: 13C NMR spectrum of 1-L-Ins-1-P (2-15) in D2O. 
 
In addition, the 1H-decoupled 31P NMR spectroscopic data was used to confirm the 
presence of phosphate moiety by showing a strong resonance at 5.23 ppm which was 
in agreement with that reported in the literature.20a  
 
However, in order to confirm that the phosphorus moiety is attached to the inositol 
ring, the 1H-coupled 31P NMR spectrum of 1-L-Ins-1-P was obtained. The key feature 
of this spectrum was the appearance of doublet, caused by H-C-O-P splitting 
resonating at 5.14 ppm. Thus, providing an additional proof that phosphorus moiety is 
attached to the inositol ring. The observed coupling constant between H-1 and 
phosphorus is 9.0 Hz, a value in good agreement with the observation made 
considering the coupling is long range. The present 1H-coupled 31P NMR spectral 
evidence for the formation of 1-L-Ins-1-P (2-15) is in agreement with the work of 
Spiers et al20a who reported 1-L-Ins-1-P as the biscyclohexylammonium salt. The 1H-
coupled 31P NMR spectrum further corroborated with the study of Chen et al.20b 
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which reported 1H-coupled 31P NMR spectrum of 1-L-Ins-1-P isolated from cell 
extracts as a doublet with the a large coupling constant (JHP 8.5). 
 






















Figure 2-10: Superimposed 31P NMR spectra of 1-L-Ins-1-P (2-15) in D2O. 1H-decoupled 31P NMR 
shows a strong singlet peak (Blue). 1H-coupled 31P NMR appears as a doublet due a splitting caused by 
H-C-O-P (Green). 
 
Finally, a HRMS evaluation gave an m/z 262.0358 [M]+, C6H13O9P which requires 
m/z 262.0340 [M]+, thus supporting the proposed structure of compound (2-15) (Fig. 
2-11). In addition, a base peak fragment of m/z 244.1900 [M] +, corresponding to a 
possible loss of one oxgen molecule in C6H13O9P was observed. 
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Figure 2-11: TIC extracted (top) and ESI HRMS spectrum (bottom) of 1-L-Ins-1-P (2-15) 
 
2.6 Conclusion 
In conclusion, the substrate (1-L-Ins-1-P) (2-15) was successfully synthesized in total 
of 9 steps from myo-inositol. Furthermore no steric hindrance at the phosphorylation 
step was experienced with the latter procedure in comparison with the former 
procedure. The spectroscopic techniques employed unambiguously supported the 
target molecule structure. Thus, through this synthetic effort 1-L-Ins-1-P was 
available for enzyme assays using Corynebacterium glutamicum MshA. Although, in 
the end commercially obtained substrates (1-L-Ins-1-P and UDP-GlcNAc) sufficed 
for the enzyme assays performed here. However, larger sized libraries screening will 
require more substrate. The details of the enzyme assays will be discussed in Chapter 
5.  
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2.7 Experimental 
All the dry solvents used in all the reactions were purchased from commercial 
suppliers. 1H NMR spectra were performed in deuterated solvents [chloroform 
(CDCl3), dimethyl sulfoxide (DMSO), methanol (CD3OD) and D2O] on either a 
Varian unity spectrometer 400 MHz (100 MHz for 13C) or Varian mercury 
spectrometer 300 MHz (75 MHz for 13C) using TMS as an internal standard and 
H3PO4 for 31P NMR. The chemical shift (δ) is given in ppm relative to TMS (δ 0.00) 
or Na2HPO4. The coupling constant J is given in Hz. The melting points were 
determined using the Reichert Jung Thermovar hot stage microscope and are 
uncorrected. The reactions were monitored by thin layer chromatography (TLC) using 
Merck aluminium silica gel F254 plates. All the fluorescent compounds were 
visualized under ultra violet (UV) light at the wavelength of 254 nm and all the non-
fluorescent compounds were visualized by spraying the TLC plate with anisaldehyde, 
ninhydrin or ceric ammonium sulfate spray respectively followed by heating the plate 
until the colour develops.  
 
2.7.1 Synthesis of 1,2-O-cyclohexylidine-DL-myo-inositol (2-4)35 
A mixture of myo-inositol, 1-ethoxycyclohexene and p-
toluenesulphonic acid monohydrate in dry DMF was heated at 
100 C for 4 hr. The solution was allowed to cool down to 
room temperature before being diluted with DCM and washed 
sequentially with 5% aqueous NaHCO3, water and saturated NaCl. The organic phase 
was dried and evaporated to give an oil. Subsequently the oil was dissolved in the 
minimum amount of acetone into which petroleum ether was added. The product 
crystallized out as a white solid. After re-acidification (0.2 g TsOH), the filtrate 
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and washed several times with pet ether to afford 1,2-O-cyclohexylidine-DL-myo-
inositol (2-4) as a white solid (11.0 g, 76%). M.p (179-181 C) (lit. 179-180).35 
 
2.7.2 Synthesis of 3,4,5,6-tetra-O-benzyl-1,2-O-cyclohexylidine-DL-myo-inositol 
(2-5)36a 
Anhydrous 1,2-O-cyclohexylidine-DL-myo-inositol (0.60 
g, 2.31 mmol) in THF (10 mL) was cooled to 0 C, 
followed by the addition of NaH (60%, 1.06 g, 15.9 
mmol) portion-wise whilst stirring. After 30 min, benzyl 
bromide (1.4 mL) was added slowly, followed by the removal of the ice bath and the 
heterogeneous mixture were heated at reflux overnight. The resulting clear solution 
was quenched with methanol (10 mL), which was allowed to stir for 5 minutes, 
followed by the addition of water (10 mL). The organic solvent was removed under 
reduced pressure and the aqueous mixture was extracted with ethyl acetate (100 mL x 
2). The pooled organic layers were then dried over MgSO4 after which it was 
concentrated under reduced pressure. Purification by chromatography using silica-gel 
column (60 g; EtOAc/Pet ether, 3:7) gave 3,4,5,6-tetra-O-benzyl-1,2-O-
cyclohexylidene-D,L-myo-inositol as an oil (1.22 g, 85%). 1H NMR (400 MHz, 
CDCl3) δ 7.45 – 7.17 (m, 20H, 4 x Ph), 4.94 – 4.67 (m, 8H, 4 x PhCH2), 4.29 (dd, J = 
5.7, 3.8 Hz, 1H, H-2), 4.11 (dd, J = 7.2, 6.3 Hz, 1H, H-6), 3.91 (t, J = 8.2 Hz, 1H, H-
3), 3.82 (dd, J = 9.6, 7.0 Hz, 1H, H-4), 3.69 (dd, J = 8.3, 3.8 Hz, 1H, H-1), 3.41 (dd, J 
= 9.6, 8.2 Hz, 1H, H-5), 1.84 – 1.30 (m, 10H, C(CH2)5,-cyclohexylidene). 13C NMR 
(75 MHz, CDCl3): δ 138.71, 138.66, 138.62, 137.34, 138.33, 128.34, 128.32, 128.26, 
128.23, 127.96, 127.94, 127.91, 127.73, 127.58, 127.50, 127.45, 110.44 (quaternary 
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74.03, 73.93, 73.11(2 x PhCH2), 37.38, 35.04, 25.08, 23.94, 23.68 (5 x CH2, 
cyclohexylidene). 
 
2.7.3 Synthesis of 3,4,5,6-tetra-O-benzyl-myo-inositol (2-6)36b,c 
3,4,5,6-Tetra-O-benzyl-1,2-O-cyclohexylidine-DL-myo-
inositol (1 g, 1.61 mmol) was suspended in aqueous acetic 
acid (80%, 25 mL) and the reaction mixture was heated to 
reflux at 100 C for 2 hr. Upon completion, the solvent was removed under reduced 
pressure. The residue was dissolved in petroleum ether upon which a white solid 
crystallized (0.69 g, 79%). M.p (127 - 129 C) (lit.36b 127 - 128 C, lit.36c 127 C) 1H 
NMR (400 MHz, CDCl3): δ 7.45 – 7.14 (m, 20H, 4 x Ph), 4.99 – 4.58 (m, 8H, 4 x 
PhCH2), 4.18 (t, J = 2.9 Hz, 1H, H-2), 3.97 (t, J = 9.5 Hz, 1H, H-4), 3.88 (t, J = 9.5 
Hz,1H, H-6), 3.49 (t, J = 9.5 Hz, 1H, H-5), 3.47 (m, 1H, H-1), 3.46 (t, J = 9.5 Hz,1H, 
H-3), 2.50 (s, 2H, -OH). 13C NMR (100 MHz, CDCl3): δ 138.78, 138.68, 138.65, 
137.82, 128.72, 128.63, 128.56, 128.44, 128.41, 127.93, 127.91, 127.76, 127.68, 
127.67, 127.63, 127.61, 83.34, 81.73, 81.42, 80.15, 75.94, 75.75, 75.63, 72.81, 71.77, 
69.24. 
 
2.7.4 Synthesis of 1-O-allyl-3,4,5,6-tetra-O-benzyl-DL-myo-inositol (2-7) 
A mixture of 3,4,5,6-tetra-O-benzyl-myo-inositol (2-6) 
(0.5 g, 0.925 mmol) and Bu2SnO (0.025 g, 0.100 mmol) 
was dissolved in toluene (20 mL) and the reaction 
mixture was heated to reflux (111 C) for 4 hr. The reaction mixture was then cooled 
to room temperature and the solvent was removed under reduced pressure. The 
residue was dissolved in DMF (5 mL) followed by the addition of allyl bromide (10 
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fluoride (0.04 g, 0.263 mmol). Subsequently, the reaction mixture was allowed to 
equilibrate to room temperature whilst stirring overnight. Upon completion, the 
reaction mixture was extracted with EtOAc (100 mL) and washed with water (100 
mL). The organic layer was concentrated under the reduced pressure. Purification by 
chromatography using a silica-gel column (50 g, EtOAc/Pet ether, 3: 7, Rf 0.1) gave 
1-O-allyl -3,4,5,6-tetra-O-benzyl-DL-myo-inositol (2-7) as an oil (0.45 g, 83%). 1H 
NMR (400 MHz, CDCl3): δ 7.38 – 7.21 (m, 20H, 4 x Ph), 5.93 (m, 1H, H-2'), 5.28 
(dd, J = 17.2, 1.4 Hz, 1H, H-3'a), 5.18 (dd, J = 10.4, 1.4 Hz, 1H, H-3'b) 4.91 – 4.70 (m, 
8H, 4 x PhCH2), 4.22 (t, J = 2.8 Hz, 1H, H-2), 4.20 – 4.15 (m, 2H, H-1'a, H-1'b), 4.22 
(t, J = 9.5 Hz, 1H, H-6), 3.47 – 3.39 (m, 1H, H-4), 3.97 (t, J = 9.6 Hz, 1H, H-5), 3.42 
(dd, J = 9.6, 2.8 Hz, 1H, H-3), 3.29 (dd, J = 9.6, 2.8 Hz, 1H, H-1).13C NMR (101 
MHz, CDCl3): δ 138.78, 138.68, 138.65, 138.27, 128.48, 128.42, 128.36, 128.34, 
128.01, 127.83, 127.79, 127.76, 127.68, 127.63, 127.60, 127.54, 83.63, 82.19, 81.92, 
81.15, 77.34, 75.85, 75.73, 75.50, 74.77, 73.01, 72.45. 
 
2.7.5 Synthesis of 1-O-allyl -2,3,4,5,6-penta-O-benzyl-DL-myo-inositol (2-8) 
To a solution of 1-O-allyl -3, 4, 5, 6-tetra-O-benzyl-L-
myo-inositol (2-7) (0.20 g, 0.344 mmol) in THF (2 mL) 
was added portion-wise NaH (60 %, 0.0840 g, 3.50 
mmol) at 0 C. The reaction mixture was allowed to stir for 30 min at 0 C, followed 
by the addition of benzyl bromide (0.06 mL, 0.504 mmol). The reaction mixture was 
heated to reflux (66 C) for 3 hr. The reaction mixture was quenched with MeOH (5 
mL) and allowed to stir for 30 minutes, followed by the addition of water (5 mL). The 
MeOH was removed under reduced pressure and the aqueous phase extracted with 
EtOAc (100 mL x 2). The organic solvent was washed twice with saturated NaCl (100 
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concentrated under reduced pressure. Purification by chromatography using a silica-
gel column (20 g, EtOAc/Pet ether, 1: 19) gave 1-O-allyl -3,4,5,6-tetra-O-benzyl-L-
myo-inositol (2-8) as an oil (0.180 g, 90%). 1H NMR (300 MHz, CDCl3): δ 7.37 – 
7.19 (m, 25H, 5 x Ph), 5.97 – 5.84 (m, 1H, H-2'), 5.30 (dd, J 17.2 Hz, 1.7 Hz, 1H, H-
3' a), 5.17 (dd, J 10.4 Hz, 1.6 Hz, 1H, H-3' b) 4.96 – 4.73 (m, 10H, 5 x PhCH2), 4.13 – 
3.96 (m, 5H, H-2, H-4, H-6, H-1' a, H-1' b ), 3.46 (t, J = 9.2 Hz, 1H, H-5), 3.37 (dd, J 
= 9.9, 2.3 Hz, 1H, H-3), 3.26 (dd, J = 9.8, 2.3 Hz, 1H, H-1). 13C NMR (101 MHz, 
CDCl3): δ 139.05, 138.97, 138.95, 138.93, 138.91, 138.43, 128.54, 128.35, 128.17, 
128.14, 128.08, 127.82, 127.77, 127.68, 127.56, 127.54, 127.45, 127.42, 127.39, 
116.64, 83.77, 81.74, 81.71, 80.94, 80.78, 77.02, 76.69, 75.83, 74.42, 74.14, 72.86, 
71.63.  
 
2.7.6 Synthesis of 2,3,4,5,6-penta-O-benzyl-DL-myo-inositol (2-9) 
To a solution of 1-O-allyl -3,4,5,6-tetra-O-benzyl-D-myo-
inositol (2-8) (0.70 g, 1.04 mmol) in EtOH/MeOH (1:1, 8 
mL) was added PdCl2 (0.034 g, 0.192 mmol). The mixture 
was allowed to stir at room temperature for 5 hr. Upon 
completion the PdCl2 solids were filtered through celite and the filtrate was 
concentrated under reduced pressure. Purification by chromatography using a silica-
gel column (70 g, EtOAc/Pet ether, 3:7, Rf 0.2) gave 2,3,4,5,6-penta-O-benzyl-DL-
myo-inositol (2-9) as an oil (0.52 g, 79%). 1H NMR (300 MHz, CDCl3): δ 7.40 – 7.22 
(m, 25H, 5 x Ph), 5.01 – 4.67 (m, 10H, 5 x PhCH2), 4.09 (d, J = 9.6 Hz, 1H, H-4), 
4.04 (t, J = 2.0 Hz, 1H, H-2), 3.86 – 3.78 (m, 1H, H-6), 3.52 (d, J = 4.3 Hz, 1H, H-3), 
3.51 – 3.47 (m, 1H, H-5), 3.47 – 3.44 (m, 1H, H-1), 2.23 (d, J = 6.4 Hz, 1H, OH). 13C 
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128.31, 128.00, 127.82, 127.77, 127.75, 127.67, 127.61, 127.58, 127.54, 83.63, 82.20, 
81.92, 81.20, 76.70, 75.85, 75.73, 75.50, 74.77, 73.01, 72.44.  
 
2.7.7 Synthesis of 2,3,4,5,6-penta–O-benzyl-1-O-[(1S-(-)-camphanoyl]-L-myo-
inositol (2-10) 
To a solution of 2,3,4,5,6-penta-O-benzyl-D/L-myo-
inositol (2-9) (1.56 g, 2.48 mmol) in DCM (20 mL) 
was added camphanic acid chloride (0.695 g, 3.21 
mmol), Et3N (1.35 mL, 9.85 mmol) and DMAP (0.06 
g, 0.49 mmol). The reaction was allowed to stir at 
room temperature overnight. 2,3,4,5,6-Penta–O-benzyl-1-O-[(1S-(-)-camphanoyl]-L-
myo-inositol (2-10) was obtained as an amorphous solid. Purification by 
chromatography using a silica-gel column (n-hexane/diethyl ether, 1: 1, Rf = 2.5) gave 
2,3,4,5,6-penta–O-benzyl-1-O-[(1S-(-)-camphanoyl]-L-myo-inositol (2-10) as a white 
solid (0.963 g, 48%) M.p (116-118 C), [α]20D = -18° (c = 1, CHCl3 1H NMR (400 
MHz, CDCl3): δ 7.39 – 7.19 (m, 25H, 5 x Ph), 5.02 – 4.68 (m, 10H, 5 x PhCH2), 4.62 
(dd, J = 10.2, 2.2 Hz, 1H, H-1), 4.22 (t, J = 2.0 Hz, 1H, H-6), 418 (1H, dd, J = 10.2, 
9.5 Hz, H-2), 4.12 (t, J = 9.5 Hz, 1H, H-4), 3.58 (t, J = 9.5 Hz, 1H, H-3), 3.55 (1H, 
dd, J = 9.5, 2.3 Hz, H-5), 2.29 – 2.22 (m,1H, H-1'a). 1.92 – 1.78 (m, 2H, H-1'b, H-2'b) 
1.70 – 1.59 (m, 1H, H-2'a) 1.06, (s, 3H, CH3, camphonyl), 1.05, (s, 6H, CH3, 
camphonyl). 13C NMR (101 MHz, CDCl3): δ 177.89, 166.46 (2 x C=O), 138.61, 
138.41, 138.35, 138.28, 138.03, 128.46, 128.41, 128.35, 128.32, 128.31, 128.26, 
128.00, 127.97, 127.79, 127.75, 127.69, 127.61, 127.58, 127.40, 127.23, 83.56, 81.42, 
80.98, 78.94, 75.89, 75.27, 75.26, 75.25, 74.70, 73.09, 54.77, 54.07, 30.92, 28.93 
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2.7.8 Synthesis of 2,3,4,5,6-penta-O-benzyl-L-myo-inositol (2-12)29 
A mixture of 2,3,4,5,6-penta-O-benzyl-D-myo-inositol (2-10) 
(0.093 g, 0.115 mmol) and potassium hydroxide (0.065 g, 1.16 
mmol) in absolute ethanol (20 mL) was gently refluxed for 2 
hr. Upon completion of the reaction, the solvent was removed under reduced pressure 
followed by the addition of water (10 mL) to the residue, and thereafter the mixture 
was extracted with DCM (50 mL x 2). The organic layers were collected and dried 
over MgSO4. The solvent was removed under reduced pressure. Purification by 
chromatography using a silica-gel column (EtOAc/Pet ether, 3:7) gave 2,3,4,5,6-
penta-O-benzyl-L-myo-inositol (2-12) as an oil (0.0616 g, 85%). 1H NMR (300 MHz, 
CDCl3): δ 7.40 – 7.22 (m, 25H, 5 x Ph), 5.01 – 4.67 (m, 10H, 5 x PhCH2), 4.09 (d, J = 
9.6 Hz, 1H, H-4), 4.04 (t, J = 2.0 Hz, 1H, H-2), 3.86 – 3.78 (m, 1H, H-6), 3.52 (d, J = 
4.3 Hz, 1H, H-3), 3.51 – 3.47 (m, 1H, H-5), 3.47 – 3.44 (m, 1H, H-1), 2.23 (d, J = 6.4 
Hz, 1H, OH). 13C NMR (101 MHz, CDCl3): δ 138.74, 138.66, 138.61, 138.25, 128.46, 
128.41, 128.35, 128.31, 128.00, 127.82, 127.77, 127.75, 127.67, 127.61, 127.58, 
127.54, 83.65, 82.23, 81.97, 81.23, 77.44, 75.86, 75.78, 75.54, 74.77, 73.03, 72.41. 
 
2.7.9 Synthesis of 4-O-camphanoyl-2,3,5,6-di-O-cyclohexylidene-L-myo-inositol 
(2-18) 
To a solution of 4-O-camphanoyl-2,3,5,6-di-O-
cyclohexylidene-1-O-benzyl-L-myo-inositol (2-17) 
(0.5 g, 0.819 mmol) in ethanol/THF (50:50) was 
added 10% Pd/C (0.25 g, 2.35 mmol) followed by 
hydrogenation at 50 psi at room temperature for 24 
hr. Upon the completion of the reaction, Pd/C was filtered through a celite pad. The 
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O-cyclohexylidene-L-myo-inositol (2-18) as a white solid (0.470 mg, 91%). The 
product was used in the next step without further purification. M.p (220-222 C).  
 
2.7.10 Synthesis of 4-O-camphanoyl-2,3,5,6-di-O-cyclohexylidene-1-O-
diphenylphosphoryl-L-myo-inositol (2-19) 
To a solution of 4-O-camphanoyl-2,3,5,6-di-O-
cyclohexylidene-L-myo-inositol (2-18) (0.2 g, 
0.384 mmol) in DCM (10 mL) was added Et3N 
(0.111 mL), catalytic amount of DMAP and 
(PhO)2POCl (0.276 mL). The reaction mixture 
was allowed to stir overnight at room temperature. Upon the completion, the solvent 
was removed under reduced pressure. Purification by chromatography using a silica-
gel column (20 g, EtOH/Pet ether, 1: 1) gave 4-O-camphanoyl-2,3,5,6-di-O-
cyclohexylidene-1-O-diphenylphosphoryl-L-myo-inositol (2-19) as a white solid 
(0.289 g, 100%). M.p (183-186 C). 31P NMR (162 MHz, CDCl3) δ -12.45; 1H NMR 
(400 MHz, CDCl3): δ 7.36- 7.13 (m, 10H, 5 x Ph), 4.92 – 475 (m, 1H, H-4), 4.65 – 
4.19 (m, 1H, H-1), 3.65-362 (m, 2H, H-3, H-5), 3.47 - 3.42 (m, 2H, H-2, H-6), 2.51 – 
2.38 (m,1H, H-1'a), 2.09 – 1.98 (m, 1H, H-1'b), 1.94 – 1.87 (m, 1H, H-2'b) 1.80 – 1.75 
(m, 1H, H-2'a) 1.63 – 1.28 (m, 20H, C(CH2)10, cyclohexylidene) 1.10, (s, 3H, CH3, 
camphonyl), 1.05, (s, 3H, CH3, camphonyl), 0.96, (s, 3H, CH3, camphonyl). 13C NMR 
(75 MHz, CDCl3): δ 167.35, 166.32, 150.44, 129.66, 125.52, 120.15, 114.00, 111.52, 
71.06. 68.23, 64.45, 54.78, 54.20, 37.45, 36.27, 31.71, 29.69, 29.00, 24.81. 23.62. 
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2.7.11 Synthesis of 4-O-camphanoyl-2,3,5,6-di-O-cyclohexylidene-1-O-
dibenzylphosphoryl-L-myo-inositol (2-20) 
To a solution of 4-O-camphanoyl-2,3,5,6-di-O-
cyclohexylidene-1-O-diphenylphosphoryl-L-
myo-inositol (2-19) (0.882 g, 1.17 mmol) in 
THF (8 mL) at 0 C was added NaH (0.0452 g, 
1.13 mmol). The reaction mixture was allowed 
to stir for 30 mins before BnOH (0.293 mL) was added. The reaction mixture was 
allowed to equilibrate to room temperature whilst stirring overnight. The reaction was 
judged as complete by TLC (EtOAc/Pet ether, 3: 7, Rf 0.1). The solvent was 
concentrated under reduced pressure and 4-O-camphanoyl-2,3,5,6-di-O-
cyclohexylidene-1-O-dibenzylphosphoryl-L-myo-inositol (2-20) was obtained as a 
semi-solid material (0.576 g, 63%). 1H NMR (400 MHz, CDCl3): δ 7.41 – 7.19 (m, 
10H, 2 x Ph), 5.13 – 503 (m, 4H, CH2Ph), 4.75 – 4.66 (m, 1H, H-4), 4.56 – 4.50 (m, 
1H, H-1), 4.06-3.91 (m, 2H, H-3, H-5), 3.86 - 3.80 (m, 1H, H-6), 3.34-3.26 (m, 1H, 
H-2), 2.29 – 2.22 (m, 1H, H-1'a), 1.92 – 1.78 (m, 2H, H-1'b, H-2'b), 1.70 – 1.59 (m, 
1H, H-2'a), 1.64 – 1.27 (m, 20H, C(CH2)10, cyclohexylidene), 1.06 (s, 3H, CH3, 
camphonyl), 1.05 (s, 6H, CH3, camphonyl). HRMS (ESI) calculated for C42H53O12P: 
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2.7.12 Synthesis of 2,3,5,6-di-O-cyclohexylidene-1-O-dibenzylphosphoryl-L-myo-
inositol (2-21) 
To a solution of 4-O-camphanoyl-2,3,5,6-di-O-
cyclohexylidene-1-O-diphenylphosphoryl-L-myo-inositol 
(2-20) (0.55 g, 0.705 mmol) in absolute ethanol (10 mL) 
was added powdered KOH (0.39 mg, 0.007 mmol). The 
reaction was heated to a reflux and followed on TLC (50 
g, MeOH/EtOAc, 0.2: 9.8, Rf 0.2) and was judged as complete after 2 hr. The solvent 
was removed under reduced pressure to give 2,3,5,6-di-O-cyclohexylidene-1-O-
dibenzylphosphoryl-L-myo-inositol (2-21) as a colourless film (0.275 g, 65%). The 
product was used in the next step without any further purification. 
 
2.7.13 Synthesis of 1-O-dibenzylphosphoryl-L-myo-inositol (2-22) 
2,3,5,6-di-O-Cyclohexylidene-1-O-dibenzylphosphoryl-L-
myo-inositol (2-21) (0.2 g, 0.333 mmol) was suspended in 
aqueous acetic acid (80%, 5 mL) and the suspension was 
heated to reflux at 100 C for 2 hr. Upon the completion, 
the solvent was evaporated under reduced pressure and the residue was dissolved in 
petroleum ether upon which 1-O-dibenzylphosphoryl-L-myo-inositol (2-22) 
crystallized as a white solid (0.0616 g, 42%). 1H NMR (400 MHz, D2O): δ 7.41 – 
7.32 (m, 10H, 5 x Ph), 5.17 – 5.03 (m, 4H, 2 x PhCH2), 3.92-3.80 (m, 3H, H-6, H-2, 
H-1), 3.69 – 3.58 (m, 2H, H-3, H-5), 3.52 – 3.38 (m, 1H, H-4). HRMS (ESI) 
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2.7.14 Synthesis of 1-L-Ins-1-P (2-15) 
To a solution of 1-O-dibenzylphosphoryl-L-myo-inositol 
(2-22) (30 mg, 0.0682 mmol) in ethanol/water (50 mL, 
80:20) was added 10% Pd/C (35 mg, 0.329 mmol), 
followed by hydrogenation at 50 psi at room temperature 
for 24 hr. Upon the completion of the reaction, Pd/C was filtered through celite and 
the filtrate was concentrated under reduced pressure. The resulting aqueous solution 
was passed through C18 and eluted with Milli-Q water, after which it was lyophilized 
to give 1-L-Ins-1-P (2-15) as a white solid (25 mg, 71%). M.p (105 – 108 C). 1H 
NMR (400 MHz, D2O) δ 4.65 (1H, H-1), 4.10 (m, 2H, H-6, H-2,), 3.98 – 3.88 (m, 2H, 
H-3, H-5), 3.86 – 3.75 (m, 1H, H-4). 13C NMR (101 MHz, D2O) δ 66.80, 66.00 (2 x 
C), 62.45 (2 x C), 60.45. 31P NMR (1H NMR decoupled) (162 MHz, D2O): δ 5.23 (s); 
31P NMR (1H NMR coupled) (121.5 MHz, D2O): δ 5.14 (JPH = 9.0 Hz). HRMS (ESI) 
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CHAPTER 3 
Design and synthesis of potential inhibitors against MshA 
3.1 Introduction 
In this chapter the design of potential inhibitors of MshA using computational 
modeling and simulation studies is reported. Computational modeling and simulation 
studies play a significant role in modern day drug discovery and have become an 
essential tool in rational drug design.1 
 
In medicinal chemistry, computational modeling and simulation has been used as a 
tool not only for in silico hit identification and lead optimization but also to predict 
the binding and interaction between the ligand and the target.2,3 In addition, 
computational modeling are often used to predict the pharmacokinetics and 
pharmacological analysis of ADMET (Absorption, distribution, metabolism, excretion 
and toxicity) properties of drug molecules.2-4  
 
In order to improve on the traditional methods of drug discovery, computational 
scientists have developed modern drug discovery approaches through the 
development of improved simulation algorithms. The advantage of computational 
methods is that it enables one to tailor drugs with desired drug-like properties before 
starting with actual synthesis of target compounds. The concept of drug design begins 
with a hypothesis that modulate the interaction between a drug and biological drug 
target that may be considered to be of high therapeutic significance.5 While 
computational approaches have already provided significant benefits, they hold a 
great promise for future in drug discovery and development. However, the computer 
assisted drug discovery and development is an emerging technology and has a number 
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of limitation such as generation of undesirable chemical structures which may be 
chemically unstable, synthetically unfeasible or have high toxicity. 
 
The progress in molecular modeling studies of glycosyltransferases has been very 
slow owing to the limited number of available crystal structures. Helm et al.6 
proposed that the crystal structures of existing glycosyltransferases could serve as 
starting points for the design of substrate analogues for other related 
glycosyltransferases mainly because of their structural similarities. Fortunately in this 
study, the availability of a MshA crystal structure from Corynebacterium glutamicum 
(cgMshA) made it possible to search for potential selective inhibitors of 
glycosyltransferase MshA.7a  
 
Comparison of the MshA structures of M. tuberculosis, Corynebacterium glutamicum 
and M. smegmatis were reported to have a high sequence homology. According to the 
literature reports, the monomeric homology model of M. tuberculosis MshA was 
created using CPH-models 2.0 with the UDP-complexed cgMshA (PDB: 3C4Q) as 
template. Superimposition of the model of M. tuberculosis MshA (consisting of 
Arg46–Ile445) and the chain B from UDP/inositol-phosphate bound cgMshA (PDB: 
3C4V) yields an root mean square deviation (RMSD) of 0.65 Å, indicating a high 
homology between MshA.7b Prior to that Newton and co-workers also reported a high 
sequence homology between MshA structures of M. tuberculosis and M. smegmatis.7c 
Thus, it can be conluded that there is high sequence homology between MshA 
structures of the isolates. 
 
Walker and co-workers have developed a high throughput assay (HTS) for E. coli 
glycosyltransferase MurG and used it to screen a library of over 50 000 compounds to 
identify selective glycosyltransferase MurG inhibitors.8 The HTS identified several 
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compounds with heterocyclic cores including rhodanine and its analogues 2-
iminothiazolidin-4-one. Interestingly, the inhibitors 3-1 (IC50 = 1.4 µM), 3-2 (IC50 = 
27 µM) and 3-3 (IC50 = 27 µM) (Fig 3-1) were selective of glycosyltransferase, MurG 
over another closely related enzyme, MurA, having strong structural and mechanistic 
similarities. Furthermore, compound 3-1 was found to be a competitive inhibitor of 

























Figure 3-1: Inhibitors of glycosyltransferase MurG.8 
 
The previous studies by Carlson et al.9 and Soltero-Higgin et al.10 identified the 
inhibitors for UDP-galactopyranose mutase (UGM) enzyme, which also uses a UDP 
coupled sugar as a substrate. Furthermore, the UGM inhibitors demonstrated the 
ability to be selective, when its ability to block galactosyltransferase activity was 
tested. The concept of selectivity of the inhibitors towards specific enzyme presented 
an exciting opportunity for design and development of novel enzyme-selective 
inhibitors for glycosyltransferase. 
 
Amongst the compounds screened, the most potent compounds contained a 
heterocyclic ring and they appeared to have high binding affinity in the active site of 
glycosyltransferase MurG and galactosyltransferase respectively. It was against this 
background that the molecular docking of the thiazolidinethione (rhodanine/ 
rhodanine-3 acetic acid) scaffold (Fig. 3-2) in the active site of glycosyltransferase 
MshA was conceptualized. 
 








Figure 3-2: General structure of thiazolidinethione (rhodanine). 
 
Thiazolidinethione derivatives were our preferred choice because of their structural 
similarities with the classes of the compounds assessed on glycosyltransferase MurG.8 
Furthermore there is overwhelming literature support that thiazolidinethione 
derivatives possess broad-spectrum of biological activities.11-13 In order to investigate 
the binding mode of thiazolidinethione derivatives, selected classes of 
thiazolidinethione derivatives were docked into the active site of MshA. 
 
3.2 Molecular docking studies  
Following a computational simulation procedure described (software Autodock 4.2), 
molecular docking simulations were performed on selected thiazolidinethiones. With 
the availability of crystal structure coordinates of MshA, a model was created using a 
complex of MshA (PDB: 3C4Q) with bound ID (identification number) ligands. To 
provide enough space for free movements of the ligands the grid box was constructed 
to cover the whole uridine diphosphate (UDP) active site using Autodock tools and it 
was defined using AutoGrid4. The grid points were set to 50, 40 and 42 (xyz 
dimension), at a grid centre of (xyz) 79.66, 46.78 and 13.02 with spacing of 0.375 Å. 
In these calculations a maximum possible torsional degree of freedom for each 
molecule was utilized. For a population of 150 individuals, 5 x 106 maximum energy 
evaluations and operations were applied. All other parameters were set to Autodock 
4.2 default values including the rate of gene mutation (0.02) and rate of crossover 
(0.8). A total of 50 generic algorithm (GA) trials were executed for each ligand. The 
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based on their binding energies. Autodock tools were used to view and analyze the 
best docked conformations. 
 
3.2.1 Docking of thiazolidinethione compounds in the active site of MshA 
Prompted by the previous studies on glycosyltransferase MurG.8 A library of twelve 
2-thioxo-thiazolidin-4-one derivatives have been designed in silico and analyzed by 
molecular docking simulation to identify the thiazolidinethione derivatives that 
occupy the active binding pocket of MshA, without wobbling into other important 
parts of the binding pocket. Docking of these thiazolidinethiones into the UDP-
GlcNAc binding pocket of MshA gave some indication that these molecules may 
occupy the same binding site as UDP-GlcNAc (Fig. 3-3).  
 
The docking studies further revealed that the thiazolidinethiones were best 
accommodated in the binding site when the thiazolidinethione ring is located in the 
vicinity of the diphosphate binding site, facing toward the GlcNAc binding site, 
whereas the benzene ring is orientated towards the uridine binding site. The position 
and the orientation of the representative thiazolidinethione derivative and 
superimposed substrate (UDP) inside the binding pocket of MshA are illustrated in 
Fig. 3-3. 
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Figure 3-3: Crystal structure of MshA with UDP-GlcNAc substrate (light blue) and thiazolidinethione 
(yellow). Newly formed hydrogen bonds are indicated by green lines. 
 
In addition, it has been observed that the thiazolidinethione interacts with essential 
vicinal amino acid residues (GLY17, ARG231, GLY22, LYS236 and GLY23) in the 
binding pocket, thus, forming six new hydrogen bonds (Fig. 3-3). Furthermore, it has 
been observed that amino acid residues (ARG231, GLY23, and LYS236) could be 
essential for both interaction of substrate and potential inhibitor respectively. In the 
absence of the inhibitor, these amino acid residues interact with substrate (UDP-
GlcNAc) (Fig. 3-4). This observation suggest that it could be possible that the 
thiazolidinethione fit better than the substrate in the binding pocket and subsequently 
compete with the substrate for interacting with the active site amino acids residues 
(Fig. 3-4).  
 
Chapter 3                                                      Synthesis of thiazolidinethione derivatives 
80 
 
                                A                                                                      B 
Figure 3-4: Comparison between the crystal structures of MshA with/without inhibitors. A: Shows an 
inhibitor-substrate complex inside the binding pocket of MshA. B: Substrate inside the binding pocket. 
 
The docking accuracy was validated by comparing difference between the crystal 
structure and the regenerated structure which was found to be 0.56 Å RMS (Root 
Mean Square). All the thiazolidinethione derivatives docked in the binding site shown 
some similar trend in their binding energies and inhibition constants owing to their 
structural similarities. The binding energies and inhibition constants for the docked 
thiazolidinethione derivatives range between -7.11 and -9.24 kcal/mol and 6.1 and 
0.17 µM respectively. The orientation of the inhibitor in the binding pocket was in 
agreement with previous studies.8 The study by Walker and co-workers demonstrated 
that the thiazolidinethione ring in the crystal structure of MurG is located near the 
phosphate bridge with the nitrogen orientated towards the GlcNAc binding pocket 
(Fig. 3-5). This phenomenon was further supported by previous studies by Sim et al.14 
and Andres et al.15, whereby they suggested that the thiazolidinethione ring acts as a 
possible mimic for the diphosphate. 
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Figure 3-5: Crystal structure of MurG with UDP-GlcNAc substrate (blue) and competitive 
thiazolidinethione inhibitor (red).8 
 
Based on the crystal structure of MshA and the orientation of the thiazolidinethione 
ring, the ring nitrogen allows possible extension of the thiazolidinethione moiety 
towards the GlcNAc binding pocket of the substrate. Subsequent modifications on this 
nitrogen with a propargyl moiety, lead to a significant improvement of the binding 
energy (-9.24 kcal/mol) and inhibition constant (Ki 0.17 µM) of the representative 
molecule (Fig. 3-6). The results suggest that propargylated thiazolidinethione 
derivatives could be potential inhibitors as evident with the lower binding energy, 
lower inhibition constant (Ki) and involves three hydrogen bonds interactions with 
amino acid residues (GLY17 and ARG231) of the active site. Other modifications 
such as N-CH2CO2H, N-(CH2)3SO3H were also performed on the N-terminal of the 
thiazolidinethione derivatives, in an effort to probe for an improved binding in the 
UDP-GlcNAc binding pocket. The simulation results (Table 3-1), summarily suggest 
that thiazolidinethione derivatives could be potential inhibitors of MshA. As a result, 
the next section (Section 3.3.1) has been dedicated to the description of synthesis of 
the potential thiazolidinethione based inhibitors of MshA. 
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Figure 3-6: Crystal structure of MshA with UDP-GlcNAc substrate (light blue) and propargylated 
thiazolidinethione (yellow). 
 
Table 3-1: Summary of the thiazolidinethione derivatives docked in MshA binding pocket 
Entry Code Binding energy (Kcal/mol) 
Inhibition constant 
(µM) 
1 MJ3A -7.61 6.1 
2 MJ2B -8.53 5.2 
3 MJ7B -8.76 3.7 
4 MJ12B -8.92 4.9 
5 MJ029-1 -8.61 1.1 
6 MJ029-2 -9.11 0.28 
7 MJ029-3 -9.17 0.21 
8 MJ029-5 -9.19 0.19 
9 MJ029-9 -9.24 0.17 
10 MJ029-11 -9.03 0.19 
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3.3 Synthesis of thiazolidinethione derivatives 
Rhodanine represents a very important privileged scaffold in drug discovery and the 
importance of its derivatives such as thiazolidinethione-based compounds in 
pharmacological activities has been well documented.16,17 Because of their biological 
importance in the development of new drug candidates, several possible methods for 
the synthesis thiazolidinethione derivatives have since been reported in the 
literature.18  
 
Established methods for the preparation of thiazolidinethione derivatives require few 
steps and generally involve preparation of the rhodanine moiety followed by 
Knoevenagel condensation with aldehydes.19 Eltsov et al.20 reported a convenient 
one-pot cyclization reaction protocol which involved the reaction of ethyl 5-phenyl-
thioureido-3H-imidazole-4-carboxylate with bromoacetic acid to obtain the desired 
thiazolidinethione derivative. 
 
Pratap et al. recently reported the synthesis of 2,3-diaryl-4-thiazolidinones by utilizing 
the lipase from baker’s yeast (Saccharomyces cerevisiae) as a catalyst.21 Microwave 
assisted reactions between benzylidene-anilines and mercaptoacetic acid were 
reported recently by Bolognese et al.22 These reactions were performed in the 
presence of benzene at room temperature and excellent yields between 65-90% were 
isolated after purification by silica gel column chromatography. 
 
3.3.1 Synthesis of thiazolidinethione derivatives (MJ1A – MJ12A) via the 
Knoevenagel condensation 
Herein we report the synthesis of the thiazolidinethione derivatives (Table 3-2) 
following a modified procedure (Scheme 3-1) reported by Gouveia et al.23 using the 
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Knoevenagel condensation between aldehydes and rhodanine in refluxing glacial 







Scheme 3-1: Synthesis of thiazolidinethione derivatives (MJ1A - MJ12A). 
 
This procedure resulted in the formation of several key corresponding 2-
thioxothiazolidin-4-one derivatives. The compounds were crystallized from the 
reaction mixture as bright yellow solids with high purity and isolated in high yields 
(Table 3-2). The thiazolidinethione derivatives were washed with petroleum ether 
followed by ice cold water and samples were subsequently lyophilized to give desired 
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93 202-203 (205-206)24 220.9969 220.9961 
2 MJ2A 
OH  
96 187-189 236.9918 236.9910 
3 MJ3A 
ClCl  
94 181-183 288.9190 288.9190 
4 MJ4A 
Br  
92 213-215  298.9074 298.9069 
5 MJ5A 
But  


















90 148-150 293.0544 293.0548 
10 MJ10A 
HO  
93 292-294 (294-295)25 236.9918 236.9910 
11 MJ11A MeO
 





96 159-161 268.9816 268.9809 
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3.3.2 Characterization of thiazolidinethione derivatives (MJ1A – MJ12A) 
The structures of the prepared thiazolidinethione derivatives were characterized and 
confirmed using 1H, 13C NMR and IR spectroscopic techniques. Melting points and 
HPLC were employed to assess the purity of prepared compounds. The HPLC results 
have indicated a high purity which exceeded 95%.  
 
The 1H NMR spectra of compounds (MJ1A – MJ12A) showed one common singlet 
proton which resonated at the region δH 7.51-7.79 ppm, corresponding to the 
methylidene proton. These protons appeared at high chemical shifts due to the 
deshielding effect of the adjacent phenyl rings. The signals were a clear indication 
that the coupling of the two molecules has taken place. The 13C NMR spectral data of 
this series of compounds showed that only one geometrical isomer (Z) is present and 
no traces of the isomer (E) could be detected which was in agreement with the 
literature.23,25 Mass spectrometry was used to confirm the required accurate mass of 
each compound. The IR spectroscopy of all the compounds showed the diagnostic 
bands in the regions 3014 – 3348, 3054 – 3076, 2848 - 2953 and 3087 – 3348 cm-1 
which were assigned to NH, CH, C=C and OH stretches respectively. 
 
3.3.3 Synthesis of thiazolidinethione derivatives (MJ1B – MJ12B) 
A second series of thiazolidinethione derivatives (MJ1B – MJ12B) was deemed 
necessary as part of extension into the GlcNAc binding pocket. This series of 
compounds was also synthesized in the same manner as described in section 3.3.1. 
Knoevenagel condensation was achieved through the coupling of different aldehydes 
with rhodanine-3 acetic acid in refluxing glacial acetic acid (Scheme 3-2). This series 
of compounds shared similar properties with the thiazolidinethione derivatives (MJ-
1A – MJ12A); the compounds precipitate out of the reaction mixture as bright yellow 
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crystals without requiring further purification. The compound properties are 
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Entry Code R Yields (%) MP Mw M+ 
1 MJ1B 
 
95 118–120 (247-248)26 279.0024 279.0024 
2 MJ2B 
OH  
94 221-224 294.9973 294.9969 
3 MJ3B 
ClCl  
97 209-213 346.9244 346.9238 
4 MJ4B 
Br  
93 244-247 356.9129 356.9122 
5 MJ5B 
But  




98 252-254 328.9583 328.9583 
7 MJ7B HO
OMe  










94 231-236 351.0599 351.0589 
10 MJ10B 
HO  
93 >300 294.9973 294.9973 
11 MJ11B 
MeO  





95 228-231 326.9871 326.9862 
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3.3.4 Characterization of thiazolidinethiones (MJ1B – MJ12B) structures 
Similarly, the 1H, 13C NMR and IR spectroscopic techniques were employed to 
confirm the structures of synthesized compounds. Melting points and HPLC were 
employed to assess the purity of the compounds. The HPLC results have indicated a 
high purity which exceeded 95%.  
 
Besides the methylidene proton resonating between δH 7.60 and 8.07 ppm, 1H NMR 
spectroscopic data further showed the -CH2-CO2H as a key diagnostic signal. The 
other noticeable signal was the presence of the more deshielded broad singlet peak 
corresponding to the COOH.  
 
The IR spectroscopy of all the compounds revealed new absorption bands in the 
regions 1600 – 1700 cm-1 for COOH apart from similar patterns of signals noted in 
the previous series of compounds. As expected no amine (NH) stretches were present. 
 
3.4 Synthesis of propargylated thiazolidinethione derivatives (MJ029 series) 
Propargylated thiazolidinethione derivatives (MJ029-1 – MJ029-12) were prepared 
in low yields ranging from 23-38% by N-alkylation of the corresponding 2-
thioxothiazolidin-4-one with propargyl bromide (Scheme 3-3). In each reaction, 1 mol 
equivalent of each compound (MJ1A – MJ12A) was dissolved in dry DMF followed 
by addition of 1.5 mol equivalents of K2CO3. After 30 min of the reaction time, 1.5 
mol equivalents of propargyl bromide were added at ambient temperature. The 
reaction was allowed to stir at room temperature for 24 h. The reaction progress was 
monitored by thin layer chromatography (TLC), which showed full conversion to 
form products. The DMF was co-evaporated several times with toluene to give 
brown-yellowish residues. The products were isolated in poor yields as bright yellow 
solids after purification with silica-gel chromatography. However, the reaction 
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condition was not optimized since enough material was obtained for subsequent 







Scheme 3-3: K2CO3, C3H3Br, DMF, RT. 
 
























3.4.1 Characterization of propargylated thiazolidinethione derivatives (MJ029 
series) 
The prepared series of compounds was characterized using 1H, 13C NMR and IR 
spectroscopic techniques. HPLC traces and melting points were employed to assess 
the purity of target compounds. The 1H NMR spectra of (MJ029-1 – MJ029-12) 
showed a triplet signal that resonated between δH 2.52 and 2.54 ppm, corresponding 
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methylene protons ranging between δ 3.95 and 4.78 ppm. Furthermore, the absence of 
a NH associated peak from the 2-thioxothiazolidin-4-one provided additional proof 
that N-alkylation had taken place. The chemical shifts of the propargyl moiety were in 
agreement with those reported in literature.27 The methylene protons appear as 
singlets downfield due to the deshielding effects of the adjacent nitrogen. The 13C 
NMR spectrum was employed to confirm the structure and the assignment of the 
carbon atoms and that it was consistent with the literature.28 In addition, the propargyl 
carbon atom bonded to nitrogen (N-C) appeared slightly deshielded because of the 
strong electronegativity conferred by nitrogen, thus confirming that the molecule is N-
alkylated.  
 
3.5 Synthesis of sulfonated thiazolidinethione derivatives (MJ081 series) 
The synthesis of the sulfonated thiazolidinethione derivatives (MJ081 series) was 
accomplished by N-alkylating the 2-thioxothiazolidin-4-one ring in the presence of 
NaH and 1,3-propanesultone in DMF (Scheme 3-4) at 0 C. The compound properties 
are summarized in Table 3-5. 
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This series of compounds was characterized by 1H and 13C NMR spectroscopic 
techniques. The melting points were employed to check the purity of the compounds. 
The 1H NMR spectra showed some distinct signal peaks resonating at δH 4.14 - 4.05 
ppm (triplet, H-10), δH 2.55 – 2.45 ppm (triplet, H-8) and δH 2.04 – 1.94 ppm (quintet, 
H-9), which were assigned to alkyl protons of the propanesulfonate moiety. Likewise, 
the 13C NMR spectrum was employed to confirm that alkylation occurred on the 
nitrogen of the rhodanine moiety. Again, the carbon bonded to nitrogen (N-C) 
appeared downfield due to the deshielding nature of the adjacent nitrogen, thus the 
confirming that the molecule is N-alkylated. The 2-thioxothiazolidin-4-one 
derivatives prepared here were subjected to a screen for anti-mycobacterial activity in 
an in vitro assay against M.tb. The results of the enzyme assays and whole cell 
inhibition will be discussed in Chapter 5 and Chapter 6 respectively. 
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3.6 Conclusion 
In summary, a series of thiazolidinethione-based compounds have been successfully 
prepared as directed by molecular docking studies. The molecular docking studies 
were performed in the UDP-GlcNAc active binding site to aid with drug design. 
Furthermore the prepared thiazolidinethione-based libraries of compounds were fully 
characterized using spectroscopic and analytical techniques including: IR, 1H and 13C 
NMR spectroscopy. LC-MS was employed to determine the accurate masses of the 
novel compounds. The inhibition studies of the thiazolidinethione-based derivatives 
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3.7 Experimental 
3.7.1 General procedure for the synthesis of thiazolidinethione derivatives 
(MJ1A - MJ12A and MJ1B - MJ12B) 
To a solution of either rhodanine or rhodanine-3-acetic acid and anhydrous sodium 
acetate (4 equiv.) in glacial acetic acid was added to the respective aldehydes (4 
equiv.) (2,4- dichlorobenzaldehyde, 2-bromobenzaldehyde, 4-tert-butylbenzaldehyde, 
5-chlorosalicylaldehyde, vanillin, O-vanillin, 3-tert-butyl-2-hydrobenzaldehyde, 4-
hydrobenzaldehyde, 4-methoxybenzaldehyde, 2,4,6-trihydroxybenzaldehyde, 
benzaldehyde and salicaldehyde). The mixture was heated at 100 C and allowed to 
stir under reflux overnight. Immediately after cooling, the solution was added to ice-
cold water and the resulting precipitate was filtered, washed with water, followed by 
n-hexane, dried and purified by column chromatography. 
 
3.7.1.1 (Z)-5-benzylidene-2-thioxothiazolidin-4-one (MJ1A)24,25 
Bright yellow crystal (1.22 g, 92%); Rf 0.4 (EtOAc/Pet ether, 
3: 7). M.p. 202 – 203 C (lit. 205 – 206 C16a); υmax (KBr)/cm-
1 3159s υ (NH), 3057s υ (CH), 2848s υ (C=C), 1707s υ (C=O), 
1193s υ (C=S) 1H NMR (400 MHz, DMSO-d6): δ 7.64 (s, 1H, H-7), 7.55 (m, 5H, 
Ph).13C NMR (101 MHz, DMSO-d6): δ 196.16, 169.82, 133.45, 132.08, 131.18, 
130.91 (2 x C), 129.90 (2 x C), 126.04. EI-MS: C10H7NOS2 found: m/z 220.9961[M-
H]+, calculated 220.9969. 
 
3.7.1.2 2-((Z)-5-Benzylidene-4-oxo-2-thioxothiazolidin-3-yl) acetic acid (MJ1B) 
Bright yellow crystal (1.11 g, 95%) Rf 0.4 (EtOAc/Pet 
ether, 3: 7). M.p 118 – 120 C (lit. 254 – 256 C),  υmax 
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(C=S) 1H NMR (400 MHz, DMSO-d6): δ 13.17 (s, 1H, OH), 7.64 (s, 1H, H-7), 7.55 
(m, 5H, Ph), 4.57 (s, 2H, CH2).13C NMR (101 MHz, DMSO-d6): δ 203.27, 174.19, 
167.74, 134.43, 133.28, 131.21, 130.02, 129.71 (2C), 129.00 (2C), 45.39. HRMS 
(ESI): m/z C12H9NO3S2 found: 279.0024 [M-H]+, calculated 279.0024. 
 
3.7.1.3 (Z)-5-(2-hydroxybenzylidene)-2-thioxothiazolidin-4-one (MJ2A) 
Bright yellow crystal (1.10 g, 95%) Rf 0.4 (EtOAc/Pet ether, 
3: 7). M.p (221-224 C) 1H NMR (400 MHz, DMSO) δ 7.88 
(s, 1H, H-7), 7.78 (dd, J = 7.7, 0.8 Hz, 1H), 7.58 – 7.51 (m, 
2H), 7.46 – 7.36 (m, 1H). 13C NMR (101 MHz, DMSO) δ 193.57, 167.61, 166.46, 
134.26, 133.02, 131.73, 130.13, 129.35, 125.97, 45.60. HRMS (ESI): m/z 
C10H7NO2S2 found: 236.9910 [M-H]+, calculated 236.9918. 
 
3.7.1.4 2-((Z)-5-(2-hydroxybenzylidine)-4-oxo-2-thioxothiazolidin-3-yl)acetic acid 
(MJ2B) 
Bright yellow crystal (1.34 g, 95%); Rf 0.4 (EtOAc/Pet 
ether, 3: 7). M.p (221-224 C) 1H NMR (400 MHz, 
DMSO) δ 7.88 (s, 1H, H-7), 7.78 (dd, J = 7.7, 0.8 Hz, 
1H), 7.58 – 7.51 (m, 2H), 7.46 – 7.36 (m, 1H), 4.69 (s, 2H, CH2). 13C NMR (101 
MHz, DMSO) δ 193.57, 167.61, 166.46, 134.26, 133.02, 131.73, 130.13, 129.35, 
125.97, 45.60. HRMS (ESI): m/z C12H9NO4S2 found: 294.9969 [M]+, calculated 
294.9973. 
 
3.7.1.5 (Z)-5-(2,4-dichlorobenzylidene)-2-thioxothiazolidin-4-one (MJ3A) 
Bright yellow crystal (1.40 g, 94%); Rf 0.4 (EtOAc/Pet 
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DMSO-d6): δ 7.70 (s, 1H, H-7), 7.11 – 7.26 (m, 3H, H-3, H-5, H-6). 13C NMR (101 
MHz, DMSO-d6): δ 194.59, 172.03, 138.03, 136.99, 133.74, 133.42, 132.69, 131.61, 
131.39, 129.70. HRMS (ESI): m/z C10H5Cl2NOS2 found: 288.9190 [M+H]+, 




Bright yellow crystal (1.50 g, 90%); Rf 0.4 (EtOAc/Pet 
ether, 3: 7). M.p (209-213 C) 1H NMR (400 MHz, 
DMSO-d6): δ 7.74 (s, 1H, H-7), 7.23 - 6.91 (m, 3H, 
Ph), 4.37 (s, 2H, CH2). 13C NMR (101 MHz, DMSO-d6) δ 192.98, 166.91, 166.19, 
154.22, 133.52, 130.52, 130.36, 126.24, 120.77, 45.01. HRMS (ESI): m/z 
C12H7Cl2NO3S2 found: 346.9238 [M]+, calculated 346.9244. 
 
3.7.1.7 (Z)-5-(2-bromobenzylidene)-2-thioxothiazolidin-4-one (MJ4A) 
Bright yellow crystal (1.63 g, 92%); Rf 0.4 (EtOAc/Pet ether, 
3: 7). M.p. 213 – 215 C, 1H NMR (400 MHz, DMSO-d6): δ 
7.70 (s, 1H, H-7), 7.40 (m, 1H, H-3), 7.18 – 7.14 (m, 2H, H-5, 
H-6), 7.01 (m, 1H, H-4). 13C NMR (101 MHz, DMSO-d6): δ 193.44, 169.28, 142.33, 
132.69, 132.41, 129.59, 129.34, 129.09, 129.01, 125.88. HRMS (ESI): m/z 
C10H6BrNOS2 found: 298.9069 [M+H]+, calculated 298.9074 [M+H]+. 
 
3.7.1.8 2-((Z)-5-(2-bromobenzylidene)-4-oxo-2-thioxothiazolidin-3-yl)acetic acid 
(MJ4B) 
Bright yellow crystal (1.63 g, 93%); Rf 0.4 
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(400 MHz, DMSO-d6): δ 7.74 (s, 1H, H-7), 7.40 (m, 1H, H-3), 7.18 – 7.14 (m, 2H, H-
5, H-6), 6.95-6.88 (m, 1H, H-4), 4.37 (s, 2H, CH2). 13C NMR (101 MHz, DMSO-d6): 
δ 193.90, 167.25, 158.43, 132.49, 132.41, 129.59, 129.34, 129.09, 129.01, 128.80, 
125.88, 48.08. HRMS (ESI): m/z C12H8BrNO3S2 found: 356.9122 [M+H]+, calculated 
356.9129 [M+H]+. 
 
3.7.1.9 (Z)-5-(4-tert-Butylbenzylidene)-2-thioxothiazolidin-4-one (MJ5A) 
Bright yellow crystal (1.60 g, 93%); Rf 0.4 (EtOAc/Pet 
ether, 3: 7); m.p. 149 – 152 C; υmax (KBr)/cm-1 3170s υ 
(NH), 3076s υ (CH), 2953s υ (C=C), 1701s υ (C=O), 
1223s υ (C=S) 1H NMR (300 MHz, DMSO-d6): δ 7.60 (s, 1H, H-7), 7.56 (m, 2H, H-
2, H-6), 7.52 (m, 2H, H-3, H-5), 1.30 (s, 9H, (CH3)3. 13C NMR (75 MHz, DMSO-d6): 
δ 195.44, 176.32, 169.20, 153.78, 131.38, 130.15 (2C), 126.11 (2C), 124.35, 34.52, 
30.60. HRMS (ESI): m/z C14H15NOS2 found: 278.0673 [M+H]+, calculated 278.0664 
[M+H]+. 
 
3.7.1.10 2-((Z)-5-(4-tert-Butylbenzylidene)-4-oxo-2-thioxothiazolidin-3-yl) acetic 
acid (MJ5B) 
Bright yellow crystal (1.34 g, 95%); Rf 0.4 
(EtOAc/Pet ether, 3: 7). M.p 201 – 202 C, υmax 
(KBr)/cm-1 1727s υ (C=O), 1208s υ (C=S) 1H 
NMR (300 MHz, DMSO-d6): δ 9.98 (s, 1H, 
OH), 7.60 (s, 1H, H-7), 7.56 (m, 2H, H-2, H-6), 7.52 (m, 2H, H-3, H-5), 4.75 (s, 2H, 
CH2), 1.31 (s, 9H, (CH3)3. 13C NMR (101 MHz, DMSO-d6): δ 193.71, 167.70, 
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Bright yellow crystal (1.30 g, 97%); Rf 0.4 (EtOAc/Pet 
ether, 3: 7). M.p. 220 – 223 C; 1H NMR (400 MHz, 
DMSO-d6): δ 7.73 (s, 1H), 7.12 – 6.68 (m, 3H, H-3, H-4, H-
6). 13C NMR (101 MHz, DMSO-d6): δ 194.40, 173.42, 167.54, 154.61, 143.32, 
130.02, 129.01, 128.36, 127.21, 126.43. HRMS (ESI): m/z C10H6ClNO2S2 found: 
270.9521 [M-H]+, calculated 270.9528 [M-H]+. 
 
3.7.1.12 2-((Z)-5-(5-chloro-2-hydroxybenzylidene)-4-oxo-2-thioxothiazolidin-3-
yl)acetic acid (MJ6B) 
Bright yellow crystal (1.34 g, 98%); Rf 0.4 
(EtOAc/Pet ether, 3: 7). M.p. 252 – 254 C; 1H NMR 
(400 MHz, DMSO-d6): δ 7.94 (s, 1H, H-7), 6.92 – 
6.49 (m, 3H, Ph), 4.30 (s, 2H, CH2). 13C NMR (101 MHz, DMSO-d6): δ 192.73, 
174.20, 166,74, 155.43, 137.90, 130.01, 128.91, 127.68, 119.20, 119.18, 116.30, 





Bright yellow crystal (1.43 g, 89%); Rf 0.4 (EtOAc/Pet 
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(KBr)/cm-1 3348s υ (NH), 3260s υ (OH); 1715s υ (C=O), 1155s υ (C=s) 1H NMR 
(300 MHz, DMSO-d6): δ 9.93 (s, 1H, NH), 7.56 (s, 1H, H-7), 7.14 (d, J = 2.1 Hz, 1H, 
H-5), 7.08 (m, 1H, H-6), 6.94 (d, J = 8.2 Hz, 1H, H-2), 3.84 (s, 3H, OCH3).13C NMR 
(75 MHz, DMSO-d6): δ 195.26, 169.23, 149.84, 148.03, 132.49, 124.91, 124.31, 
121.14, 116.26, 114.36, 55.61. HRMS (ESI): m/z C11H9NO3S2 found: 268.0108 
[M+H]+, calculated 268.0102 [M+H]+. 
 
3.7.1.14 2-((Z)-5-(4-Hydroxy-3-methoxybenzylidene)-4-oxo-2-thioxothiazolidin-3-
yl) acetic acid (MJ7B) 
Bright yellow crystal (1.31 g, 96%); Rf 0.4 
(EtOAc/Pet ether, 3: 7). M.p. 255 – 256 C; υmax 
(KBr)/cm-1 3351s υ (OH), 1737s υ (C=O),1698s υ 
(C=O), 1182s υ (C=S) 1H NMR (400 MHz, 
DMSO-d6): δ 10.19 (s, 1H, OH), 9.78 (s, 1H), 7.81 (s, 1H, H-7), 7.44 – 7.39 (m, 2H), 
7.24 – 7.16 (m, 2H), 6.99 – 6.93 (m, 2H), 4.75 (s, 2H, CH2), 3.86 (s, 3H, OCH3).13C 
NMR (101 MHz, DMSO-d6): δ 191.41, 167.76, 151.02, 135.42, 126.46, 125.98, 
124.81, 116.95, 115.88, 115.26, 111.29, 56.15, 45.45. HRMS (ESI): m/z C13H11NO5S2 




Bright yellow crystal (1.45 g, 90%); Rf 0.4 (EtOAc/Pet 
ether, 3: 7). M.p. 249 – 251 C; υmax (KBr)/cm-1 3312s υ 
(NH), 3145s υ (OH), 3054s υ (CH), 2851s υ (C=C),1707s υ 
(C=O), 1210s υ (C=S); 1H NMR (300 MHz, DMSO-d6): δ 9.72 (s, 1H, NH), 7.87 (s, 
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NMR (75 MHz, DMSO-d6): δ 195.85, 169.23, 148.01, 146.83, 127.11, 124.22, 
120.23, 120.16, 119.61, 114.33, 55.96. HRMS (ESI): C11H9NO3S2 found: m/z 
268.0102 [M+H]+, calculated 268.0185 [M+H]+. 
 
3.7.1.16 2-((Z)-5-(2-Hydroxy-3-methoxybenzylidene)-4-oxo-2-thioxothiazolidin-3-
yl) acetic acid (MJ8B) 
Bright yellow crystal (1.34 g, 98%); Rf 0.4 (EtOAc/Pet 
ether, 3: 7). M.p. 249 – 251 C; υmax (KBr)/cm-11725s υ 
(C=O), 1219s υ (C=S) 1H NMR (400 MHz, DMSO-d6): 
δ 8.07 (s, 1H, H-7), 7.15 (dd, J = 7.7, 1.7 Hz, 1H, H-4), 
7.02 – 6.91 (m, 2H, H-5, H-6), 4.74 (s, 2H, CH2), 3.86 (s, 3H, OCH3).13C NMR (101 
MHz, DMSO-d6): δ 194.23, 167.76, 167.00, 148.64, 147.65, 130.11, 121.27, 121.18, 
120.55, 120.41, 115.36, 56.57, 45.46. HRMS (ESI): m/z C13H11NO5S2 found: 




Bright yellow crystal (1.59 g, 90%); Rf 0.4 (EtOAc/Pet ether, 3: 
7). M.p. 148 – 150 C; υmax (KBr)/cm-1 3172s υ (NH), 3087s υ 
(OH), 2865s υ (C=C), 1712s υ (C=O), 1191s υ (C=S) 1H NMR 
(400 MHz, DMSO-d6): δ 13.12 (s, 1H, NH), 11.83 (s, 1H, OH), 9.97 (s, 1H, H-7), 
7.65 (dd, J = 7.6, 1.7 Hz, 1H, H-4), 7.57 (dd, J = 7.7, 1.6 Hz, 1H, H-6), 7.08 – 6.98 
(m, 1H, H-5), 1.38 (s, 9H, (CH3)3. 13C NMR (101 MHz, DMSO-d6): δ 205.72, 
199.18, 177.10, 160.41, 137.55, 134.42, 132.96, 124.71 121.18, 120.01, 34.87, 29.80 
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3.7.1.18 2-((Z)-5-(3-tert-Butyl-2-hydroxybenzylidene)-4-oxo-2-thioxothiazolidin-
3-yl)acetic acid (MJ9B) 
Bright yellow crystal (1.29 g, 94%); Rf 0.4 
(EtOAc/Pet ether, 3: 7). M.p. 231 – 233 C; 1H NMR 
(400 MHz, DMSO-d6): δ 11.84 (s, 1H, OH), 7.74 (s, 
1H, H-7), 7.67 (dd, J = 7.6, 1.7 Hz, H-4), 7.58 (dd, J 
= 7.7, 1.6 Hz, H-6), 7.12 – 6.92 (m, 1H, H-5), 4.70 (s, 2H, CH2), 1.38 (s, 9H, CH3)3. 
13C NMR (101 MHz, DMSO-d6): δ 193.44, 167.73, 166.90, 162.24, 134.56, 133.55, 
132.96, 125,71, 121.18, 120.01, 118.92, 115.70, 34.89, 29.83 (3C). HRMS (ESI): m/z 
C16H17NO4S2 found: 351.0589 [M+H]+, calculated 351.0599. 
 
3.7.1.19 (Z)-5-(4-hydroxybenzylidene)-2-thioxothiazolidin-4-one (MJ10A) 
Bright yellow crystal (1.50 g, 90%); Rf 0.4 (EtOAc/Pet 
ether, 3: 7). M.p. 184-185 C; 1H NMR (300 MHz, 
DMSO-d6): δ = 7.57 (s, 1H, H-7), 7.53 (d, J = 8.7 Hz, 2H, 
H-2 and H-6), 7.03 (d, J = 8.7 Hz, 2H, H-3 and H-5). 13C NMR (75 MHz, DMSO-d6): 
δ = 195.67, 169.72, 160.28, 132.90, 132.26, 123.92 (2C), 121.14, 116.44 (2C). HRMS 
(ESI): m/z C10H7NO2S2 found: 236.9910 [M-H]+, calculated 236.9918. 
 
3.7.1.20 2-((Z-5-(4-hydoxybenzylidene)-4-oxo-2-thioxothiazolidin-3-yl)acetic acid 
(MJ10B) 
Bright yellow crystal (1.50 g, 90%); Rf 0.4 
(EtOAc/Pet ether, 3: 7). M.p. >300 C; 1H NMR 
(300 MHz, DMSO-d6): δ = 7.57 (s, 1H, H-7), 7.53 
(d, J = 8.7 Hz, 2H, H-2 and H-6), 7.03 (d, J = 8.7 
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173.72, 166.28, 156.90, 142.26, 123.92, 121.14, 116.44, 45.62. HRMS (ESI): m/z 
C12H9NO4S2 found: 294.9973 [M]+, calculated 294.9973. 
 
3.7.1.21 (Z)-5-(4-Methoxybenzylidene)-2-thioxothiazolidin-4-one (MJ11A) 
Bright yellow crystal (1.38 g, 91%); Rf 0.4 (EtOAc/Pet 
ether, 3: 7). M.p. 254 – 255 C (lit.16b 260-261 C); υmax 
(KBr)/cm-1 3014s υ (NH), 1683s υ (C=O), 1165s υ 
(C=S);.1H NMR (400 MHz, DMSO-d6): δ 7.60 (s, 1H, H-7), 7.59 – 7.54 (m, 2H, H-3, 
H-5), 7.14 – 7.08 (m, 2H, H-2, H-6), 3.84 (s, 3H, OCH3).13C NMR (101 MHz, 
DMSO-d6): δ 195.97, 169.90, 161.83, 133.12 (2C), 132.32, 125.98, 122.77, 115.57 
(2C), 56.03. HRMS (ESI): m/z C11H9NO2S2 found: 252.0134 [M+H]+, calculated 
252.0153 [M+H]+. 
 
3.7.1.22 2-((Z)-5-(4-Methoxybenzylidene)-4-oxo-2-thioxothiazolidin-3-yl) acetic 
acid (MJ11B) 
Bright yellow crystal (1.26 g, 97%); Rf 0.4 
(EtOAc/Pet ether, 3: 7). M.p. 136 – 138 C (lit. 250 
– 253 C); υmax (KBr)/cm-1 1742s υ (C=O), 1732s υ 
(C=O), 1976s υ (C=S); 1H NMR (400 MHz, DMSO-d6): δ 7.82 (s, 1H, H-7), 7.61 (m, 
2H, H-3, H-5), 7.10 (m, 2H, H-2, H-6), 4.70 (s, 2H, CH2), 3.82 (s, 3H, OCH3).13C 
NMR (101 MHz, DMSO-d6): δ 203.27, 174.19, 167.74, 134.62, 133.56 (2C), 119.85, 
115.72 (2C), 45.28, 36.42. HRMS (ESI): m/z C13H11NO4S2 found: 310.0201 [M+H]+, 
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3.7.1.23 (Z)-5-(2,4,6-tryhydroxybenzylidene)-2-thioxothiazolidin-one (MJ12A) 
Bright yellow crystal (1.10 g, 96%); Rf 0.4 (EtOAc/Pet 
ether, 3: 7). M.p. 159 - 161 C; 1H NMR (400 MHz, 
DMSO-d6): δ = 7.73 (s, 1H, H-7), 5.91 (s, 2H, H-3, H-5). 
13C NMR (101 MHz, DMSO-d6): δ 194.37, 168.10, 167.77, 161.12, 133.25, 130.47, 




yl)acetic acid (MJ12B) 
Bright yellow crystal (1.12 g, 95%); Rf 0.4 
(EtOAc/Pet ether, 3: 7). M.p. 228 - 231 C; 1H 
NMR (400 MHz, DMSO-d6): δ = 7.74 (s, 1H, H-7), 
5.90 (s, 2H, H-3, H-5), 4.72 (s, 2H, CH2). 13C NMR (101 MHz, DMSO-d6): δ 194.40, 
168.08, 167.75, 161.10, 160.06, 133.25, 130.47, 118.19, 117.92, 48.47. HRMS (ESI): 
m/z C12H9NO6S2 found: 268.9809 [M+H]+, calculated 268.9816 [M+H]+. 
 
3.7.2 General procedure for the synthesis of propargylated thiazolidinethiones 
(MJ029 series) 
To a solution of 2-thioxothiazolidin-4-one (100 mg) in 
DMF (2 mL) was added 1.5 equivalents of K2CO3 and 
propargyl bromide respectively. The reaction mixture 
was allowed to stir at room temperature overnight. The reaction progress was 
monitored on TLC (EtOAc/Pet ether, 3: 7) and upon completion the DMF was co-
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chromatography using a silica-gel column (EtOAc/Pet Ether, 3: 7) giving bright 
yellow compounds in low yields. 
 
3.7.2.1 (Z)-5-Benzylidene-3-(prop-2-ynyl)-2-thioxothiazolidin-4-one (MJ029-1) 
Bright yellow powder (0.0404 g, 23%). M.p (115-117 
C) 1H NMR (300 MHz, CDCl3): δ 8.06 (s, 1H, H-7), 
7.63 – 7.18 (m, 5H, Ph), 4.78 (d, J = 2.5 Hz, 2H, H-3a, 
H-3b), 2.53 (t, J = 2.5 Hz, 1H, H-1).13C NMR (75 MHz, CDCl3): δ 191.96, 166.38, 




Bright yellow powder (0.0323 g, 25%). M.p (133-134 
C) 1H NMR (300 MHz, CDCl3): δ 8.10 (s, 1H, H-7), 
7.70 (d, J = 8.0 Hz, 1H, Ph), 7.53 – 7.39 (m, 2H, Ph), 
7.34 – 7.23 (m, 1H, Ph), 4.78 (d, J = 2.5 Hz, 2H, H-3a, H-3b), 2.53 (t, J = 2.4 Hz, 1H, 
H-1), 1.56 (s, 1H, OH).13C NMR (75 MHz, CDCl3): δ 192.64, 166.36, 165.16, 




Bright yellow powder (0.0650 g, 38%). M.p (86-87 
C) 1H NMR (300 MHz, CDCl3): δ 7.78 (s, 1H, H-
7), 7.56 – 7.42 (m, 3H, Ph), 4.78 (d, J = 2.5 Hz, 
2H, H-3a, H-3b), 2.52 (t, J = 2.5 Hz, 1H, H-1).13C NMR (101 MHz, CDCl3): δ 192.98, 
























































Bright yellow powder (0.0556 g, 33%). M.p (105-
107 C) 1H NMR (300 MHz, CDCl3): δ 7.74 (s, 
1H, H-7), 7.26 (s, 1H, Ph), 7.15 – 7.13 (m, 2H, 
Ph), 3.95 (d, J = 2.5 Hz, 2H, H-3a, H-3b), 2.54 (t, J = 2.4 Hz, 1H, H-1 ), 1.26 (s, 9H, 3 
x CH3). 13C NMR (101 MHz, CDCl3): δ 193.03, 167.02, 151.09, 139.48, 130.11, 




Bright yellow powder (0.0501 g, 29%). M.p (130-
132 C) 1H NMR (300 MHz, CDCl3): δ 7.79 (s, 
1H, H-7), 7.53 – 7.46 (m, 4H, Ph), 4.92 (s, 3H, 
CH3), 4.78 (d, J = 2.5 Hz, 2H, H-3a, H-3b), 2.52 (t, J = 2.5 Hz, 1H, H-1).13C NMR 
(101 MHz, CDCl3): δ 192.84, 166.98, 165.23, 134.17, 133.19, 131.00, 130.69 (2C), 
129.40 (2C), 122.64, 75.81, 53.30, 44.58. 
 
3.7.3 General procedure for the synthesis of sulfonated thiazolidinethiones 
(MJ081 series) 
To a solution of 2-thioxothiazolidin-4-one 
(100 mg) in DMF (2 mL) was added NaH 
(60%, 30 mg, 0.75 mmol) at low 
temperature (0 C). The reaction mixture 
was allowed to stir for 30 minutes at low temperature (0 C) before 1,3-
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to stir for an additional 30 minutes at low temperature before the reaction mixture was 
allowed to attain room temperature overnight. The reaction progress was monitored 
through TLC (EtOAc/Pet ether, 7:3) and upon the completion the DMF was co-
evaporated with toluene. The residue was dissolved in water (5 mL) and was washed 
in EtOAc (50 mL) several times to remove the unreacted material. The aqueous layer 
was lyophilized and the product was isolated as yellow crystals in high yields. 
 
3.7.3.1 Sodium 3-((Z)-5-benzylidene-4-oxo-2-thioxothiazolidin-3-yl)propane-1-
sulfonate (MJ 081-1) 
Yellow crystals (0.132 g, 80%). M.p (158-
161 C)1H NMR (400 MHz, D2O): δ 8.40 (s, 
1H, H-7), 7.59 (d, J = 7.5 Hz, 2H, H-2, H-
6), 7.42 (d, J = 7.5 Hz, 2H, H-3, H-5), 7.35 
(d, J = 8.3 Hz, 1H, H-4), 3.65 (t, J = 6.4 Hz, 2H, H-10), 2.66 (t, J = 7.2 Hz, 1H, H-8). 
1.98 - 1.88 (m, 2H, H-9). 13C NMR (101 MHz, DMSO-d6): δ 192.19, 166.24, 141.39, 




Yellow crystals (0.123 g, 81%). M.p 
(114-118 C) 1H NMR (400 MHz, 
DMSO-d6): δ 7.69 (s, 1H, H-7), 7.56 (m, 
2H, H-2, H-6), 6.96 (m, 2H, H-3, H-5), 
4.08 (t, J = 7.3 Hz, 2H, H-10), 3.44 (t, J = 6.4 Hz, 2H, H-8), 2.03 – 1.92 (m, 2H, H-9), 
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CDCl3): δ 192.21, 166.32, 149.18, 142.03, 132.14, 126.04, 124.90, 116.06, 49.43, 
41.73, 40.69, 31.39, 21.96. 
 
3.7.3.3 Sodium 3-((Z)-5-(2-hydroxy-3-methoxybenzylidene)-4-oxo-2-
thioxothiazolidin-3-yl)propane-1-sulfonate (MJ 081-8) 
Yellow crystals (0.128 g, 83%). M.p (269-272 
C) 1H NMR (400 MHz, DMSO-d6): δ 7.79 (s, 
1H, H-7), 7.63 (d, J = 8.8 Hz, 2H), 7.13 (d, J = 
8.8 Hz, 2H), 4.10 (t, J = 7.3 Hz, 2H, H-10), 3.85 (s, 3H, OCH3), 2.51 – 2.50 (t, J = 
7.3, 2H, H-8), 2.08 – 1.87 (m, 2H, H-9). 13C NMR (101 MHz, DMSO-d6): δ 192.34, 





Yellow crystals (0.134 g, 85%). M.p 
(324-327 C) 1H NMR (400 MHz, 
DMSO-d6): δ 7.81 (s, 1H, H-7), 7.60 (m, 
2H, H-3, H-5), 7.64 – 7.47 (m, 2H, H-2, H-6), 4.10 (t, J = 7.3 Hz, 2H, H-10), 3.83 (s, 
3H, OCH3), 2.50 (t, J = 7.0 Hz, 2H, H-8), 1.98 (m, 2H, H-9). 13C NMR (101 MHz, 
DMSO-d6): δ 192.21, 166.22, 160.01, 142.78, 127.54, 127.45, 116.11, 114.17, 56.02, 
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CHAPTER 4 
Synthesis of substrate mimics as potential inhibitors of MshA 
4.1 Introduction 
Glycosyltransferase inhibitors attracted considerable attention in recent years, not 
only for their involvement as a tool for fundamental studies of complex carbohydrate-
mediated biological processes but also as a foundation for the development of new 
drugs against many diseases.1-4 This include natural product sugar nucleotide mimic 
inhibitors such as nikkomycins, tunicamycin as well as a variety of synthetic 
inhibitors (Fig. 4-1).5,6 Sugar nucleotides play an essential role in carbohydrate 



















































Figure 4-1: Examples of sugar nucleotide mimic inhibitors. 
 
In an attempt to find a replacement for the polar pyrophosphate link in sugar 
nucleotides, Wang et al.6 investigated malonic and tartaric moieties. However, all the 
compounds tested showed poor inhibition towards the glycosyltransferases. Kimura 
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and Bugg, proposed that tunicamycin utilized a L-rhamnose sugar moiety to mimic 
the pyrophosphate-Mn2+ complex of UDP-GlcNAc and subsequently inhibits the 
transfer of GlcNAc-1-P from UDP-GlcNAc to polyprenyl monophosphates in a 
variety of organisms.7 Tunicamycin is a non-selective inhibitor of 
glycosyltransferases and hence, relatively toxic.  
 
However, the rational drug design of inhibitors requires information about the three-
dimensional structure of the enzyme.8,9 As this would ensure the donor and acceptor 
portions of the substrate mimic are placed in correct orientation that allow their 
binding into their respective binding sites. Vetting et al.10 reported the three-
dimensional structure and basic kinetic properties of the retaining glycosyltransferase 
MshA from Corynebacterium glutamicum (cgMshA) and subsequently Framton et 
al.11 reported UDP-(5F)-GlcNAc as the first competitive inhibitor of UDP-GlcNAc, 
the natural substrate of the MshA. The study further revealed that cgMshA undergoes 
large conformational change upon the binding of the UDP-(5F)-GlcNAc and 
subsequently assume the oxocarbenium transitional-state proposed for retaining 
glycosyltransferase enzymes. Although, the kinetic data revealed that UDP-(5F)-
GlcNAc is a slow inhibitor of MshA, the study has provided invaluable information in 
the design of MshA inhibitors. Since the appearance of the three-dimensional 
structure of MshA, enormous effort has been made to identify and design potential 
inhibitors of MshA. 
 
The main focus in this chapter is to report the design and synthesis of the substrate 
mimics for glycosyltransferase, MshA. The substrate mimics were designed in such a 
way that they mimic the naturally occurring substrate UDP-GlcNAc (Fig. 4-1) of 
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MshA by retaining the sugar moiety and nucleoside fragments of the natural substrate, 
which are both involved in binding inside the MshA active site.  
 
The rationale behind the design of the substrate mimic derivatives was the desire to 
find a potential substitute for the pyrophosphate moiety of UDP-GlcNAc. Studies 
have revealed that all three parts of UDP-GlcNAc (uridine, the pyrophosphate and the 
sugar moiety) are involved to some extent in binding to the glycosyltransferase active 
site. The pyrophosphate moiety bind strongly to a divalent metal cation usually Mn2+ 
in the glycosyltransferase active site. Therefore finding the replacement of the 
pyrophosphate moiety of sugar-nucleoside diphosphate donors with an isosteric group 
like 1,2,3 triazole or phosphonate is desirable.  
 
The synthetic strategy to produce substrate mimic analogs centered on the 
incorporation of a stable 1,2,3-triazole or phosphonate to replace the pyrophosphate 
moiety or anomeric oxygen of the natural substrate of MshA respectively. The 
incorporation of sulphur on the anomeric position of the sugar donor will result in the 
formation of a more stable thioglycosylated molecule. 
 
The use of thioglycosides towards the synthesis of inhibitors has received widespread 
attention due to their versatility in the biological field.12 The advantage of 
thioglycosides is that they are well tolerated by most biological systems13,14, more 
resistant to enzymatic or chemical degradation14 and more likely to reach their target. 
In this chapter, molecular dynamic docking experiments were performed in the mshA 
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4.2 Docking of the substrate mimics in the MshA substrate binding pocket 
Following a computational simulation procedure described (Chapter 3, Section 3.2), 
molecular docking simulations were performed on the substrate mimics (4-25 and 4-
34) prior to their synthesis. The docking results showed that all the substrate mimics 
assumed the same orientation as natural substrate (UDP-GlcNAc) within the MshA 
binding pocket, with 1,2,3-triazole (4-25) occupying same position as pyrophosphate 
moiety of the natural substrate.  
 
Furthermore, docking analysis showed a strong interaction between the substrate 
mimic (4-25) and specific amino acid residues (ARG231, GLU316, LYS236 and 
GLU324 (x2) in the binding pocket of MshA, thus forming five new hydrogen bonds. 
The newly formed hydrogen bonds are indicated by dashed yellow lines (Fig. 4-2). 
From the estimated free energy of ligand binding (ΔG), the inhibition constant (Ki) 
for each ligand was calculated. Ki is calculated by the equation: Ki = exp [(ΔG* 
1000)/ (R*T)] where ΔG is the docking energy, R (gas constant) is 1.98719 
kcal/Kmol and T (Temperature) is 298.15 K. Only the best pose with the lowest 
binding energy and Ki was considered. The binding energy for the docked substrate 



























Figure 4-2: Docked structures of substrate mimic (4-25) in the active site of MshA. Newly formed 
hydrogen bonds are indicated by dotted yellow lines. 
 
Similar observations were made with substrate mimic (4-34). The molecular docking 
studies revealed key amino acid residues (THR134, LYS236 (x2), ARG231, VAL321, 
GLY23, CYS262, ARG294 and GLU324 (x2) interact with substrate mimic (4-34) in 
the binding pocket of MshA, thus forming ten new hydrogen bonds (Fig. 4-3). The 
binding energy for the docked substrate mimic (4-34) was found to be -94.40 
kcal/Kmol, thus making it the best potential inhibitor for MshA. This observation was 
in agreement with the previous studies on the glycosyltransferase MurG.31 





















Figure 4-3: Docked structures of substrate mimic (4-34) in the active site of MshA. Newly formed 
hydrogen bonds are indicated by dotted yellow lines. 
 
Following the successful docking of the substrate mimics in the MshA binding 
pocket, several attempts were made to dock tunicamycin, a natural inhibitor of 
glycosyltransferases in the MshA binding pocket. However, the docking results 
returned poor binding energies and inhibition constants (Data not shown). This could 
be attributable to the large size or long aliphatic side chain of tunicamycin that renders 
the molecule too flexible. However, despite the setback with docking of tunicamycin 
in the active site of MshA, the synthesis of substrate mimics (4-25, 4-29 and 4-34) 
was conceptualized following successful docking experiments of these target 
substrate mimics.  
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Figure 4-4: A retrosynthetic approach towards the synthesis of the target molecules. 
 
As indicated by the retrosynthetic analysis (Fig. 4-4), the total synthesis of the target 
substrate mimics (4-25 and 4-29) was conceived as achievable via a convergent 
strategy involving the coupling of terminal alkyne moiety (4-19) and 5'-deoxy-5'-
azido-uridine (4-24). Huisgen coupling of the two intermediates (4-19 and 4-24) will 
result in the formation of a substrate mimic with the desired 1,2,3-triazole as a 
substitute for pyrophosphate. 5'-Deoxy-5'-azido-uridine (4-24) can be achieved in 4 
steps from commercially available uridine. Terminal alkyne moiety (4-19) can be 
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achieved in a series of steps from glucosamine. Likewise, the total synthesis of the 
target substrate mimic (4-34) can be achieved via the coupling of the target 
intermediate (4-33) and uridine monophosphate (UMP).  
 
4.3.1 Synthesis of thioglycosides 
Since the appearance of the first report of glycosyl thiol synthesis by Fischer and 
Delbruck in 1909, various methods for the synthesis of glycosyl thiols (4-1) have been 
reported. The most frequently used method involves the treatment of glycosyl halides 
(4-2) (Scheme 4-1) with thiourea in acetone followed by mild hydrolysis with alkali 












Scheme 4-1: Reaction conditions: (i) Thiourea, (ii) Na2S2O5, DCM/water, (iii) KSAc (iv) NaSMe, 
MeOH/CHCl3. 
 
Generally the synthesis of α-glycoside intermediates by the direct glycosylation of the 
anomeric carbon has been a challenge for numerous reasons. Stereoselectivity at the 
anomeric carbon is governed by a number of factors such as the type of solvent used, 
reaction conditions e.g. temperature, anomeric effect and the possible involvement of 
the participating group on the carbon adjacent to the anomeric carbon.15,16 The 
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carbonyl oxygen with anomeric carbon. Furthermore, complexation with the 
glycoside donors, activating reagents and other Lewis acids.17  
 
β-anomers are generally prepared by equatorial addition of the nucleophiles to the 
anomeric carbon whereas α-anomers are prepared by axial addition. However, the 
interaction of these groups with anomeric centres affords the formation β-anomers 
since the nucleophile can only approach from the top. The substituent on the anomeric 
carbon would prefer the more stable equatorial position with minimised unfavoured 
interactions. 
 
However, Bernades et al.18 have described a direct procedure for the synthesis of 
anomeric α-glycosyl thiols in one synthetic step from their anomeric alcohols using 







Scheme 4-2: Reaction conditions: (i) Lawesson’s reagent, dioxane/toluene. 
 
Similar studies were reported by Davis and co-workers using Lawesson’s reagent 
which was found to be able to directly convert the reducing sugars or unprotected 
sugars into their corresponding α-glycosyl thiols. However, this procedure was found 
to have some setbacks because of the tendency to form numerous by-products making 
it difficult to purify and resulting in lower yields. Thus, a procedure for the synthesis 
of α-glycosyl thiols was lacking. Such a procedure would facilitate the synthesis of α-
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Knapp and Myers19 reported a procedure for the synthesis of glycosyl thiol (4-1) 
whereby 2-acetamido-2-deoxy-1,3,4,6-tetra-O-acetyl-β-D-galactopyranose (4-7) 
(Scheme 4-3) was treated with Lawesson’s reagent in hot toluene to form the 
GalNAc-thiazolidine ring (4-8). Following the successful formation of the thiazoline 
ring and subsequent hydrolysis of the ring through the cleavage of the C-S bond led to 
the desired α-GalNAc mercaptan (4-9). This procedure was found to be very efficient 






Scheme 4-3: Reaction conditions: (i) Lawesson’s reagent, toluene, 80 C; (ii) TFA, wet MeOH. 
 
The deprotection of (4-8) to the α-mercaptan (4-10) has been achieved under Zemplén 
conditions (Scheme 4-4). The successful preparation of glycosyl thiol (4-1), presented 
a valuable intermediate toward the synthesis of GalNAc thioconjugates.  
 
Scheme 4-4: Reaction conditions: (i) NaOMe, MeOH; (ii) TFA, wet MeOH. 
 
The substrate mimics have been designed to compete with UDP-GlcNAc for binding 
to the active site of MshA. It is for this reason that it was decided to pursuit the 
synthesis and evaluation of these substrate mimics as part of identifying selective 
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mimics began with the synthesis of the key substrate intermediate α-GlcNAc 
mercaptan (4-17). 
 
4.3.2 Synthesis of α-GlcNAc mercaptan 
The synthesis of 2-acetamido-2-deoxy-3,4,6-tri-O-acetyl-1-α-thio-D-glucopyranose 
(α-GlcNAc mercaptan) (4-17) (Scheme 4-5) has been successfully achieved in a series 
of steps following the modified protocols of Knapp and Myers19,20 and Myszka et al.21 
respectively. 2-Deoxy-2-[p-methoxybenzylidene(amino)]-D-glucopyranose (4-12) 
was prepared from commercially available D-glucosamine hydrochloride (4-11) in a 
procedure that utilizes p-anisaldehyde to protect the amine (NH2) as a Schiff base 
followed by the global acetylation of the remaining hydroxyl groups in the presence 
of pyridine and acetic anhydride to give 1,3,4,6-tetra-O-acetyl-2-deoxy-2-[p-
methoxybenzylidene(amino)]-β-D-glucopyranose (4-13). The 4-methoxybenzylidene 
protecting group was hydrolyzed by the treatment of compound (4-13) with 5 M HCl 
in acetone to afford 1,3,4,6-tetra-O-acetyl-β-D-glucosamine hydrochloride (4-14), 
which was subsequently acetylated to afford 2-acetamido-2-deoxy-1,3,4,6-tetra-O-
acetyl-β-D-glucopyranose (4-15) in excellent yields. The structure of (4-15) was 
confirmed by the 1H and 13C NMR spectra with the presence of the strong resonance 
of the OAc (s, 12 protons) at δH 1.97 ppm and another resonance at δH 2.04 ppm (s, 3 
protons) which correspond to NHAc. 
 


























































Scheme 4-5: Reaction conditions: (i) aq 1M NaOH, p-CH3O-C6H4-CHO; (ii) Py, Ac2O; (iii) Acetone, 
5M HCl; 99% (iv) Py, Ac2O; 97% (v) Lawesson’s reagent, toluene, 80 C; 100 (vi) TFA, wet MeOH, 
H2O, 0 C; 2 hr; 95%.. 
 
Following the successful synthesis of compound (4-15), the next step was to treat 
compound (4-15) with Lawesson’s reagent in the presence of toluene to convert the 
amide into the GlcNAc-thiazoline (4-16). The structure of the latter was confirmed by 
1H and 13C NMR spectroscopy, which showed key diagnostic signals at δH 2.28 ppm 
(1H NMR) and δC 20.7 ppm (13C NMR) corresponding to methyl (CH3) attached to 
the thiazoline ring. Another diagnostic feature was the presence of the downfield 
doublet for H-1 (J = 7.1 Hz) confirming the alpha anomeric stereochemistry at C-1 
position.  
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The GlcNAc-thiazoline ring was hydrolyzed by the cleavage of the imine carbon-
sulphur bond rather than the anomeric carbon-sulphur bond and the opening of the 
thiazoline ring to give 2-acetamido-2-deoxy-3,4,6-tri-O-acetyl-1-thio-α-D-
glucopyranose (4-17)22 as a golden brown syrup in 100% yield. The structure of (4-
17) was confirmed using the 1H NMR and 13C NMR spectroscopic data. 
 
The disappearance of the methyl singlet of the thiazoline ring resonating at δH 2.28 
ppm in the spectrum of (4-16) was diagnostic in (4-17). The 13C NMR spectrum of (4-
17) also confirmed the absence of the methyl and imine carbon resonance and the 
appearance of the NHAc methyl resonance at δC 22.79 ppm.  
 
4.3.3 Synthesis of thioglycoside analogues 
The successful synthesis of α-mercaptan (4-17) (Scheme 4-5) enabled subsequent 
synthesis of the desired substrate mimics. The S-alkylation of α-mercaptan (4-17) in a 
mixture of 1:1 propargyl bromide and triethylamine produced propargyl thioglycoside 
(4-18) which was subsequently deacetylated under standard Zemplén deacetylation 
conditions (sodium methoxide in methanol) to furnish N-((2R,3R,5S)-tetrahydro-4,5-
dihydroxy-6-(hydroxymethyl)-2-(prop-2-ynylthio)-2H-pyran-3-yl)acetamide (4-19) in 
a 100% yield (Scheme 4-6). 
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The 1H NMR spectroscopic data of compound (4-18) showed the presence of the 
propargyl group. Thus, resonating at δH 5.05 ppm and integrating for two methylene 
protons as well as δH 2.21 ppm for the alkyne proton respectively. This was further 
supported by the notable absence of the thiol group observed in the 1H NMR spectrum 
of (4-18). Finally, ESI HRMS evaluation gave a m/z 402.1222 [M+H]+ (C17H24NO8S) 
which required m/z 402.1223 [M+H]+, thus supporting the proposed structure of 
compound (4-18). 
 
The structure of compound (4-19) was also confirmed by the 1H NMR spectrum 
showing the complete disappearance of O-acetyl associated signals which resonated at 
δH 2.02, 2.01, and 1.90 ppm and the appearance of new hydroxyl group signals 
resonating at δH 5.11, 4.85 and 4.58 ppm, respectively. Finally, ESI HRMS evaluation 
gave a m/z 275.0826 [M+H]+ (C11H17NO5S) which required m/z 275.0827 [M+H]+, 
thus supporting the proposed structure of compound (4-19). 
 
With pure (4-19) in hand, the next objective was to synthesize the 1,2,3-triazole as a 
linking component between α-glycoside and nucleotide (5'-deoxy-5'-azido-uridine).  
 
4.3.4 Synthesis of 5'-deoxy-5'-azido-uridine derivatives (4-21 – 4-24) 
In order to secure a complete synthesis of the desired substrate mimic, the 5'-deoxy-
5'-azido-uridine (4-24) had to be synthesized. The synthesis of this nucleotide has 
been achieved in a four step synthesis from relatively cheap and commercially 
available uridine. Thus, the synthesis of 5'-deoxy-5'-azido-uridine derivatives (4-24) 
(Scheme 4-7) has been achieved following the modified procedure of Winans and 
Bertozzi.23 The synthesis of 2',3'-O-isopropylidene (4-21) has been synthesized using 
the commercially available uridine (4-20). 
















Scheme 4-7: Reactions conditions: Reagents and conditions: (i) TsOH, 2.2-dimethoxypropane, DMF, 
65 C, 100%; (ii) TsCl, Pyridine, DMF, 65 C, 93%; (iii) NaN3, DMF, 65 C, 98%; (iv) 90% 
TFA/H2O, 95%. 
 
The uridine moiety was selectively protected at position 2' and 3' using 2,2-
dimethoxypropane to furnish compound (4-21) as a white solid in 100% yield after 
silica gel column chromatography. The 1H NMR spectroscopic data showed the 
presence of two strong methyl peaks resonating at δH 1.58 and δH 1.36 ppm, 
respectively. These signals indicated successful protection of the two hydroxyl groups 
in compound (4-20). The tosylation of compound (4-21) at position five using p-
toluenesulfonyl chloride (TsCl) and in the presence of pyridine in DMF provided the 
tosylated product (4-22) in good yield (100%).  
 
The diagnostic features in the 1H NMR spectrum of (4-22) were the tosyl methyl 
resonance at δH 2.45 and the aromatic resonances at δH 7.78 and δH 7.34 ppm 
respectively. Furthermore, the infrared (IR) spectrum showed two strong absorbances 
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absence of the hydroxyl group resonance in 1H NMR spectrum was further evidence 
that the tosylation had taken place. 
 
The tosyl group was subsequently substituted with a azide moiety in the presence of 
sodium azide (NaN3) in DMF to produce 5'-deoxy-5'-azido-2',3'-O-isopropylidene 
uridine (4-23) (Scheme 4-7) in quantitative yield. The 1H NMR spectrum of (4-23) 
showed the disappearance of the two aromatic protons resonating at δH 7.78 and δ 
7.34 ppm, and the absence of the tosyl methyl resonance at δH 2.45 ppm, respectively. 
 
Deprotection of compound (4-23) ultimately gave 5'-deoxy-5'-azido-uridine (4-24) in 
90% yield. The 1H NMR spectrum of (4-24) showed the disappearance of the two 
methyl resonances at δH δ 1.58 and δH 1.36 ppm respectively and the appearance of a 
broad singlet resonating at δH 5.30 ppm, integrating for two protons. Another 
significant feature in the 1H NMR spectrum of compound (4-24) is the protons 
resonating at δH 3.70 ppm assigned to 5'-deoxy-5'-azido-uridine.  
 
The coupling of the terminal alkyne moiety of (4-19) and 5'-deoxy-5'-azido-uridine 
(4-24) in the presence Cu(II) sulphate pentahydrate and sodium ascorbate as a 
reducing agent led to formation of triazole thioglycoside (4-25) (Scheme 4-8), which 
is one of the target molecules in this study. This substrate mimic has been tailored in 
such a way that it retains the carbohydrate and nucleoside fragments of the natural 
substrate UDP-GlcNAc, which are both involved in binding of MshA active site while 
the pyrophosphate of the natural substrate is substituted by the 1,2,3-triazole.  
 
However, prior to the synthesis of thioglycosides (4-25) using the Cu(II) catalyzed 
reaction, several attempts were made using Cu(I) mediated reaction as a catalyst in a 
mixture of water and t-BuOH (1:1) at room temperature resulted in a mixture of 
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products as witnessed by TLC, which proved difficult to separate. Other challenges 
encountered with this synthetic procedure ranged from the lengthy reaction times and 
poor isolated yields. The reaction took more than seven days for significant product 
formation and this is despite the increase in temperature and reagents. The slow 
reaction using just Cu(I) in the mixture of t-BuOH and water could be due to Cu(I) 
being oxidized to Cu(II). Cu(I) is the active species needed to facilitate this triazole-
forming reaction. 
 
Surprisingly the use of a combination of Cu(II) and sodium ascorbate tremendously 
improved product formation and a slightly improved yield of 30% was obtained at 
room temperature within 24 hr. Unlike in the Cu(I) catalysed reaction, the Cu(II) 
catalysed reaction gave much better chemoselectivity with the desired product being 
identified. The persistently low yields of the copper assisted cycloaddition reactions 
could be attributed to inability to consume all the starting material during the reaction 



































Scheme 4-8: Reactions conditions: (i) CuSO4.5H2O and sodium ascorbate; 33%. 
 
The structure of thioglycoside (4-25) was confirmed by the 1H NMR spectrum and the 
key diagnostic feature in the spectrum of this compound was the presence of a 
deshielded triazole singlet proton resonating at δH 8.01 ppm which was consistent 
with that reported in the literature.25,26 Further evidence of formation of this 
compound (4-25) was the disappearance of the alkyne proton in compound (4-19). 13C 
Chapter 4                                                                           Synthesis of substrate mimics 
130 
NMR spectrum analysis supported the formation of the triazole further with the 
presence of a carbon signal resonating at δC 143.25 which was consistent with the 
triazole. Finally, ESI HRMS evaluation gave a m/z 545.1663 [M+H]+, C20H29N6O10S 
which required m/z 545.1666 [M+H]+), thus supporting the proposed structure of the 
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4.3.5 Synthesis of [1'-(5''-deoxyuridin)-1'H-1',2',3'-triazol-4'-yl] methyl 2-
acetamido-2-deoxy-α-D-glucopyranoside (4-29). 
Having successfully synthesized the α-propargyl thioglycoside (4-19), the α-propargyl 
glycoside was attempted for utilization in the Huisgen coupling. N-Acetyl 
glucosamine (4-27) (Scheme 4-9) has been successfully synthesised from relatively 
cheap and commercially available glucosamine hydrochloride (4-26) in a procedure 
described by Babic and Pecar.27 In this procedure, glucosamine hydrochloride (4-26) 
was allowed to stir in the solution of NaOMe/MeOH for 1 hr at room temperature 
before acetic anhydride was added, subsequently the mixture was allowed to stir 
overnight.27 The structure of (4-27) was confirmed by the spectroscopic data with 1H 
NMR spectrum showing the presence of the methyl resonance (NHAc) as a singlet 
resonating at δH 2.01 ppm integrating for three protons. The alkylation of (4-27) in the 
presence of propargyl alcohol and excess H2SO4 immobilized on silica gel gave the 
propargyl glycoside (4-28) as a racemic mixture. The activated silica gel was prepared 
as reported recently by Roy and Mukhopadhyay using concentrated H2SO4 on silica 
gel.28 
 
The desired α-propargyl glycoside (4-28) was obtained through the recrystallization 
of the anomeric mixture. The 1H NMR spectrum of compound (4-28) has confirmed 
that the alkylation had taken place, with the presence of two methylene protons on the 
propargyl moiety resonating at δH 3.30 ppm and triplet resonating δH 2.83 ppm for the 
alkyne proton. By using the same conditions used to access [1'-(5''-deoxyuridin)-1'H-
1',2',3'-triazol-4'-yl] methyl 1-thio-2-acetamido-2-deoxy-α-D-glucopyranoside (4-25) 
(Scheme 4-7), [1'-(5''-deoxyuridin)-1'H-1',2',3'-triazol-4'-yl] methyl 2-acetamido-2-
deoxy-α-D-glucopyranoside (4-29) was successfully synthesized in 33% yield 
(Scheme 4-9). 










































Scheme 4-9: Reactions conditions: (i)MeOH, NaOMe solution, Ac2O, RT; (ii) Propargyl alcohol, 
H2SO4-silica, 65 C; (iii) CuSO4.5H2O, Ascorbic acid, 1:1 H2O/TBA, 33%. 
 
4.3.6 Synthesis of bis-triethylammonium uridin-5'-yl (2-acetamido-2-deoxy-α-D-
glucopyranosylthiomethylphosphono) phosphate (4-34). 
As indicated by the retrosynthetic analysis (Fig. 4-4), the total synthesis of the target 
substrate mimic (4-34), requires the coupling of deacetylated glycosylthiomethyl 
phosphonate (4-33) and uridine monophosphate (UMP). The synthesis of deacetylated 
glycosylthiomethyl phosphonate (4-33) involves a series of activation steps from 2-
acetamido-2-deoxy-3,4,6-tri-O-acetyl-1-thio-α-D-glucopyranose (4-17) (Scheme 4-
10). 
 










































































Scheme 4-10: Reactions conditions: (i) DBU, DCM; 46% (ii) Et3PO4; 65% (iii) TMSBr, 2,6-lutidine, 
CAN; 95% (iv) MeOH, NaOMe; (v) Py, 1H-tetrazole, UMP-morpholidate, 37%. 
 
By using a procedure described by Zhu and Schmidt,29,30 2-acetamido-2-deoxy-3,4,6-
tri-O-acetyl-1-thio-α-D-glucopyranose (4-17) was treated with dichloromethane 
(DCM) and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) to furnish glycosylthiomethyl 
chloride (4-30) in 46% yield. The Arbuzov reaction of methylene chloride (4-30) with 
triethyl phosphite gave rise to the desired glycosylthiomethyl phosphonate (4-31) as 
an amorphous salt in quantitative yield. 
 
The structure of (4-31) was confirmed by the analysis of NMR spectroscopic data 
which was in agreement with the literature.30 The 1H NMR spectrum showed a triplet 
integrating for ten ethoxy protons (2  OEt) resonating at δH 1.25 ppm. 
Glycosylthiomethyl phosphonate (4-31) was subsequently treated with the 
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bromotrimethylsilane (TMSBr) in the presence of excess 2,6-lutidine to deprotect the 
phosphate ester, thus, giving rise to phosphonic acid compound (4-32) as a lutidinium 
salt in quantitative yield. 
 
The 1H NMR spectrum of (4-32) confirmed the deprotection of the molecule by virtue 
of the complete disappearance of OEt protons from the 1H NMR spectrum. 
Subsequently, the deacetylation of phosphonic acid compound (4-32) to 
glycosylthiomethyl phosphonate (4-32) was achieved under standard Zemplén 
deacetylation conditions. Toward the synthesis of target substrate mimic (4-34), 
glycosylthiomethyl phosphonate (4-33) was coupled with UMP-morpholidate in the 
presence of anhydrous 1H-tetrazole to produce the desired bis-triethylammonium 
uridin-5'-yl (2-acetamido-2-deoxy-α-D-glucopyranosylthiomethylphosphono) 




In summary, substrate mimics (4-25, 4-29 and 4-34) were successfully prepared as 
inspired by molecular docking simulations. The phosphate bridge of UDP-GlcNAc 
was modified by substitution of the scissile phosphate oxygen with a methylene or 
complete substitution of the phosphate bridge with triazole. Furthermore, the docking 
studies have revealed that substrate mimics assume the same orientation as the UDP-
GlcNAc in the MshA binding site, thus forming interactions with the key vicinal 
amino acid residues. In addition, the prepared substrate mimics and their 
intermediates were characterized using a variety of complementary techniques 
including LC-MS, IR, 13C and 1H NMR. Finally, the screening of the prepared 
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substrate mimics as the potential inhibitors of glycosyltransferase MshA will be 
reported in the subsequent Chapters (Chapter 5 and Chapter 6 respectively). 
 
4.5 Experimental: 
4.5.1 Synthesis of 1,3,4,6-tetra-O-acetyl-β-D-glucosamine hydrochloride (4-14)20 
An aqueous solution of NaOH (1M, 120 mL) was 
added to D-glucosamine hydrochloride (4-11) (25g, 
116 mmol) and the mixture was allowed to dissolve 
while stirring. p-Anisaldehyde (17 ml, 0.14mol) was added in small aliquots after 
which product crystallization started. The solution was allowed to stir for 6 hr and 
refrigerated for overnight. The precipitated product was filtered and washed with cold 
water followed by a mixture of ethanol and diethyl ether to give 2-deoxy-2-[p-
methoxybenzylidene (amino)]-D-glucopyranose (4-12). This intermediate compound 
was completely dried before being added to an ice cooled mixture of pyridine (135 
mL, 113 mmol) and Ac2O (75 mL, 0.9 mmol). The mixture was allowed to stir in an 
ice-bath for 1 hr and then overnight at room temperature. The solution was poured 
into approximately 500 mL of ice-water after which a precipitate formed. The 
precipitated white product was filtered, washed with cold water and dried under 
vacuum to give (2S,3R,4R,5S,6R)-6-(acetoxymetoxymethyl)-3-((E)-4-
methoxybenzylideneamino)tetrahydro-2H-pyran-2,4,5-triyl triacetate (4-13) as a 
white solid (54.0 g, 100%). The Schiff base product (50 g, 108 mmol) was dissolved 
in warm acetone (300 mL) followed by the addition of HCl (5 M; 15 mL) which 
immediately formed of a white precipitate. The mixture was allowed to cool, after 
which diethyl ether (300 mL) was added and the precipitate refrigerated overnight. 
The precipitated product was filtered and washed with diethyl ether (100 mL) and 








Chapter 4                                                                           Synthesis of substrate mimics 
136 
solid (41.0 g, 99%). The product was used in the next reaction without any further 
purification. 
 
4.5.2 Synthesis of 2-acetamido-2-deoxy-1,3,4,6-tetra-O-acetyl-β-D-glucopyranose 
(4-15)32 
To a solution of 1,3,4,6-tetra-O-acetyl-β-D-
glucosamine hydrochloride (4-14) (22.5 g, 58.7 
mmol) in DCM (150 mL) at 0 C was added acetic 
anhydride (18 mL) followed by pyridine (18 mL). 
The solution was allowed to stir for 30 min followed by the addition to ice-water. 
After organic extraction (DCM 150 mL) and drying with MgSO4 the solution was 
filtered through celite and the filtrate was concentrated under reduced pressure to give 
2-acetamido-2-deoxy-1,3,4,6-tetra-O-acetyl-β-D-glucopyranose (4-15) as a white 
solid (22.2 g, 97%). M.p (184-185 C) 1H NMR (400 MHz, CDCl3): δ 5.95 (d, J = 9.5 
Hz, 1H, NH), 5.65 (d, J = 8.8 Hz, 1H, H-1), 5.13 (dd, J = 10.4, 9.4 Hz, 1H, H-3), 5.04 
(dd, J = 9.7, 9.5 Hz, 1H, H-4), 4.24 (m, 1H, H-2), 4.19 (m,1H, H-6a), 4.07 (dd, J = 
2.3, 12.4 Hz, H-6b), 3.57 (m, 1H, H-5), 2.04 (s, 3H, NHAc), 1.97 (s, 12H, 4 x OAc). 
13C NMR (101 MHz, CDCl3): δ 171.14, 170.61, 170.16, 169.48, 169.27, 92.55, 72.74 
(2C), 68.05, 61.77, 52.91, 23.05, 20.81, 20.57 (3C). 
 
4.5.3 Synthesis of (3aR,5R,6R,7R,7aR)-5-(acetoxymethyl-6,7-diacetoxy-2-methyl-
5,6,7,7a-tetra-hydro-3aH-pyrano[3,2-d]thiazole (4-16)20 
To a solution of 2-acetamido-2-deoxy-1,3,4,6-tetra-O-
acetyl-β-D-glucopyranose (4-15) (3.2 g, 8.22 mmol) in 
toluene (30 mL) was added Lawesson’s reagent (2.1 g, 
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1.5 hr, after which the pH of the reaction was adjusted by the addition of sodium 
bicarbonate (3.0 g, 35.7 mmol). The reaction mixture was concentrated under reduced 
pressure. Purification by chromatography using a silica-gel column (320 g, 
EtOAc:DCM, 4:6, Rf 0.2) gave (3aR,5R,6R,7R,7aR)-5-(acetoxymethyl-6,7-
diacetoxy-2-methyl-5,6,7,7a-tetra-hydro-3aH-pyrano[3,2-d]thiazole (4-16) as a 
golden yellow syrup (2.84 g, 100%). 1H NMR (300 MHz, CDCl3): δ 6.22 (d, J = 7.1 
Hz, 1H, H-1), δ 5.55 (dd, J = 3.4, 1.9 Hz, 1H, H-3), 4.97 (ddd, J = 9.5, 1.7, 1.3 Hz, 
1H, H-4), 4.45 (m, 1H, H-2), 4.06 (m, 2H, H-6), 3.52 (m, 1H, H-5) 2.28 (s, 3H, CH3), 
2.11 (s, 3H, OAc) 2.06 (s, 3H, OAc) 2.05 (s, 3H, OAc).13C NMR (101 MHz, CDCl3): 
δ 170.31, 169.30, 169.03, 167.85, 88.63, 76.53, 70.56, 69.15, 68.28, 63.09, 20.71, 
20.63, 20.49, 20.44. 
 
4.5.4 Synthesis of 2-acetamido-2-deoxy-3,4,6-tri-O-acetyl-1-thio-α-D-
glucopyranose (4-17)20 
A solution of (3aR,5R,6R,7R,7aR)-5-(acetoxymethyl-6,7-
diacetoxy-2-methyl-5,6,7,7a-tetra-hydro-3aH-pyrano[3,2-
d]thiazole (4-16) (1 g, 2.9 mmol) in MeOH (10 mL) was 
cooled to 0 C, before addition of TFA (300 µL) and H2O 
(300 µL). The reaction mixture was allowed to warm to room temperature over a 
period of 2 hr. The reaction mixture was concentrated under reduced pressure. 
Purification by chromatography using a silica-gel column (100 g, EtOAc:DCM; 1:1; 
Rf 0.4) gave 2-acetamido-2-deoxy-3,4,6-tri-O-acetyl-1-thio-α-D-glucopyranose (4-17) 
as an oil (0.988 g, 95%). 1H NMR (400 MHz, CDCl3): δ 7.17 (s, 1H, N-H), 5.87 (d, J 
= 8.1 Hz, 1H, H-1), 5.68 (dd, J = 7.0, 5.3 Hz, 1H, H-3), 5.02 (m, 2H, H-6), 4.39 (m, 
1H, H-5), 4.17 (dd, J = 12.3, 4.2 Hz, 1H, H-4), 4.03 (dd, J = 12.2, 2.0 Hz, 1H, H-2), 
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171.38, 170.74, 170.61, 169.23, 78.68, 70.44, 68.87, 68.20, 61.80, 52.40, 22.79, 
20.56, 20.55, 20.44. 
 
4.5.5 Synthesis of (2R,3S,4R,5R,6Rl)-5-acetamido-2-(acetoxymethyl)-6-(prop-2-
ynylthio)tetrahydro-2H-pyran-3,4-diyl diacetate (4-18) 
2-Acetamido-2-deoxy-3,4,6-tri-O-acetyl-1-thio-
α-D-glucopyranose (4-17) (0.220 g, 0.606 mmol) 
was dissolved in 4 mL of DCM and 1.1 mol 
equivalents of triethylamine and propargyl 
bromide were added to yield (2R,3S,4R,5R,6R)-5-acetamido-2-(acetoxymethyl)-6-
(prop-2-ynylthio)tetrahydro-2H-pyran-3,4-diyl diacetate (4-18) as cream white 
crystals (0.187 g, 77%). M.p (175 - 178 C). 1H NMR (300 MHz, CDCl3) δ 5.94 (d, J 
= 8.6 Hz, 1H, H-1), 5.62 (d, J = 5.4 Hz, 1H, H-3), 5.05 (d, J = 9.3 Hz, 2H, H-1'), 4.52 
(ddd, J = 10.6, 8.8, 5.4 Hz, 1H, H-5), 4.25 (m, 2H, H-6), 4.04 (dd, J = 12.0, 2.0 Hz, 
1H, H-4), 3.44 (m, 1H, H-2), 2.21 (m, 1H, H-2'), 2.10 (s, 3H, NHAc) 2.02 (s, 3H, 
OAc), 2.01 (s, 3H, OAc), 1.90 (s, 3H, OAc). 13C NMR (75 MHz, CDCl3): δ 171.30, 
170.45, 169.99, 169.09, 83.45, 78.66, 76.99, 71.86, 71.00, 68.71, 68.11, 61.68, 52.00, 
22.89, 20.47, 19.11, 17.95. HRMS (ESI): m/z C17H24NO8S found: 402.1222 [M-H]+, 
calculated 402.1223. 
 
4.5.6 Synthesis of N-((2R,3R,5S)-tetrahydro-4,5-dihydroxy-6-(hydroxymethyl)-2-
(prop-2-ynylthio)-2H-pyran-3-yl)acetamide (4-19)  
(2R,3S,4R,5R,6Rl)-5-Acetamido-2-
(acetoxymethyl)-6-(prop-2-ynylthio)tetrahydro-
2H-pyran-3,4-diyl diacetate (4-18) (0.4 g, 0.997 
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followed by the addition of NaOMe (0.080 g, 1.448 mmol). The reaction was allowed 
to stir at room temperature overnight. Subsequently, the reaction was quenched by the 
addition of amberlyst® A-21 iron-exchange resin (0.5 g). The amberlyst® A-21 iron-
exchange resin were filtered at the end of the reaction and the filtrate was 
concentrated under reduced pressure. Purification by chromatography using a silica-
gel column (40 g, MeOH:DCM, 1:9, Rf 0.1) to give N-((2R,3R,5S)-tetrahydro-4,5-
dihydroxy-6-(hydroxymethyl)-2-(prop-2-ynylthio)-2H-pyran-3-yl)acetamide (4-19) as 
a solid (0.20 g, 52%). M.p (176 - 178 C). 1H NMR (400 MHz, DMSO-d6): δ 7.87 (s, 
1H, NH), 5.54 (d, J = 5.2 Hz, 1H, H-1), 5.11 (s, 1H, OH), 4.85 (s, 1H, OH), 4.58 (s, 
1H, OH), 3.95 – 3.83 (m, 1H, H-2), 3.69 (dd, J = 9.2, 4.2 Hz, 2H, H-6), 3.58 – 3.48 
(m, 1H, H-5), 3.48 – 3.39 (m, 1H, H-4), 3.30 (dd, J = 4.8, 2.4 Hz, 2H, H-1'), 3.10 (s, 
1H, H-2'), 1.86 (s, 3H, NHAc).13C NMR (75 MHz, DMSO-d6): δ 169.40, 81.94, 
80.20, 73.53, 73.03, 70.73, 70.67, 60.46, 53.81, 22.32, 15.93. HRMS (ESI): m/z 
C11H17NO5S found: 275.0826 [M+H]+, calculated 275.0827. 
 
4.5.7 Synthesis of 2,3-O-isopropylidine uridine (4-21)23 
Uridine (4-20) (5.0 g, 21.0 mmol) and p-toluenesulfonic acid 
(0.6 g, 3.48 mmol) were added to a flask followed by DMF 
(68 mL). The reaction was allowed to stir until a complete 
solution was obtained. 2,2-Dimethoxypropane (10 mL, 82 
mmol) was then added to the reaction followed by heating at 
65 C. The reaction was monitored by TLC and was judged to be complete after 2 hr. 
Approximately 1 g Amberlyst® A-21 ion-exchange resin was added to neutralize the 
reaction. The reaction mixture was stirred briefly before it was filtered through celite. 
Subsequently, the filtrate was concentrated under reduced pressure. Purification by 
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isopropylidine uridine (4-21) as a white solid (6 g, 100%). M.p (169 – 161 C) 1H 
NMR (300 MHz, CDCl3) δ 7.82 (d, J = 8.1 Hz, 1H, H-6), 5.87 (d, J = 8.1 Hz, 1H, H-
1'), 5.57 (d, J = 3.0 Hz, 1H, H-5), 5.04 (dd, J = 3.0, 6.6 Hz, 1H, H-2'), 4.98 (dd, J = 
3.0, 6.6 Hz, 1H, 3'), 4.29 (m, 1H, H- 4'), 3.93 (dd, J = 2.4, 12.0 Hz, 1H, H-5'α), 3.81 
(dd, J = 3.5, 12.0 Hz, 1H, H-5'β), 2.17 (s, 1H, OH), 1.58 (s, 3H, CH3), 1.36 (s, 3H, 
CH3). 13C NMR (101 MHz, CDCl3) δ 166.19, 152.05, 143.88, 114.90, 102.39, 94.15, 
88.34, 85.79, 82.19, 63.03, 27.58, 25.54. 
 
4.5.8 Synthesis of 2,3-O-isopropylidine-5-O-toluenesulfonyluridine (4-22)23 
2,3-O-Isopropylidine uridine (4-21) (4.1 g, 14.4 mmol) was 
suspended in DCM (58 mL) and subsequently pyridine (11.7 
mL, 114 mmol) was added resulting in complete dissolution. 
p-Toluenesulfonyl chloride (TsCl) (7.5 g, 39.3 mmol) was 
added to the reaction and the solution turned yellowish and 
slightly warm. The reaction was heated by the reflux for approximately 2 hr, at which 
point it was judged to be complete by TLC (DCM: MeOH 10:1). The reaction was 
diluted with 250 mL of DCM and washed with 0.5 M HCl (5 x 100 mL) and saturated 
NaHCO3 (2 x 100 mL) followed by the drying of the organic layer over Na2SO4. The 
solvent was concentrated under reduced pressure. Purification by chromatography 
using a silica-gel column (400 g; MeOH:DCM, 1–5% gradient) gave 2,3-O-
isopropylidine-5-O-toluenesulfonyluridine (4-22) as a white solid (5.87 g, 93 %). M.p 
(145 – 147 C) 1H NMR (400 MHz, CDCl3) δ 9.06 (s, 1H, NH), 7.78 (d, J = 8.3 Hz, 
2H, Ts), 7.34 (d, J = 8.0 Hz, 2H, Ts), 7.25 (m, 1H, H-6), 5.71 (d, J = 8.0 Hz, 1H, H-
1'), 5.66 (d, J = 2.1 Hz, 1H, H-5), 4.93 (dd, J = 2.4, 6.4 Hz, 1H, H-2'), 4.79 (dd, J = 
3.6, 6.4 Hz, 1H, H-3'), 4.35 (m, 1H, H-4'), 3.74 (m, 1H, H-5'α), 3.55 (m, 1H, H-5'β), 
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163.82, 150.17, 145.30, 142.73, 132.66, 129.91, 127.96, 115.01, 103.11, 95.27, 84.89, 
84.31, 80.81, 69.18, 27.03, 25.20, 21.71. 
 
4.5.9 Synthesis of 5-azido-deoxy-2,3-O-isopropylidene uridine (4-23)23 
2,3-O-Isopropylidine-5-O-toluenesulfonyluridine (4-22) (6.0 
g, 14 mmol) was dissolved in DMF (34 mL) followed by the 
addition of NaN3 (3.4 g, 68 mmol). The suspension was 
allowed to stir overnight at 65 C. Upon the completion of the 
reaction water was added to the reaction mixture and the 
aqueous solution was extracted with ethyl acetate (3 x). The organic layers were 
combined and dried over MgSO4. Subsequently the organic solvent was concentrated 
under reduced pressure. Purification by chromatography using a silica-gel column 
(600 g; MeOH:DCM, 1 – 5%) gave 5-azido-deoxy-2,3-O-isopropylidene uridine (4-
23) as a white solid (4.2 g, 98%). M.p (108-110 C) 1H NMR (400 MHz, CDCl3) δ 
10.03 (s, 1H, N-H), 7.31 (d, J = 8.0, 1H, H-6), 5.76 (d, J = 8.0 Hz, 1H, H-1'), 5.67 (d, 
J = 2.4 Hz, 1H, H-5), 5.01 (dd, J = 4.0, 6.4 Hz, 1H, H-2'), 4.82 (dd, J = 4.0, 6.4 Hz, 
1H, H-3'), 4.24 (m, 1H, H-4'), 3.66 (d, J = 5.6, 2H, H-5'), 1.56 (s, 3H, CH3), δ 1.34 (s, 
3H, CH3).13C NMR (101 MHz, CDCl3) δ 163.21, 150.03, 142.31, 114.82, 102.89, 
94.72, 85.75, 84.31, 81.49, 52.36, 27.10, 25.25. 
 
4.5.10 Synthesis of 5-azido-5-deoxy uridine (4-24)23 
5-Azido-deoxy-2,3-O-isopropylidene uridine (4-23) (2.6 g, 
8.41 mmol) was added to 90 % TFA/water (50 mL). The 
reaction mixture was monitored by TLC (DCM:MeOH, 6:1) 
and judged to be complete within 20 minutes. The reaction 
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by chromatography using a silica-gel column (250 g;.MeOH/DCM, 1–5% gradient) 
gave 5-azido-5-deoxy uridine (4-24) as a white glasslike product (2.14 g, 95 %). M.p 
(150-151 C, Lit33 150-150.5 C) 1H NMR (300 MHz, DMSO) δ 11.29 (s, 1H, N-H), 
7.70 (d, J = 9.0 Hz, 1H, H-6), 5.82 (d, J = 5.4 Hz, 1H, H-1'), 5.71 (dd, J = 2.4, 8.1 Hz, 
1H, H-5), 5.30 (s, 2H, OH), 4.22 (m, 1H, H-2'), 4.10 (m, 1H, H-3'), 4.00 (m, 1H, H-
4'), 3.70 (dd, J = 3.2, 13.4 Hz, H-5').13C NMR (101 MHz, CDCl3) δ 166.05, 142.61, 
125.23, 101.62, 91.70, 83.71, 74.77, 71.68, 53.01. 
 
4.5.11 Synthesis of [1'-(5''-deoxyuridin)-1'H-1',2',3'-triazol-4'-yl] methyl 1-thio-2-
acetamido-2-deoxy-α-D-glucopyranoside (4-25) 
To a solution of product N-((2R,3R,5S)-
tetrahydro-4,5-dihydroxy-6-
(hydroxymethyl)-2-(prop-2-ynylthio)-2H-
pyran-3-yl)acetamide (4-19) (0.0325 g, 0.5 
mmol) and 5'-adizo-5'-deoxyuridine (4-24) (0.0337 g, 0.5 mmol) in a 1:1 mixture of 
water and tert-butyl alcohol (1 mL) at room temperature was added sodium ascorbate 
(300 µL of freshly prepared 1 M solution in water, 0.1 mmol) and copper (II) sulphate 
pentahydrate (300 µL of freshly prepared 0.1 M solution in water, 0.1 mmol). After 
72 hr, the product was formed and the reaction mixture was concentrated under 
reduced pressure. Purification by chromatography using a silica-gel column (3 
g;.MeOH/DCM, 1: 6) to give [1'-(5''-deoxyuridin)-1'H-1',2',3'-triazol-4'-yl] methyl 1-
thio-2-acetamido-2-deoxy-α-D-glucopyranoside (4-25) as an oil (0.090 g, 33%). 1H 
NMR (400 MHz, D2O) δ 7.90 (s, 1H, H-7), 7.27 (d, J = 8.2 Hz, 1H, H-6), 5.79 (d, J = 
7.9 Hz, 1H, H-1'), 5.71 (d, J = 3.4 Hz, 1H, H-5), 5.26 (d, J = 5.5 Hz, 1H, H-9), 4.25 
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1H, H-14a'), 3.76 (m, 1H, H-13), 3.74 (m, 1H, H-5'), 3.72 (s, 2H, H-8), 3.65 (m, 1H, 
H-3'), 3.54 (dd, 1H, H-14b'), 36 (m, 1H, 12), 1.89 (s, 3H, NHAc). 13C NMR (75 MHz, 
D2O): δ 174.15, 166.21, 151.53, 142.36, 142.12, 125.41, 102.61, 91.47, 90.12, 80.88, 
77.56, 76.63, 72.59, 71.92, 70.34, 58.64, 53.87, 51.50, 50.75, 21.83. HRMS (ESI): 
m/z C20H29N6O10S found: 545.1663 [M+H]+, calculated 545.1666. 
 
4.5.12 Synthesis of N-(tetrahydro-2,4,5-trihydroxy-6-(hydroxymethyl)-2H-pyran-
3-yl)acetamide (4-27) 
Glucosamine hydrochloride (4-26) (5 g, 23.2 mmol) 
was dissolved in NaOMe which was further diluted 
to a 0.5 M solution using methanol (50 mL). The 
mixture was allowed to stir for 1 hr at room 
temperature before acetic anhydride (1.5 equiv) was added. The mixture was allowed 
to shake gently overnight, after which a milky solution was produced, filtration and 
storage of the filtrate at -41 C resulted in the crystallization of the desired product N-
acetyl-D-glucosamine (4-27). Rf 0.2 (MeOH/DCM, 1:4). 
 
4.5.13 Synthesis of N-((2S,3R,5S)-tetrahydro-4,5-dihydroxy-6-(hydroxymethyl)-
2-(prop-2-ynyloxy)-2H-pyran-3-yl)acetamide (4-28)25 
H2SO4-silica28 (6 g) was added to a stirred 
suspension of N-acetyl-D-glucosamine (4-27) (1 
g, 4.52 mmol) in propargyl alcohol (4 mL). The 
reaction mixture was allowed to stir at 65 C 
overnight. The reaction was monitored using TLC (MeOH/DCM, 1:4) and the reaction 
mixture was concentrated in vacuo upon the completion. The residue was purified 
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recrystallization in methanol to give the desired product N-((2S,3R,5S)-tetrahydro-
4,5-dihydroxy-6-(hydroxymethyl)-2-(prop-2-ynyloxy)-2H-pyran-3-yl)acetamide (4-
28) as a white solid (0.260 g, 22%). M.p (173 – 175 C, Lit 172 – 173 C). 1H NMR 
(300 MHz, MeOH) δ 4.98 (d, J = 3.8 Hz, 1H, H-1), 4.25 (1H, dd, J = 2.3 Hz, J = 16.1 
Hz, H-1'a), 4.24 (1H, dd, J = 2.3 Hz, J = 16.1 Hz, H-1'b), 3.94 (1H, dd, J = 3.8 Hz, J = 
10.7 Hz, H-2), 3.85 (1H, dd, J = 2.2 Hz, J = 12.3 Hz, H-6), 3.77 (1H,dd, J = 5.0 Hz, J 
= 12.3, H-6), 3.69–3.72 (2H, m, H-3, H-5), 3.47 (t, J = 9.5 Hz, 1H, H-4), 2.83 (t, J = 
2.3 Hz, 1H, H-2'), 2.01 (s, 3H, NHAc). 13C NMR (125 MHz, MeOH): δ 174.53, 95.93, 
79.04, 75.77, 72.28, 70.88, 69.79, 60.32, 55.10, 53.39, 21.83. 
 
4.5.14 Synthesis of [1'-(5''-deoxyuridin)-1'H-1',2',3'-triazol-4'-yl] methyl 2- 
acetamido-2-deoxy-α-D-glucopyranoside (4-29)25 
To a solution of product N-((2S,3R,5S)-
tetrahydro-4,5-dihydroxy-6-(hydroxymethyl)-
2-(prop-2-ynyloxy)-2H-pyran-3-yl)acetamide 
(4-28) (0.0325 g, 0.5 mmol) and 5'-adizo-5'-deoxyuridine (24) (0.0337 g, 0.5 mmol) 
in a 1:1 mixture of water and tert-butyl alcohol (1 mL) at room temperature was 
added sodium ascorbate (300 µL freshly prepared 1 M solution in water, 0.1 mmol) 
and copper (II) sulphate pentahydrate (300 µL freshly prepared 0.1 M solution in 
water, 0.1 mmol). After 72 hr, the product was formed and the reaction mixture was 
concentrated under reduced pressure. Purification by chromatography using a silica-
gel column (3 g; MeOH/DCM, 1: 6) to give [1'-(5''-deoxyuridin)-1'H-1',2',3'-triazol-
4'-yl] methyl 2-acetamido-2-deoxy-α-D-glucopyranoside (4-29) as an oil (33%). 1H 
NMR (400 MHz, DMSO-d6) δ 8.01 (s, 1H), 7.32 (d, J = 8.2 Hz, 1H), 5.77 (d, J = 8.2 
Hz, 1H), 5.69 (d, J = 3.6 Hz, 1H), 4.87 (d, J = 3.8 Hz, 1H), 4.68 (1H, d, J = 12.9 Hz), 
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(dd, J = 3.6 Hz, J = 5.7 Hz, 1H), 4.12 (t, J = 6.3 Hz, 1H), 3.85 (1H, dd, J = 3.8 Hz, J = 
10.7 Hz), 3.65–3.76 (m, 3H), 3.55–3.59 (1H, ddd, J = 10 Hz, J = 4.4 Hz, J = 2.8 Hz), 
3.42 (t, J =10 Hz, 1H), 1.89 (s, 3H). 13C NMR (125 MHz, D2O): δ 174.18, 166.09, 
151.19, 143.78, 142.53, 126.08, 102.18, 96.21, 91.53, 80.69, 72.47, 72.11, 70.79, 
69.88, 69.77, 60.38, 60.01, 53.47, 50.81, 21.69. 
 
4.5.15 Synthesis of chloromethyl 3,4,6-tri-O-acetyl-2-acetamido-2-deoxy-1-thio-α-
D–glucopyranoside (4-30)25,26 
To a solution of 2-acetamido-2-deoxy-3,4,6-tri-O-
acetyl-1-α-thio-D-glucopyranose (4-17) (1 g, 2.75 
mmol) in anhydrous DCM (46 mL) was added 
DBU (0.5 mL, 3.3 mmol). The reaction mixture was 
allowed to stir overnight at room temperature, after which the TLC indicated the 
disappearance of the starting material. The reaction mixture was concentrated under 
reduced pressure. Purification by chromatography using a silica-gel column (100 g; 
EtOAc/Pet ether, 2:1) gave the desired product chloromethyl 3,4,6-tri-O-acetyl-2-
acetamido-2-deoxy-1-thio-α-D–glucopyranoside (4-30) as a off-white foam, (0.486 g, 
43%). 1H NMR (300 MHz, CDCl3): δ 5.87 (d, J = 8.2 Hz, 1H, H-1), 5.67 (d, J = 5.5 
Hz, 1H, H-3), 5.04 (d, 9.3 Hz, 2H, H-1'), 4.48 (ddd, J = 10.6, 8.3, 5.6 Hz, 1H, H-2), 
4.23 (ddd, J = 13.6, 6.5, 3.5 Hz, 2H, H-6), 4.04 (dd, J = 13.0, 3.2 Hz, 1H, H-5), 3.70 
(m, 1H, H-4), 2.03 (s, 3H, NHAc), (s, 9H, 3 x 3 OAc). 13C NMR (75 MHz, CDCl3): δ 
171.40, 170.39, 170.17, 169.13, 81.84, 71.18, 68.66, 61.80, 51.91, 29.99, 22.84, 
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4.5.16 Synthesis of diethyl (3,4,6-tri-O-acetyl-2-acetamido-2-deoxy-α-D-
glucopyranosylthiomethyl) phosphonate (4-31)26 
Chloromethyl 3,4,6-tri-O-acetyl-2-acetamido-2-
deoxy-1-thio-α-D–glucopyranoside (4-30) (0.381 
g, 0.930 mmol) was refluxed in P(OEt)3 (7.3 
mL) at 160 C for 48 hr. The reaction mixture 
was concentrated under reduced pressure. Purification by chromatography using a 
silica-gel column (40 g; toluene:acetone, 5:1) to give diethyl (3,4,6-tri-O-acetyl-2-
acetamido-2-deoxy-α-D-glucopyranosylthiomethyl) phosphonate (4-31) as a white 
amorphous solid (0.309 g, 65%). 1H NMR (400MHz, CDCl3) δ 6.24 (d, J = 7.1 Hz, 
1H), 5.76 (d, J = 5.1 Hz, 1H), 5.17 (m, 2H), 4.47 (m, 1H), 4.30 (m, 1H), 4.24 (m, 1H), 
4.11 (m, 5H), 3.55 (m, 1H), 3.48 (m, 1H), 2.10, 2.05, 2.04, 1.96 (4s, 12H), 1.25 (t, J = 
7.1 Hz, 6H). 13C NMR (101 MHz, CDCl3): δ 170.08, 169.88, 169.79, 168.83, 82.71, 
75.12, 73.14, 68.18, 62.68, 62.12, 61.68, 52.23, 21.11, 20.03, 19.97, 15.83, 15.67. 
 
4.5.17 Synthesis of bis-2,6-lutidinium (3,4,6-tri-O-acetyl-2-acetamido-2-deoxy-α-
D-glucopyranosylthiomethyl) phosphonate (4-32)26 
To a stirred solution of diethyl (3,4,6-tri-O-
acetyl-2-acetamido-2-deoxy-α-D-
glucopyranosylthiomethyl) phosphonate (4-
31) (7.7 g, 15.0 mmol) in dry CH3CN (8.6 
mL) was added 2,6-lutidine (2.58 mL, 2.4 
mmol) under N2 gas. After cooling at 0 C, TMSBr (2.37 mL, 1.9 mmol) was added 
dropwise to the mixture. The cooling bath was removed after 30 min, and the reaction 
mixture was allowed to stir at room temperature for 24 hr. The solvent was removed 
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to give bis-2,6-lutidinium (3,4,6-tri-O-acetyl-2-acetamido-2-deoxy-α-D-
glucopyranosylthiomethyl) phosphonate (4-32) as a white solid (6.6 g, 97%). The 
litidium salt was used in the next reaction without any further purification. 
 
4.5.18 Synthesis of (2-acetamido-2-deoxy-α-d-glucopyranosylthiomethyl) 
phosphonate (4-33) 
To a stirred solution of bis-2,6-lutidinium (3,4,6-
tri-O-acetyl-2-acetamido-2-deoxy-α-D-
glucopyranosylthiomethyl) phosphonate (4-32) 
(2.0 g, 6.08 mmol) in methanol (4 mL) was added 
NaOMe (0.149 g, 2.8 mmol). The reaction mixture was allowed to stir at room 
temperature for overnight. The following day the reaction mixture was neutralized by 
the addition of Dowex iron exchange resins and equivalent volume of water. The 
solution was filtered and lyopholized to give 2-acetamido-2-deoxy-α-d-
glucopyranosylthiomethyl phosphonate (4-33). 1H NMR (400MHz, D2O):  5.08 (d, J 
= 5.7 Hz, 1H, H-1), 3.86 (d, J = 9.9 Hz, 2H, H-2, H-3), 3.63 (m, 1H), 3.56 (m, 2H), 
3.16 (t, J = 9.5 Hz, 1H, H-4), 2.25 (m, 2H, H-1') 1.78 (s, 3 H, NHAc). 
 
4.5.19 Synthesis of bis-triethylammonium uridin-5'-yl (2-acetamido-2-deoxy-α-D-
glucopyranosylthiomethylphosphono) phosphate (4-34)26 
The crude lutidium salt (4-33) (148 mg, 0.22 
mmol) was coevaporated several times with dry 
pyridine. After addition of 4-morpholine-N,N-
dicyclohexylcarboxamidinium uridine 5'-
monophosphomorpholidate (0.165 g, 0.24 mmol), the mixture was again 
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hours. Subsequently, the solid was taken up in dry pyridine (6 mL) under nitrogen gas 
and to this solution pre-dried 1H-tetrazole (0.031 g, 0.44 mmol) was added. After the 
solution was allowed to stir at room temperature for three days, Hünigs base (0.17 
mL, 0.99 mmol) and water (6 mL) were added, and then the solution was 
concentrated under reduced pressure. The residue was coevaporated again with the 
same amount of Hünigs base-water and dried under vacuum. 1H NMR (400 MHz, 
D2O): δ 7.50 (d, J = 8.1 Hz, 1H), 5.53 (d, J = 7.1 Hz, 2H), 5.23 (d, J = 5.4 Hz, 1H), 
4.85 (t, J = 10.3 Hz, 1H), 4.73 (t, J = 9.7 Hz, 1H), 4.36 (dd, J = 10.7, 4.3 Hz, 2H), 
4.23 (dd, J = 12.7, 3.3 Hz, 1H), 4.12 (m, 4H), 3.89 (m, 1H), 3.90 (d, J = 12.3 Hz, 1H), 
2.74 (t, J = 14.3 Hz, 1H), 2.64 (t, J = 14.2 Hz, 1H). 13C NMR (101 MHz, D2O): δ 
174.41, 166.49, 151.09, 141.01, 102.01, 87.79, 83.20, 81.89, 73.22, 71.79, 70.31, 














Chapter 4                                                                           Synthesis of substrate mimics 
149 
4.6 References: 
1. Compain, P. and Martin, O. R. 2003. Design, synthesis and biological 
evaluation of iminosugar-based glycosyltransferase inhibitors. Current Topics 
in Medicinal Chemistry. 3: 541-560. 
2. Qian, X. and Palcic, M. M. 2000. Glycosyltransferase inhibitors. In 
Carbohydrates in Chemistry and Biology. Wiley-VCH: Weinheim, 3: 293-
312. 
3. Zou, W. 2005. C-glycosides and aza-C-glycosides as potential glycosidase 
and glycosyltransferase inhibitors. Current Topics in Medicinal Chemistry. 5: 
1363-1391. 
4. Sears, P. and Wong, C. H. 1999. Carbohydrate mimetics: A new strategy for 
tackling the problem of carbohydrate-mediated biological recognition. 
Angewandte Chemie International Edition. 38: 2301-2324.  
5. Qiao, L., Murray, B. W., Shimazaki, M., Schultz, J. and Wong, C-H. 
1996. Synergistic inhibition of human α-1,3-fucosyltransferase V. Journal of 
the American Chemical Society. 118: 7653-7662.  
6. Wang, R., Steensma, D. H., Takaoka, Y., Yun, J. W., Kajimoto, T and 
Wong, C-H. 1997. A search for pyrophosphate mimics for the development of 
substrates and inhibitors of glycosyltransferases. Bioorganic and Medicinal 
Chemistry. 4: 661-672.  
7. Kimura, K. and Bugg, T. D. H. 2003. Recent advances in antimicrobial 
nucleoside antibiotics targeting cell wall biosynthesis. Nature Products 
Reports. 20: 252–273. 
8. Ünligil, U. M. and Rini, J. M. 2000. Glycosyltransferase structure and 
mechanism. Current Opinion in Structural Biology. 10: 510-517. 
Chapter 4                                                                           Synthesis of substrate mimics 
150 
9. Compain, P. and Martin, O. R. 2001. Carbohydrate mimetics-based 
glycosyltransferase inhibitors. Bioorganic and Medicinal Chemistry. 9: 3077-
3092.  
10. Vetting, M. W., Frantom, P. A. and Blanchard, J. S. 2008. Structural and 
enzymatic analyses of MshA from Corynebacterium glutamicum: Substrate-
assisted catalysis. Journal of Biochemistry and Molecular Biology. 283(23): 
15834-15844.  
11. Frantom, P. A., Coward, J. K. and Blanchard, J. S. 2010. UDP-(5F)-
GlcNAc acts as a slow-binding inhibitor of MshA, a retaining 
glycosyltransferase. Journal of the American Chemical Society. 132: 6626–
6627. 
12. El Ashry, E. S. H., Awad, L. F., Abdel Hamid, H. M. and Atta. A. I. 2006. 
Microwave irradiation for accelerating the synthesis of thioglycosides. 
Synthetic Communications. 36: 2769–2785. 
13. Cohen, S. B. and Halcomb, R. L. 2000. Synthesis and characterization of an 
anomeric sulfur analogue of CMP-sialic acid. The Journal of Organic 
Chemistry. 65(19): 6145–6152. 
14. Driquez, H. 2001. Thiooligosaccharides as tools for structural biology. 
ChemBioChem. 2(5): 311-318.  
15. Fugedi, R. and Levy, D. E. 2006. The organic Chemistry of sugars. CRC 
Press, New York, pp. 90-93, 102-104.  
16. Juaristi, E. and Cuevas, G. 1995. The anomeric effect. CRC Press, USA, pp. 
4, 8.  
Chapter 4                                                                           Synthesis of substrate mimics 
151 
17. Castro-Palomino, J. C. and Schmidt, R. R. 2000. N-Thiodiglycoloyl 
derivatives of glucosamine as glycosyl donors. Tetrahedron Letters. 4: 629–
632.  
18. Bernardes, G. J. L., Gamblin, D. P. and Davis, B. G. 2006. The direct 
formation of glycosyl thiols from reducing sugars allows one-pot protein 
glycoconjugation. Angewandte Chemie International Edition. 45: 4007–4011. 
19. Knapp, S. and Myers, D. S. 2002. Synthesis of α-GalNAc thioconjugates 
from an α-GalNAc mercaptan. Journal of Organic Chemistry. 67: 2992-2999. 
20. Knapp, S. and Myers, D. S. 2001. α-GlcNAc thioconjugates. Journal of 
Organic Chemistry. 66: 3636-3638. 
21. Myszka, H., Bednarczky, D., Najder, M. and Kaca, W. 2003. Synthesis and 
induction of apoptosis in B cell chronic leukemia by diosgenyl 2-amino-2-
deoxy-β-D-glucopyranoside hydrochloride and its derivatives. Carbohydrates 
Research. 338: 133-141. 
22. Knapp, S., Gonzalez, S., Myers, D. S., Eckman, L. L. and Bewley, C. A. 
2002. Shortcut to mycothiol analogues. Organic Letters. 4: 4337-4339.  
23. Winans, K. A. and Bertozzi, C. R. 2002. An inhibitor of the human UDP-
GlcNAc 4-epimerase identified from uridine-based library: A strategy to 
inhibit O-linked glycosylation. Chemistry and Biology. 9: 113-129. 
24. Horton, D. and Wander, J. D. 1980. The carbohydrates: Chemistry and 
Biochemistry. Academic press: New York, IB. 727-728. 
25. Yeoh, K. K., Butters, T. D., Wilkinson, B. L. and Fairbanks, A. J. 2009. 
Probing replacement of pyrophosphate via click chemistry; synthesis of UDP-
sugar analogues as potential glycosyl transferase inhibitors. Carbohydrate 
Research. 344: 586–591. 
Chapter 4                                                                           Synthesis of substrate mimics 
152 
26. Rowan, A. S., Nicely, N. I., Cochrane, N., Wlassoff, W. A., Claiborne, A. 
and Hamilton, C. J. 2009. Nucleoside triphosphate mimicry: a sugar triazolyl 
nucleoside as an ATP-competitive inhibitor of B. anthracis pantothenate 
kinase. Organic and Biomolecular Chemistry. 7: 4029–4036. 
27. Babic, A. and Pecar, S. 2007. An improved total synthesis of UDP-N-acetyl-
muramic acid. Tetrahedron Letters. 48: 4403-4405. 
28. Roy, B. and Mukhopadhyay, B. 2007. Sulfuric acid immobilized on silica: 
An excellent catalyst for Fischer type glycosylation. Tetrahedron Letters. 
48(22): 3783-3787. 
29. Zhu, X. and Schmidt, R. R. 2004. Glycosylthiomethyl chloride: A new 
species for S-neoglycoconjugate synthesis. Synthesis of 1-N-
glycosylthiomethyl-1,2,3-triazoles. The Journal of Organic Chemistry. 69: 
1081-1085. 
30. Zhu, X., Stolz, F. and Schmidt, R. R. 2004. Synthesis of thioglycoside-based 
UDP-sugar analogues. The Journal of Organic Chemistry. 69: 7367-7370. 
31. Trunkfield, A. E., Gurcha, S. S., Besra, G. S. and Bugg, T. D. H. 2010. 
Inhibition of Escherichia coli glycosyltransferase MurG and Mycobacterium 
tuberculosis Gal transferase by uridine-linked transition state mimics. 
Bioorganic and Medicinal Chemistry. 18: 2651–2663. 
32. Kaushal, G. P. and Elbein, A. D. 1986. Properties of solubilized UDP-
GlcNAc: dolichyl phosphate-GlcNAc-1-P-transferase from soybean cultured 
cells. Plant Physiology. 82: 748-752.  
33. Yamamoto, I., Sekine, M. and Hata, T. 1980. One-step synthesis of 5'-
azido-nucleosides. Journal of the Chemical Society. 1: 306-310. 
 
Chapter 5                                                                                    MshA inhibition studies 
153 
CHAPTER 5 
MshA inhibition studies 
5.1 Introduction 
In this chapter designed inhibitors reported in Chapters 3 and 4 respectively, are 
evaluated for their inhibitory effects against MshA. Pure enzyme (MshA) used in 
conducting enzyme assay inhibition studies was isolated from Corynebacterium 
glutamicum (cgMshA) in a procedure described by Vetting et al.1  
 
Vetting et al.1 reported the crystal structure coordinates of MshA and subsequent 
enzymatic studies defined the kinetic parameters of UDP-GlcNAc and 1-L-Ins-1-P 
substrates for cgMshA. The results corroborated with the previous studies of Newton 
and co-workers2 on MshA from a crude extract of Mycobacterium smegmatis. The 
EXPRESSO alignment of cgMshA and tbMshA protein sequence shows that there is 
99% sequence similarity (alignment of similar amino acid residues) between the two 
enzymes. However, for these studies cgMshA was preferred over tbMshA because 
cgMshA can be obtained in high purity (>95%), thereby reducing any chances that 
inhibition observed could be due to other contaminants. For the enzyme activity UDP-
GlcNAc and 1-L-Ins-1-P were obtained commercially.  
 
5.2 Screening and detection methods for MshA inhibitors  
A structure-based, in silico search approach to find selective inhibitors for 
glycosyltransferase MurG was attempted by Walker and co-workers.3 MurG is a 
member of the nucleotide-sugar glycosyltransferases (NDP-Gtases) family and this 
group of enzymes catalyze the transfer of sugars from nucleotides to a wide range of 
glycosyl acceptors.4 Walker et al. screened a 50 000 component library of compounds 
to find selective glycosyltransferase MurG inhibitors using a high throughput (HTP) 
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screening method based on a fluorescent donor displacement assay. In addition, the 
study showed that the compounds identified in the donor displacement screen on 
MurG were selective for MurG relative to other enzymes that utilize similar or 
identical substrates, including the structurally related enzymes. 
 
Considering the success of Walker et al. on the structure-based search for selective 
inhibitors for glycosyltransferase MurG, we envisaged the design of selective 
inhibitors specific to glycosyltransferase MshA using computer simulated molecular 
docking (Chapters 3 and 4 respectively). MshA is involved in the formation of 3-
phospho-1-D-myo-inosityl-2-acetamido-2-deoxy-α-D-glucopyranoside by transferring 




























Figure 5-1: MshA catalyzed reaction. 
5.2.1 Pyruvate kinase/Lactate dehydrogenase coupled enzyme assay 
The pyruvate kinase/lactate dehydrogenase (PK/LDH) coupled enzyme assay is 
normally used to assay the enzymes that use ATP during the course of the reaction. 
Vetting et al.1 used PK/LDH coupled enzyme assay to assay the activity of the MshA. 
The PK/LDH coupled enzyme assay method is based on the measurement of UDP as 
a byproduct generated during the transglycosylation reaction. During the assay, UDP 
is coupled to the conversion of NADH into NAD+ through pyruvate kinase (PK) and 
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lactate dehydrogenase (LDH); therefore NAD+ is photometrically measured at 340 
nm. The PK/LDH coupled enzyme assay is summarized in Figure 5-2 below. 
 
 
Figure 5-2: Example of coupled enzyme assay. 
 
The rationale to perform PK/LDH coupled enzyme assays was to screen small 
focused libraries of the structure-based designed compounds for the inhibitory effects 
against cgMshA. Therefore the library that shows any significant inhibitory effects 
against cgMshA in PK/LDH coupled enzyme assays would be screened further in a 
whole cell assay. In other words, the PK/LDH coupled enzyme assay would serve as a 
platform for the pre-selection of hit compounds for further development and 
screening. 
 
5.2.1.1 Inhibition studies of cgMshA using the PK/LDH coupled enzyme assay 
The PK/LDH coupled enzyme assay was used to determine the inhibition of cgMshA 
reaction by series of structure based designed inhibitors reported in Chapters 3 and 4 
respectively. This was done by measuring the initial rates of the reactions to which 
inhibitors at a set concentration 100 µM were added and comparing these to the 
uninhibited cgMshA reaction initial rate. However, the results obtained following the 
published PK/LDH coupled enzyme assay protocol by Vetting et al.1 exhibited large 
standard error bars thus making it difficult to reach a logical conclusion.  
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In an attempt to resolve the assay instability, the method published by Vetting et al.1 
was modified by increasing the amount of pyruvate kinase (PK) and 
phosphoenolpyruvate (PEP) in the reaction mixture. These modifications made the 
first step of the PK/LDH coupled enzyme assay proceed faster and significantly 

















































































































































































Figure 5-3: Inhibition of cgMshA reaction as determined by the PK/LDH coupled enzyme assay. 
Inhibition studies perfomed in triplicate, with the uninhibited cgMshA reaction used as a blank. A 
blank reaction contained cgMshA, UDP-GlcNAc, 1-L-Ins-1-P, TEA enzyme buffer and no inhibitor 
whereas the reaction mixtures contained cgMshA, UDP-GlcNAc (100 µM), 1-L-Ins-1-P (100 µM), 
inhibitor. The synthesized inhibitors were tested at 100 µM each whereas the commercially obtained 
inhibitors (tunicamycin and nikkomycin) were tested at 12 µM and 20 µM respectively. 
 
Apart from large standard error bars, it was also observed that not all the inhibitors 
reported could be analyzed using the PK/LDH coupled enzyme assay. For example, 
all the thiazolidinethione derivatives were found to be bright yellow in color (even 
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when diluted to a lower concentration 100 µM), thus interfering with the change in 
absorbance occurring during the oxidation of NADH to NAD+. To confirm the 
interference of thiazolidinethione derivatives with the oxidation NADH to NAD+, the 
ultra violet (UV) spectra of the prepared thiazolidinethione derivatives were studied. 
The representative compounds from each thiazolidinethione series displayed two 
absorption bands with maxima at 230 – 270 and 290 - 340 nm (Data not shown). It 
was against this background that it was concluded that thiazolidinethione absorbance 
interfere with the absorbance frequency indicative of oxidation of NADH to NAD+. 
 
Although it was possible to measure the inhibition of the colourless compounds using 
the PK/LDH coupled enzyme assay method, it has been observed that no statistically 
significant data differences exist between the inhibitors (substrate mimics) tested and 
a blank. In some instances, the inhibition levels exceeded the 100% threshold (Fig. 5-
3). As a result the PK/LDH coupled enzyme assay method was abandoned and an 
alternative screening method for cgMshA was required.  
 
5.2.2 Transcreener® ADP2 FI assay Kit 
The Bellbrook Laboratory Transcreener® ADP2 FI assay kit was identified as an 
alternative assay method for cgMshA. This assay kit uses an increase in the 
fluorescent intensity to measure the amount of ADP produced during the enzyme 
reaction. This is done through ADP displacing the ADP-tracer from a complex in 
which it is bound to an ADP monoclonal antibody-quencher conjugate leading to an 
increase in fluorescent intensity. Therefore, the amount of ADP produced is directly 
proportional to the increase in fluorescent intensity (Fig. 5-4). This assay method was 
considered ideal due to its reliance on the fluorescent intensity and as such it would 
allow the assay of the synthesized inhibitors.  




Figure 5-4: Transcreener® ADP2 FI assay kit mode of action. 
 
5.2.2.1 UDP standard curve and assay development 
The sensitivity of the Transcreener® kit reagent towards UDP had to be tested since 
UDP is produced during the MshA reaction instead of ADP. Two standard curves 
were generated to simulate the conversion of ATP to ADP and the conversion of 
UDP-GlcNAc to UDP respectively. This was done by adding different volumes of 50 
µM ATP and ADP together, and 50 µM UDP-GlcNAc and UDP. These different 
volumes simulate the percentage conversion of 50 µM ATP to 50 µM ADP and 50 
µM UDP-GlcNAc to 50 µM UDP respectively. From the percentage conversion 
standard curve it can be seen that although the conversion of UDP-GlcNAc and UDP 
could be tracked with the Transcreener® kit, the sensitivity towards UDP was about 
have half of what it is towards ADP (Fig. 5-5).  
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Figure 5-5: Standard curve of the simulated conversion of 100 µM UDP-GlcNAc to 100 µM UDP, 
compared to simulated conversion of 50 µM ATP to 50 µM ADP. 
 
The results obtained suggest that the Transcreener® kit could not be used for the 
continuous assay of MshA due to its relatively small increase in fluorescence that 
corresponded to the increase in UDP concentration from 0 to 50 µM. Hence it was 
further attempted to improve the sensitivity of the Transcreener® kit towards UDP so 
that the kit could be used in a non-continuous assay of MshA. Another standard curve 
was subsequently prepared to simulate the conversion of 100 µM UDP-GlcNAc to 
100 µM UDP, i.e. by using double the amount of substrate prescribed by the 
manufacturer. The simulated conversion of 100 µM UDP-GlcNAc to 100 µM UDP 
was compared to the simulated conversion of 50 µM ATP to 50 µM ADP (Fig. 5-6). 
This change has significantly increased the sensitivity of the Transcreener® kit 
towards UDP.  
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Figure 5-6: Standard curve of the simulated conversion of 100 µM UDP-GlcNAc to 100 µM UDP, 
compared to simulated conversion of 50 µM ATP to 50 µM ADP. 
However, although the sensitivity of the assay was improved, big standard error bars 
were obtained when the Transcreener® assay was performed in a non-continuous 
manner. In an attempt to improve the standard error bars of the non-continuous assay, 
double the amount of antibody-quencher conjugate compared to that prescribed by the 
manufacturer was used in the detection mixture. Although this has tremendously 
improved the standard error bars of the non-continuous assay, the sensitivity of the kit 
towards UDP has slightly dropped (Fig. 5-7). However, the increase in fluorescence 
due to the increase in UDP was fortunately still large enough to investigate the 
Transcreener-based non-continuous assay of MshA.  
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Figure 5-7: cgMshA reaction analyzed with Transcreener® kit. The cgMshA reaction mixtures 
contained 180 nM cgMshA, 100 µM UDP-GlcNAc, 100 µM 1-L-Ins-1-P and cgMshA assay buffer. 
 
5.2.2.2 Inhibition studies 
Having established the optimal conditions for the Transcreener® kit in the non-
continuous assay of cgMshA, the next objective was to determine the inhibition of 
cgMshA by substrate mimics (both commercially obtained and synthesized). The trial 
inhibition study was done with synthetic substrate mimics (4-25, 4-34) and naturally 
occurring substrate mimics such as tunicamycin and nikkomycin. However, no 
statistically significant data differences existed between the tested compounds in 
comparison with the blank, except for substrate mimic (4-34). Figure 5-8 shows the 
trial inhibition studies results obtained using the Transcreener® kit assay.  
 
 



























































Figure 5-8: Inhibition studies of cgMshA using the Transcreener® kit. A blank reaction contained 
cgMshA, UDP-GlcNAc, 1-L-Ins-1-P, TEA enzyme buffer and no inhibitor. The reaction mixtures 
contained cgMshA, UDP-GlcNAc (100 µM), 1-L-Ins-1-P (100 µM), inhibitor and TEA enzyme buffer, 
all incubated at 37 °C. At specific time intervals 25 µL aliquots were removed, the reaction stopped by 
heat inactivation of cgMshA and 25 µL Transcreener® kit detection buffer was added. The 
sample/detection buffer mixture was incubated for 1 hr at room temperature before the fluorescent 
intensity was measured at λex 590nm and λem 617nm.  
 
Based on the enzyme assay displayed in Figure 5-8, compound 4-34 has strong 
inhibitory effects against cgMshA whereas tunicamycin demonstrated insignificant 
inhibitory effects against cgMshA. Furthermore, this assay method could be adopted 
for screening other libraries of compounds.  
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Since the trial reaction Transcreener® assay kit in Figure 5-8 has shown that the bulk 
of enzyme activity occurs in the first 10 minutes, it was decided to reduce the time of 
the reaction to 5 minutes and to take the 25 µL aliquots at 0, 2 and 5 minute intervals, 
to ensure that the increase in fluorescence is linear over the measurement interval. 
Furthermore, a diverse library of compounds has been included in the assay including 
chromogenic compounds such thiazolidinethione derivatives. The results obtained 
with substrate mimic 4-34 in both trial and detailed inhibition experiments were 
consistent and reproducible (Fig. 5-8 and 5-9 respectively).  
 
Tunicamycin was not included in further cgMshA inhibition studies because there 
was little difference between tunicamycin and the blank in the trial experiment (Fig. 
5-8). Thus suggesting that tunicamycin does not bind to MshA and corroborates with 
the computational study. Full cgMshA inhibition studies results of Transcreener® 
assay kit are displayed in Figure 5-9. The initial rates for the reactions to which 
inhibitors were added were compared to the initial rate of an uninhibited reaction and 
were reported as a percentage inhibition. The percentage inhibition bar charts were 
drawn using Microsoft® Office Excel® 2007. 

























































































































































Figure 5-9: Full inhibition studies of cgMshA using Transcreener® kit. A blank reaction contained 
cgMshA, UDP-GlcNAc, 1-L-Ins-1-P, TEA enzyme buffer and no inhibitor. The reaction mixtures 
contained cgMshA, UDP-GlcNAc (100 µM), 1-L-Ins-1-P (100 µM), inhibitor and TEA enzyme buffer, 
all incubated at 37 °C. 
 
Although the Transcreener® kit has enabled the effective analysis of inhibitory effects 
of a wide range of compounds, large standard error bars remained a problem. 
Numerous attempts were made to improve the Transcreener® kit without any success. 
As a result, further screening with the Transcreener® kit was discontinued.  
 
5.3 Conclusion 
In this study an attempt was made to screen a series of structure-based designed 
inhibitors against cgMshA using the PK/LDH coupled enzyme assay and 
Transcreener® assay kit based enzyme assay approaches respectively. The PK/LDH 
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coupled enzyme assay method could not be used to assay all the compounds 
synthesized whereas Transcreener® assay kit also resulted in large standard error bars 
thus making it difficult to extract reliable SAR for the thiazolidinethione derivatives. 
However, substrate mimic (4-34) have displayed promising inhibitory properties 
against MshA in the enzyme assay and the results were consistent with the molecular 
docking dynamics observed (as reported in chapter 4). Based on the kinetic data (data 
not shown) obtained, this substrate mimic (4-34) to have lost a significant amount of 
activity owing to the presence of the competitive inhibitor. However, the information 
obtained will lay a solid foundation in the design of future inhibitors for the large 
family of MshA enzyme. Since the study focused on a relatively small library of 
compounds, the complete library was considered for whole cell screening.  
 
5.4 Experimental 
5.4.1 Coupled enzyme assays conditions 
The coupled enzyme assay conditions were as follows; 180 nM cgMshA, 100 µM 
UDP-GlcNAc, 100 µM 1-L-Ins-1-P, 200 µM NADH, 500 µM PEP 
(phosphoenolpyruvate), 0.01 M MgCl2, 6 units pyruvate kinase and 16 units lactate 
dehydrogenase in a final volume of 100 µL made up with assay buffer (50 mM TEA 
(triethylamine buffer, pH: 7.8)), at 25 C. Inhibitors were added at a final 
concentration of 100 µl (0.4% v/v DMSO). The decrease in absorbance at 340 nm was 
measured with the Thermo VarioSkanTM spectrophotometer. The synthetic inhibitors 
were tested at 100 µM each whereas the commercially obtained inhibitors 
tunicamycin and nikkomycin were tested at 12 µM and 20 µM respectively. 
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5.4.2 Transcreener® ADP2 FI assay kit 
The amount of ADP2 Antibody-IRDye® QC-1 quencher used in the ADP detection 
mixture was determined according to an equation provided by the manufacturer and 
determined to be 0.05 µg/µL. Each 25 µl ADP detection mixture contained 0.25 µL 
800 nM ADP Alexa594 Tracer, 2.5 µL 10x stop and detect buffer B, 0.90 µl ADP2 
Antibody-IRDye® QC-1 quencher and 21.35 µL cgMshA assay buffer (50 mM TEA, 
10 mM MgCl2 at pH 7.8). Later the amount of ADP2 Antibody-IRDye® QC-1 
quencher added was doubled to 1.80 µL per 25 µL ADP detection mixture. The 
standard curves were prepared by adding concentrations of ATP and ADP together 
corresponding to 0%, 4%, 6%, 8%, 10%, 20%, 30%, 40%, 60%, 100% conversion of 
ATP. The same was done for UDP-GlcNAc and UDP. The final volume of the 
standard curve samples were 25 µL to which 25 µL ADP detection mixtures was 
added. After incubation for 1 hr at RT the fluorescent signal was measured on a 
Thermo VarioSkanTM spectrophotometer, set at λex 590 nm and λem 617 nm.  
 
The cgMshA reaction mixtures contained 180 nM cgMshA, 100 µM UDP-GlcNAc, 
100 µM 1-L-Ins-1-P and cgMshA assay buffer. The reaction mixtures were incubated 
at 37 °C and 25 µL aliquots were taken at 0, 5, 10, 15, 30 and 60 mins, after which the 
reaction was stopped by incubating the aliquot at 95 °C for 5 min. After all the 
aliquots were processed 25 µL ADP detection mixture was added, the mixture 
incubated for 1 hr and the fluorescent signal measured. The reactions were performed 
in triplicate. The inhibition studies were performed similarly except for the addition of 
the specific inhibitor and the aliquots were taken at 0, 2 and 5 mins, respectively. 
Similarily, the synthesized inhibitors were tested at 100 µM whereas tunicamycin and 
nikkomycin were tested at 12 µM and 20 µM respectively. 
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CHAPTER 6 
Whole cell inhibition studies 
6.1 Introduction 
The purpose of this study was to evaluate the inhibitory effects of the structure-based 
designed inhibitors reported in Chapters 3 and 4 respectively against the non 
pathogenic M.tb H37Rv whole cells. Unlike the in vitro enzyme assay screen, whole 
cell based assays have the advantage of selecting compounds that are able to penetrate 
cells and reach the intracellular targets. Despite this advantage, the whole cell screen 
is incapable of indicating target selectivity. However, in this study the results of the 
whole cell screen assays of the structure-based designed inhibitors are presented.  
 
The rational to pursue the whole cell screen assay was based on the molecular 
dynamic docking study, which was used to design the structure-based designed 
inhibitors for the MshA enzyme active site. The molecular dynamics docking study 
revealed some excellent binding affinity data of the structure-based designed 
inhibitors in the MshA binding pocket. Additionally, excellent interaction between 
inhibitors and certain amino acids in the binding pocket of MshA were observed. 
Furthermore, lower binding energies and good inhibition constants were also 
observed during the molecular dynamic docking. 
 
6.2 Biological evaluation of substrate mimics  
The substrate mimics (synthesized and commercially obtained) were screened for 
inhibitory effects against M.tb H37Rv whole cells at an initial concentration of 100 
µM. The level of inhibition was compared with the uninhibited cells which served as 
a positive control. DMSO was included in the blank test since all the stock solutions 
of the inhibitors were prepared in DMSO. 
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Almost all the substrate mimics analyzed exhibited poor activity against M.tb H37Rv 
whole cells with the exception of tunicamycin (Fig. 6-1). Tunicamycin is natural 
nucleotide antibiotic produced by several Streptomyces species1a and mimics the 
activity of natural sugar-nucleotide substrates. The structure of tunicamycin was 
reported by Takatsuki et al.1b and shares common structural features with UDP-
GlcNAc (Fig. 6-2). The general poor activity of the substrate mimics could be 
attributed to poor membrane permeability.2 Being relatively large polar molecules, 
substrate mimics could find it difficult to cross the cell membrane due to its 
hydrophilic nature. As a result, the substrate mimics are unable to penetrate the cells 
and eventually unable to reach their intended targets. However, tunicamycin contains 
a long chain lipophilic fatty acid amide group which allows it to be more flexible, 
thereby allowing it to change its conformation and thus increasing its chances to cross 
through the lipid bilayer into the cell.  
 
As shown in Figure 6-1, tunicamycin displayed the highest potency against M.tb 
H37Rv whole cells by inhibiting the cell growth by up to 95% even when tested at a 
concentration <10 µM. The level of inhibition obtained is comparable with the level 
of inhibition obtained with isoniazid (INH, 0.365 µM), the current first line TB drug. 
The results obtained with tunicamycin corroborated with previous studies on the 
enzymes that utilize UDP-GlcNAc as substrate.3 Kaushal and Elbein have 
demonstrated that enzymes involved in the transfer of GlcNAc-1-P from UDP-
GlcNAc to dolichyl-PP-GlcNAc were very sensitive to tunicamycin.3 Furthermore, 
various studies have demonstrated that tunicamycin specifically inhibits transfer of 
GlcNAc-1-P and not other reactions involving the transfer of GlcNAc.4,5 However, 
the inhibition observed in the whole cell screening (Fig. 6-1) could be due to the non-
selective glycosyltransferase binding ability of tunicamycin.  












































































































































































i i i  t i





















Figure 6-1: Effects of substrate mimics on M.tb H37Rv whole cells.  
 
Substrate mimic (4-34) did not display the desired activity in M.tb (Fig. 6-1). 
However, this substrate was evaluated against M. smegmatis using microplate 
alamarBlue® assay (MABA) in a procedure described by Franzblau et al.11 The 
substrate displayed moderate anti-mycobacterial activity by inhibiting M. smegmatis 
between 25 and 50 µM (MABA assay results Appendix I). However, no inhibition 
was observed when the substrate was tested at lower concentration between 12.5 and 
25 µM. The whole cell inhibition results of substrate mimic (4-34) corroborated with 
the enzyme assay results (Chapter 5, Fig. 5-8), which have showed that substrate 
mimic (4-34) have inhibitory effects against MshA. The results were further in 
agreement with the earlier observation made with the molecular dynamic docking 
which indicated that substrate mimic (4-34) has a strong binding affinity towards 
MshA (Chapter 4, Fig. 4-3).  
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Different classes of naturally occurring antibiotics such as campuramycin (Fig. 6-3) 
could be considered for future lead molecule development for TB drugs. Like 
tunicamycin, these substrate mimics share some common structural similarities with 
the natural substrate of MshA, UDP-GlcNAc. The structures of these naturally 
occurring substrate mimics mainly consist of a uridine nucleoside which plays an 




































































Figure 6-3: Comparison of structural features of various natural occurring substrate mimics with the 
natural substrate (UDP-GlcNAc) of glycosyltransferase. 
 
The studies by Koga et al.6 have shown that capuramycin derivatives had significant 
inhibitory effects against mycobacterial species both in vivo and in vitro by killing 
more than 90% of the bacilli within 48 hr. Furthermore, the substrate had shown 
lower toxicity levels when administered in mice. The study by Reddy et al.7 
demonstrated that capuramycin analogues kill over 90% of the bacilli within 48 hr of 
treatment at low concentrations and this has the potential to reduce the duration for 
TB treatment. However, thorough investigation on SARs studies of capuramycin 
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analogues are required in order to improve the pharmacokinetic properties of this 
substrate mimic. 
 
6.3 Biological evaluation of thiazolidinethione-based compounds as MshA 
inhibitors 
A study by Kucukguzel et al.8 reported excellent anti-tubercular activity of 
thiazolidinone derivatives with inhibition levels as high as 90 and 98% and IC50 value 
of about 6.25 µg/mL. Andres et al.9 also reported good inhibition of the MurB 
enzyme using thiazolidinone derivatives. Similarily, Helm et al.10 synthesized and 
screened a focused library of diverse small molecules bearing the 2-thioxothiazolidin-
4-one (rhodanine) core as the potential inhibitors of glycosyltransferase (Fig. 6-4). 
The 2-thioxothiazolidin-4-one derivatives reported were rationally designed to inhibit 
the glycosyltransferase and hence we targeted 2-thioxothiazolidin-4-one derivatives as 









Figure 6-4: Representative of the compound from the family of glycosyltransferase MurG inhibitors 
with the common core highlighted.10 
 
6.3.1 Biological evaluation of thiazolidinethione derivatives (MJ1A - MJ12A and 
MJ1B - MJ12B) against M.tb 
The success of the reported studies on the 2-thioxothiazolidin-4-one derivatives 
against glycosyltransferase MurG was encouraging.10 Therefore in this study a series 
of thiazolidinethione derivatives from two different libraries (MJ1A - MJ12A and 
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MJ1B - MJ12B) were screened for activity against M.tb (Table 6-1). A fair number 
of these molecules were found to inhibit the growth M.tb in moderate to good levels 
in whole cell assays.  
 
However, the data obtained from the whole cell screening, shows that only four 
compounds (MJ3A, MJ2B, MJ7B and MJ12B) sourced from the two libraries 
displayed an IC50 ≥ 20 µM. The results of the compounds with high potency are 
shown (in red) in Table 6-1. Amongst the tested compounds (Z)-5-(2,4-
dichlorobenzylidene)-2-thioxothiazolidin-4-one (MJ3A) and 2-((Z)-5-(4-hydroxy-3-
methoxybenzylidene)-4-oxo-2-thioxothiazolidin-3-yl)acetic acid (MJ7B) were found 
to be the most potent compounds with inhibition levels of 88 and 86%, respectively. 
 
The inhibition data complemented the molecular docking studies on 
thiazolidinethione-based derivatives which indicated these set of compounds could be 
potential inhibitors for MshA based on their binding energy and good inhibition 
constants. As discussed in Chapter 3 and Chapter 4 respectively, molecular dynamics 
docking studies was performed in the MshA enzyme active site to aid further drug 
design. 
 
In addition, the lipophilicities of the thiazolidinethione derivatives were calculated 
using ChemDraw Ultra 8.0. These derivatives have shown reasonable propabilities of 
being well absorbed, with calculated partition coefficient (clog P) below 5.0 (Table 6-
1). cLog P serves as one of the most fundamental principle for prediction of ADMET 
properties of drug candidates. Thus, building accurate predictive ADMET models for 
early decision making in drug discovery would be a challenge without accurate 
prediction of log P.  
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Table 6-1: Antimycobacterial activities of thiazolidinethione derivatives (MJ1A - MJ12A and MJ1B - 
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The results obtained with the N-alkylated 2-thioxothiazolidin-4-one derivatives 
corroborated with the findings of the inhibition studies of other glycosyltransferase 
MurG,10 whereby seven out of eleven compounds screened against MurG were 
constituted by a five member ring, nitrogen containing heterocyclic aryl or alkyl 







Figure 6-5: Representative of the compound from the family of glycosyltransferase inhibitors screened 
in this study with the common core and possible N-1 extension highlighted. 
 
The most potent thiazolidinethione derivatives were selected and subjected to further 
testing at lower concentrations (10, 1 and 0.1 µg/mL). The results are summarized in 
Table 6-2. At 10 µg/mL, the compounds displayed moderate inhibition. However the 
activity was not significant when they were tested at concentrations below 1 µg/mL.  
 
Table 6-2: Effects of thiazolidinethione derivatives on the M.tb H37Rv growth. cLog P of the 
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6.3.2 Biological evaluation of N-propargylated thiazolidinethione derivatives 
(MJ029 series) against M.tb. 
As a first step towards the expansion of SARs, the thiazolidinethiones library (MJ1A 
- MJ12A) was N-alkylated using propargyl bromide to generate a series of new 
compounds (MJ029). This series of compounds (MJ029) was screened in vitro for 
their anti-tuberculosis activity and the results are displayed in Figure 6-6. Preliminary 
screening was conducted at a concentration of 100 µg/mL and this class of 
compounds showed significant anti-tubercular activity. N-alkylation of 
thiazolidinethione derivatives with the propargyl moiety led to compounds that 
exhibited significant inhibition. This suggested that the introduction of the propargyl 
moiety to the thiazolidinethione moiety leads to a significant improvement in M.tb 












































Figure 6-6: Effects of propargylated thiazolidinethione derivatives on the M.tb growth. Compounds 
were tested at initial concentration of 100 µM using BACTEC 460TM system. 
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6.3.3 The Biological evaluation of sulfonated thiazolidinethione derivatives 
(MJ081 series) against M. smegmatis 
The addition of N-propylsulfonate moiety to thiazolidinethione derivatives (MJ1A - 
MJ12A) led to the formation of a new series of compounds (MJ081). This series of 
compounds was screened in vitro for anti-mycobacterial activity against M. 
smegmatis using microplate alamarBlue® assay (MABA, (Appendix I)) in a procedure 
described by Franzblau et al.11  
 
In addition, several compounds drawn from different libraries (MJ1A-MJ12A, 
MJ1B-MJ12B, MJ029 series and substrate mimic 4-34) were screened for anti-
mycobacterial activities against M. smegmatis. This included the compounds that had 
previously displayed excellent activity against M.tb in the BACTEC 460TM system. 
The purpose of including the previously screened compounds was to establish if there 
is any correlation between the results obtained using the two assay methods.  
 
The compounds were screened at different concentrations (100 µM, 50 µM, 25 µM 
and 12.5 µM) for anti-mycobacterial activity (Table 6-3). All the compounds analyzed 
have displayed excellent anti-mycobacterial activity at the concentration of 50-100 
µM. 
 
However, moderate inhibition was observed when compounds were screened at a 
concentration of 25-50 µM, with the exception of MJ081-6 which displayed strong 
inhibitory effects at this concentration range. Finally no anti-mycobacterial activity 
was observed when compounds were screened at the concentration below 25 µM 
(Appendix I). Thus, the additions of N-propylsulfonate moiety to thiazolidinethione 
derivatives have not been able to substantially enhance the activity of these 
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derivatives in the current study. However, the data obtained here is encouraging and 
deserve further investigation. 
 
Table 6-3: Effects of thiazolidinethione derivatives on the M. smegmatis growth. cLog P of the 
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6.4 Intracellular drug testing 
The purpose of this part of the study was to further explore the inhibitory effects of 
the most potent extra-cellular inhibitors of M.tb, by comparing the fate of M.tb in 
infected macrophages. The inhibitors that have demonstrated the ability to inhibit the 
growth of M.tb in vitro at 10 µM, were selected and tested further for their ability to 
inhibit the growth within the host macrophages.  
 
However, based on the criteria used for the selection of the inhibitors for intracellular 
screening, only tunicamycin met out the set standard (higly potent at 10 µM). 
However, other inhibitors sourced from the prepared library of compounds were 
nevertheless selected and included in the intracellular screening. BACTEC 460TM 
measurements were used to analyze bacterial survival within the macrophages. 
 
6.4.1 Drug testing in the macrophages 
After extra-cellular screening of the most active compounds, intracellular testing was 
performed on a THP1 cell line. Human macrophage-like cell line THP1 (ATCC TIB-
202) was chosen for drug screening because the cells are easily accessible. The THP-1 
macrophages were infected with M.tb at a multiplicity of infection (MOI) 5:1 for up 
to 2 days. On day 3 post-infection, the M.tb infected macrophages were treated with 
inhibitors and incubated for different time intervals (4, 8, 12 and 24 hr) post-drug 
exposure. 
 
As shown in Figure 6-7 below, tunicamycin has been able to inhibit the growth of 
intracellular M.tb by up to 95% at low concentration (10 µM). The results suggest that 
it could be possible that tunicamycin binds to other glycosyltransferases other than 
MshA, thereby resulting in the inhibition of the growth of intracellular M.tb. The 
results obtained with the intracellular inhibition studies are in contrast with the earlier 
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findings in the study (molecular docking studies and enzyme (cgMshA) assay) 
whereby it demonstrated that tunicamycin does not bind to MshA. 
 
However, these results suggest that tunicamycin could be used as a potential lead 
compound. Further investigation on SARs studies of tunicamycin derivatives are 







































































































Figure 6-7: Intracellular drug testing on THP1 cells infected with M.tb at MOI 5:1. M.tb was 
inoculated into BACTEC 460™ vial containing Middlebrook 7H12 medium. INH was used as a 
positive control at 0.0365 μM concentration, while the negative control M.tb-infected macrophages 
without any drug added. 
 
6.5 Conclusion 
In summary, this study allowed the screening of numerous structure-based designed 
inhibitors. Several hit compounds that were capable of inhibiting MshA were 
identified. Due to its hydrophilic property, it was not completely suprising that none 
of the substrate mimics synthesized displayed satisfactory inhibitory activity in the 
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whole cell assay against MshA even at a concentration as high as 100 µM with the 
exception of 4-34. Tunicamycin appears to be the most potent inhibitor and has 
inhibited the growth of M.tb H37Rv up to 95% even when tested at concentrations 
below 10 µM. However, the inhibition could be due to non-selective binding of this 
inhibitor to other glycosyltransferases within the mycobacterial species. 
 
On the other hand, thiazolidinethione derivatives MJ3A, MJ2B, MJ7B, and MJ12B 
have displayed an IC50 ≥ 20 µM during the preliminary screening. N-alkylated 
thiazolidinethione derivatives (MJ029 series) proven to be excellent inhibitors of 
M.tb H37Rv and had tremendously improved (displayed an IC50 < 20 µM) the activity 
of thiazolidinethiones (MJ1A – MJ12A) after the N-alkylation. The results obtained 
from M.tb H37Rv screening have laid a foundation for future development of hit 
compounds for optimization. The hit compounds can now be optimized further to 
attain lead status.  
 
6.6 Experimental 
6.6.1 Monitoring M.tb growth in the presence of inhibitors using the BACTEC 
460™ system  
The M.tb H37Rv (1 mL aliquots) were thawed and grown directly in BACTEC 460TM 
vials with various concentrations of inhibitors (between 0 and 100 μg/mL). M.tb was 
cultured for 7 days before the addition of inhibitors. Untreated M.tb was grown under 
the same conditions (as the treated M.tb with no inhibitor added) to serve as a control. 
Mycobacterial growth was monitored by the BACTEC 460TM instrument which 
measures of the uptake of radioactively labelled 14C triacylglycerides.12 The minimal 
inhibitory concentrations for the drugs were calculated based on BACTEC 460TM 
growth index readings. 
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6.6.2 Culture conditions for the THP1 cell line  
The THP-1 human macrophage cell line were grown at 37 C in 5% CO2 in Roswell 
Park Memorial Institute (RPMI) 1640 (Sigma, USA) supplemented with 10% heat-
inactivated FCS (GibcoTM, Invitrogen, Germany) with penicillin-streptomycin, 1% 
final concentration (Invitrogen). Cells were placed in a 50 mL tube + 8 mL (+/-10 
mL) medium and pelleted by spinning at 13 000 rpm for 5 minutes at 21 C. The 
supernatant was removed and the tube was dragged over round-bottom 96 well plate 
to re-suspend the pellet. A 10 mL aliquot of complete RPMI 1640 medium was added 
to the tube to re-suspend cells. All of the liquid was aliquoted into a flask (small filter 
cap TC flask), and incubated at 37 C for three days. Cells were checked everyday 
and fresh medium added every 2nd or 3rd day. Cells were harvested at 1 week, pelleted 
and re-suspend in fresh complete RPMI, lacking antibiotics and counted using a 
haemocytometer. 
 
THP-1 cells were differentiated into macrophages by using phorbol myristic acetate 
(PMA, Sigma, USA). Once differentiated THP1 cells become adherent monolayers 
and stop dividing and to acquire typical characteristics of macrophages such as the 
capacity to phagocytize bacteria and to express bactericidal activities.13 PMA was 
added to a final concentration of 100 nM and 1 mL of cells added per well in 24 well 
plates at a concentration of 5 x 105 cells/mL (all experiments were done in triplicate). 
Cells were incubated overnight, and non-adherent cells were removed by washing 3 
times with 1 mL ice-cold phosphate buffered saline. At selected time points after 
infection with M.tb, infected macrophages were exposed to inhibitors and intracellular 
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6.6.3 Macrophage infection  
1 mL aliquots of M.tb were removed from the -80 C freezer and thawed. 
Mycobacteria were passaged 30 times through a with 1 mL insulin syringe to remove 
clumps. The required amount of mycobacteria was centrifuged at 13 000 rpm for 20 
minutes. The supernatant was removed and bacilli were re-suspended in 1 mL 
medium (RPMI, 10% FCS). The required amount was centrifuged at 13 000 rpm for 
20 minutes, and the supernatant removed. A 1 mL aliquot of medium (RPMI, 10% 
FBS) was added and passed 10 times through a 1 mL insulin syringe. Macrophages 
were infected at an MOI of 5:1 and incubated for 4 hours at 37 C, in the presence of 
5% CO2. Non-ingested M.tb was then washed off with RPMI containing 10% FCS. 
Infected macrophages were incubated at 37 C in fresh medium that was renewed 
every 2 days thereafter.  
 
6.6.4 Evaluating inhibitory effects of novel compounds designed against MshA  
At day 1 or day 2 post infection, M.tb-infected macrophages were treated with 
candidate inhibitors to determine the optimal concentrations and treatment time for 
inhibitory effect on mycobacterial growth. At selected time-points during the drug 
treatments, infected macrophages were lysed with 0.1% Triton X-100 (Sigma-
Aldrich, USA) to isolate M.tb. Mycobacteria were pelleted at 13 000 rpm for 20 
minutes, and re-suspended in 1 mL 7H12 Middlebrook medium. The samples were 
analysed for M.tb growth in a BACTEC 460TM instrument. Inhibitory effects of each 
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CHAPTER 7 
7.1 Overall summary and conclusion 
The main aim of this research project was to synthesize and evaluate 
glycosyltransferase (MshA) inhibitors. The enzyme (MshA) plays a crucial role in the 
biosynthesis of mycothiol, which is implicated in the redox maintenance of the 
mycobacteria. The enzymes involved in the redox maintenance of the bacteria have 
not been fully explored and considered to be possible drug targets. The current anti-
tuberculosis drugs and the anti-tuberculosis drug candidates in clinical stages mainly 
target the enzymes that are involved in the biosynthesis of the bacterial cell wall. 
Nevertheless, none of the anti-tuberculosis drug candidates target the enzymes 
involved in the redox maintenance of mycobacteria. 
 
A specific focus of this research project included the synthesis of mimics of the sugar-
nucleotide of the natural substrate (UDP-GlcNAc) of MshA. MshA catalyzes the first 
essential step leading towards the biosynthesis of mycothiol and requires both UDP-
GlcNAc and 1-L-Ins-1-P as substrates. Successful inhibition of this enzyme could 
lead to novel leads in an unexplored pathway targeting tuberculosis. 
 
In an attempt to design substrate mimics and thiazolidinethione derivatives, in silico 
active site docking studies of MshA, using computer simulations (Autodock 4.2 
software) was attempted. Subsequently, a series of thiazolidinethione derivatives 
(MJ1A – MJ12A and MJ1B – MJ12B) was synthesized and screened for anti-
tuberculosis activity. Of these thiazolidinethione derivatives screened, four 
compounds (MJ3A, MJ2B, MJ7B and MJ12B) were identified as potential drug-like 
inhibitors of MshA by inhibiting M. tuberculosis growth (≥ 70%).  
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Further development of thiazolidinethione derivatives (MJ1A - MJ12A), steered by 
biological activity in conjunction with docking studies culminated in a synthesis of 
potent propargylated thiazolidinethione derivatives (MJ029 series). Biological results 
have showed that the propargylated thiazolidinethione derivatives (MJ029 series) 
have excellent antituberculosis activity by inhibiting M. tuberculosis growth by >80% 
at 100 µg/mL. 
 
While the exact target could not conclusively be determined to be MshA, the 
mechanism of action of these compounds is yet unknown, the enhanced activity of 
this series of compounds is attributable to the addition of the propargyl moiety. The 
discovery that thiazolidinethione derivatives inhibit the growth of M. tuberculosis 
provides a starting point for future investigations of these scaffolds, which may yield 
more potent MshA inhibitors and provide additional structure–activity relationships.  
 
In addition, substrate mimics were synthesized and screened for anti-tuberculosis 
activity. As suspected, substrate mimics synthesized displayed moderate activity, 
except for substrate mimic (4-34) which turned out to be an interesting candidate for 
MshA inhibition by displaying the highest potency. Based on these biological results, 
it was concluded that the replacement of the pyrophosphate moiety of the naturally 
occurring substrate, UDP-GlcNAc, with a 1,2,3-triazole mimic led to non-isosteric 
analogs (4-25 and 4-29) displaying weak inhibitory activities.  
 
These results were in agreement with the previous study of Vidal et al.1 Vidal et al. 
investigated the in vitro inhibitory activities of non-isosteric analogues of natural 
nucleotide diphosphate sugars (UDP-Gal, UDP-Fuc and UDP-GlcNAc) as 
glycosyltransferases (β-1,4-GalT, FUT3 and LgtA) inhibitors. However, none of the 
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non-isosteric analogues screened displayed significant inhibitory activity at a 
concentration of up to 3.5 mM in fluorescence assay against glycosyltransferases.1 
 
In addition, tunicamycin, a naturally occurring substrate mimic, have been evaluated 
for anti-tuberculosis activity against MshA. The biological results indicated that this 
substrate mimic is highly potent against mycobacteria species at very low 
concentration. Although, tunicamycin had inhibited the growth of M.tb, the 
Transcreener® assay results have indicated that this substrate mimic is not a good 
inhibitor of MshA, which was also corroborated by docking studies. Thus, it could be 
possible that tunicamycin binds to other glycosyltransferases within the mycobacterial 
species with the exception of MshA.  
 
The study describes in detail the total synthesis of 1-L-Ins-1-P which is an important 
co-substrate required for enzyme (MshA) assays. Although this substrate is 
commercially available, the cost involved in the procurement of the substrate 
(400$/mg) were high and unsustainable considering the amount of the assays planned. 
Therefore it was decided to pursue the synthesis of this substrate in relatively large 
scale in our laboratory. The substrate was synthesized in a total of 9 steps from myo-
inositol, using a combination of protocols. Analytical techniques such as 1H NMR, 
13C NMR, 31P NMR spectroscopy as well as mass spectrometry were employed to 
fully characterize the substrate. The challenges involved with the synthesis of this 
substrate were highlighted. The synthetic route described in this thesis led to an 
improved large scale synthesis of 1-L-Ins-1-P.  
 
In conclusion, the thiazolidinethione scaffolds and substrate mimic (4-34) can be 
developed further into lead compounds considering their selective binding towards 
MshA. Although tunicamycin appears to be inhibiting the growth of the 
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mycobacterial species, the specificity of this inhibitor towards MshA needs to be 
modulated. Further in silico ADMET predictive models could be explored in 
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Microplate alamarBlue® assay (MABA) 
Slightly modified MABA assay was carried out as described by Franzblau et al.1 
Briefly, M. smegmatis culture were allowed to grow till the optical density (OD) of 
0.6 was reached before the cells were treated with different drug concentrations. 
Subsequently the treated cells were incubated for 24 hr at 37 C before resazurin was 
added and the cells were allowed to grow further for another 24 hr before the color 
development was monitored. A blue color in the wells was interpreted as no growth, 
purple color was interpreted as moderate inhibition, whereas a pink color was scored 
as growth. The outer perimeter wells of the sterile 96 well plates were filled with 
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